Gait Variability and Kinematic Alterations in People with Diabetes Mellitus and Peripheral Neuropathy by Bowling, Frank
University of Huddersfield Repository
Bowling, Frank
Gait Variability and Kinematic Alterations in People with Diabetes Mellitus and Peripheral 
Neuropathy
Original Citation
Bowling, Frank (2015) Gait Variability and Kinematic Alterations in People with Diabetes Mellitus 
and Peripheral Neuropathy. Doctoral thesis, University of Huddersfield. 
This version is available at http://eprints.hud.ac.uk/25500/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
  
Gait Variability and Kinematic Alterations in 
People with Diabetes Mellitus and Peripheral 
Neuropathy 
 
 
 
A dissertation in submission for partial fulfilment of a 
professional doctorate in Podiatric Medicine 
2015 
 
by 
 
Frank L. Bowling  
 
 
 i 
 
List of Publications 
 
Publications and Presentations directly arising from the work in this thesis 
Bowling, F.L., Reeves, N.D., Vernon, W., Stephenson, J., Ousey, K. (2014). 
Increased joint range of motion variability during gait in patients with diabetes 
and peripheral neuropathy. Proceedings of the 12th Meeting of the Diabetic Foot 
Study Group, Bratislava Oral Presentation. 
 
Bowling, F.L., Reeves, N.D., Vernon, W., Stephenson, J., Ousey, K. (2014) Gait 
Characteristics and Variability in the Aging population with Diabetic Peripheral 
Neuropathy Current Diabetes Reviews. In Review process. 
   
Bowling, F.L., Davies, C. Reeves, N.D., Kirshbaum, M. & Reeves, N.D. (2013). 
Increased joint range of motion during gait in patients with diabetes and 
peripheral neuropathy. Proceedings of the 11th Meeting of the Diabetic Foot 
Study Group, Sitges Spain, p. 50. 
 
Publications and Presentations associated with the larger projects connected to the 
grant funding body.  
Brown, S.J., Handsaker, J.C., Bowling. F.L., Maganaris, C.N., Boulton, A.J.M., 
Reeves, N.D. Do patients with diabetic neuropathy use a higher proportion of 
their maximum strength when walking? Journal of Biomechanics, In Press, 
Corrected Proof, Available online 16 October 2014 
 
Handsaker, J.C., Brown, S.J., Bowling, F.L., Cooper, G., Maganaris, C.N., 
Boulton, A.J., Reeves, N.D. Contributory factors to unsteadiness during walking 
up and down stairs in patients with diabetic peripheral neuropathy. Diabetes 
Care. (2014) Nov;37(11):3047-53. doi: 10.2337/dc14-0955. 
Reeves, N.D., Brown, S.J., Handsaker, J.C., Bowling, F.L., & Boulton, A.J.M., 
(2013). Are shear forces elevated at the foot-ground interface during gait in 
patients with diabetic neuropathy? Proceedings of the 11th Meeting of the 
Diabetic Foot Study Group, Sitges Spain, p. 25. 
Cooper, G., Teklemariam, A., Brown, S.J., Boulton, A.J.M., Bowling, F.L., & 
Reeves, N.D. (2013). Shear loading in the diabetic foot during level walking and 
stair climbing. Proceedings of the 11th Meeting of the Diabetic Foot Study Group, 
Sitges Spain, p. 39. 
Handsaker, J.C., Boulton, A.J.M., Brown, S.J, Maganaris, C.N., Cooper, G., 
Bowling, F.L., & Reeves, N.D.,(2013). Effects of Diabetic Peripheral Neuropathy 
  
ii 
 
on Muscular Activations during Stair Descent. Proceedings of the Physiological 
Society, PCA252. 
Brown, S.J., Handsaker, J.C., Boulton, A.J.M., Maganaris., C.N., Bowling F.L., 
& Reeves, N.D.(2013). Influence of Diabetes and Diabetic Peripheral 
Neuropathy on Lower Limb Joint Moment Distribution During Stair Negotiation. 
Proceedings of the Physiological Society, PCA253. 
Handsaker, J.C., Boulton, A.J.M., Brown, S.J., Maganaris, C.N., Cooper, G., 
Bowling, F.L., & Reeves N.D. (2013). Diabetic peripheral neuropathy alters 
muscle activation strategy and the rate of joint torque development during stair 
descent. Proceedings of the Staffordshire Clinical Biomechanics Conference, 
p.5-6. 
Brown, S.J., Handsaker, J.C., Boulton, A.,J.M., Maganaris, C.N., Bowling, F.L., 
& Reeves, N.D (2013). Alterations to lower limb Joint Moment Profiles during 
Stair Ascent in patients with Diabetes and Diabetic Peripheral Neuropathy. 
Proceedings of the Staffordshire Clinical Biomechanics Conference, p.13-14. 
Reeves, N.D., & Bowling, F. L., (2012). Biomechanics of the diabetic foot. The 
14th Malvern Diabetic Foot Conference, Malvern UK. [Invited faculty 
presentation] 
Handsaker, J.C., Boulton, A.J.M., Brown, S.J., Maganaris, C.N., Cooper, G., 
Bowling FL & Reeves ND (2012). Effects of diabetes and peripheral neuropathy 
on joint torque development and muscle activation characteristics during stair 
descent. Diabetologia 55(Suppl1), S479. 
 Reeves, N.D., Brown, S.J., Handsaker, J.C., Maganaris, C.N, Bowling, F.L., & 
Boulton,A.J.M. (2012). Foot-ground interaction during walking and stair 
negotiation in people with diabetes and peripheral neuropathy. Proceedings of 
the 10th Meeting of the Diabetic Foot Study Group, Berlin Germany, p. 39. 
This current work was funded through a clinical research grant from the 
European Federation for the Study of Diabetes.  
 
 
 
 
  
iii 
 
List of Figures 
Figure 1. Positions for Plug-in-gait anatomical markers ........................................... 80 
Figure 2.  Marker placements in lateral and anterior views. The current study utilised 
the lower limb only.................................................................................................... 83 
Figure 3. Marker positions from a posterior view and during level walking (lower limb 
only). ........................................................................................................................ 84 
Figure 4 . Stair ascent and descent with harness and markers attached. ................ 85 
Figure 5. Over-head harness ................................................................................... 86 
Figure 6. Ctl, DM and DPN results for ankle ROM (sagittal) during stair ascent. ... 103 
Figure 7. Knee ROM (frontal) for stair ascent.                                                           
Figure 8. Knee ROM (frontal) stair descent.                                                                                         
 ............................................................................................................................... 104 
Figure 9. Hip ROM (frontal) for stair descent.                                                                           
Figure 10. Hip ROM (transverse) for stair descent. ................................................ 105 
 
 
 
 
  
iv 
 
List of Tables 
Table 1. Score sheet for the neurodisability score.................................................... 72 
Table2. Protocol for marker placement. ................................................................... 77 
Table 3. Description of Plug-in Gait marker placement for the lower body. .............. 78 
Table 4. Segment and tracking definitions. .............................................................. 81 
Table 5. Demographics for groups. .......................................................................... 90 
Table 6. Results of ANOVA, for joint range of motion during three gait tasks. ......... 93 
Table 7. Ankle joint ROM during stair ascent, stair descent, and level walking. ....... 94 
Table 8. Knee joint ROM during stair ascent, stair descent, and level walking. ....... 95 
Table 9. Hip joint ROM during stair ascent, stair descent, and level walking. .......... 97 
Table 10. ANOVA results for gait variability in joint range of motion during  three gait 
tasks ......................................................................................................................... 99 
Table 11. Mean variability by group and multiple comparisons results................... 100 
 
 
 
  
v 
 
List of Abbreviations 
AGEs  Advanced Glycation End Products 
AR  Aldose Reductase 
ATP  Adenosine Triphosphate 
BMI  Body Mass Index 
CO2  Carbon Dioxide 
CCM  Corneal Confocal Microscopy 
COM  Centre of Mass 
Ctl  Control 
DCCT  Diabetes Control and Complications Trial 
DESMOND   Diabetes Education and Self-Management for Ongoing and Newly-
Diagnosed (type 2 diabetes) 
DFUs   Diabetic Foot Ulcers 
DH  Department of Health 
DM  Diabetes Mellitus 
DNA  Deoxyribonucleic Acid 
DPN  Diabetic Peripheral Neuropathy 
EMG  Electromyogram  
EURODIAB European Diabetes Prospective Complications Study  
EURODIALE  European Diabetes Study Group on Diabetes and the Lower Extremity 
FADH2  Flavin Adenine Dinucleotide 
  
vi 
 
GLUTs Glucose Transporter Molecules 
GP  General Practitioner 
HbA1c Glycated Haemoglobin 
HSCIC           Health and Social Care Information Centre 
IDDM  Insulin Dependent Diabetes Mellitus 
IDF  International Diabetes Federation 
IWGDF International Working Group on the Diabetic Foot  
K+  Potassium Ion 
MDF  Medium Density Fibre 
Na2+   Sodium Ion 
NAD  Nicotinamide Adenosine Dinucleotide 
NADP  Nicotinamide Adenosine Dinucleotide Phosphate 
NCS  Nerve Conduction Studies 
NDS  Neuropathy Disability Score 
NHS  National Health Service United Kingdom 
NICE  National Institute for Clinical Excellence 
NIDDM None Insulin Dependent Diabetes Mellitus  
NSF  National Services Framework 
PN  Peripheral Neuropathy 
RAGE  Receptor (for) Advanced Glycation End Product 
ROM  Range of Motion 
3D  Three-dimensional 
  
vii 
 
UK  United Kingdom 
UKPDS United Kingdom Prospective Diabetes Study  
USA  United States of America 
VPT  Vibration Perception Threshold 
WHO  World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
  
viii 
 
Thesis Outline  
The consequences of diabetes for the human body are initiated at a molecular and 
cellular level, which promotes the widespread dissemination of cell dysfunction. 
Peripheral neuropathy is a clinical manifestation of altered cell function, and, 
therefore, the mechanisms of dysfunction in diabetes are presented to demonstrate 
the materialisation/conversion of hyperglycaemia into Diabetic Peripheral 
Neuropathy (DPN).  Normal gait in humans will be summarised in order to create a 
background for a review of disruptions in gait that can lead to falls.  The current 
evidence base for altered gait patterns and the potential for this to increase falls risk 
is reviewed. Finally, data as it relates specifically to diabetes is discussed before 
presenting the study.  The hypothesis is that people with diabetic peripheral 
neuropathy will exhibit significant differences in joint range of motion and gait 
variability during three gait tasks (stair ascent, stair descent, and level walking) 
compared to people without diabetes-related peripheral neuropathy, and healthy 
controls. The differences between the groups will become more evident as the gait 
tasks become more challenging. 
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Abstract 
Background: People with diabetes and peripheral neuropathy have been reported 
to show alterations in lower limb joint function compared to healthy non-diabetic 
people. Specifically the maximum angular movement available at certain joints can 
be reduced during static, non-weight bearing tasks. Limited joint range of motion has 
the potential to compromise balance and stability thereby increasing the risk of 
falling. It is unclear whether a reduction in the extent of movement available at the 
joints is reflected by a reduction in the amount of angular movement actually utilised 
during a functional task such as stair negotiation. The aim of this study was to 
determine if people with diabetes show reduced dynamic range of motion at the 
ankle, knee and hip joints during stair ascent and descent in comparison to controls. 
Falls risk during stair negotiation was calculated by measuring the degree of 
variability in dynamic joint range of motion.  Methods: Data were generated from 
three groups: subjects with diabetes and peripheral neuropathy (DPN), diabetes 
without peripheral neuropathy (DM), and healthy controls (Ctl). The study was 
conducted in a gait laboratory using motion capture and related 3D software for 
analysis. Joint range of motion for the ankle, knee, and hip were captured  during 
level walking, stair ascent, and descent. A seven step, bespoke staircase was 
fabricated for this purpose. Analysis of Variance (ANOVA) and Newman-Keuls tests 
were used to analyse the data.  Results: Significantly reduced ankle range of 
motion, in the sagittal plane, was observed in the DPN group during stair ascent 
when compared to the controls. For stair descent, the DPN group demonstrated a 
  
x 
 
significant increase in knee and hip ROM in the frontal plane, and also hip ROM in 
the transverse plane. No significant differences between the groups were identified 
for joint variability.  Conclusions: People with DPN demonstrate alterations in 
dynamic range of motion at the lower limb joints during stair ascent and descent. The 
degree of angular movement utilised for both stair tasks was decreased at the ankle 
joint and this has the potential to undermine balance and stability.  In contrast, 
angular movement at the knee and hip joints was increased in the frontal and 
transverse planes. This may compensate for impaired balance and stability by 
increasing the base of support to maintain balance and assist in foot clearance and 
placement. The specific combination of increased angular movement at the knee 
and hip may represent a compensatory stair gait strategy in response to reduced 
angular movement at the ankle joint.  
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Chapter One  
Introduction 
Introduction to Diabetes Mellitus 
Diabetes mellitus is a serious chronic endocrinological disease characterised by 
abnormal metabolism of lipids and sugars. Chronic hyperglycaemia, if left 
unchecked, has a detrimental effect on multiple physiological systems. The 
complications associated with the hyperglycaemic state include peripheral vascular 
disease, cardiovascular diseases (Juutilainen, Lehto, Ronnemaa, Pyorala & Laakso, 
2005), retinopathy, nephropathy, and peripheral neuropathy (Fowler, 2008). The 
clinical manifestations of diabetes-related complications include tissue breakdown in 
the peripheral limbs due to vascular insufficiency, claudication pain, myocardial 
infarction, cerebrovascular attack, renal failure, visual impairment, neuropathic lower 
limb pain, and diabetic foot ulceration (Chaturvedi, 2007).  
 
Management of conditions arising from diabetes is guided by the National Service 
Framework for Diabetes (Department of Health, 2001), and National Institute of 
Healthcare Excellence (NICE) clinical guidelines (CG66) (NICE, 2008), with the aim 
of providing structured, evidence-based care.  Podiatry has a high profile in 
managing the diabetic foot as recommended by clinical guideline 10, type 2 
diabetes: prevention and management of foot problems (NICE, 2004).  One of the 
key themes of this guideline is prevention of foot complications due to high rates of 
morbidity and mortality associated with infections in the diabetic foot (Davis, Norman, 
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Bruce & Davis, 2006; Ghanassia et al., 2008).  Peripheral neuropathy plays a 
significant part in the causal pathway to foot ulceration, as loss of sensation prevents 
the foot from responding appropriately to the presence of abnormal pressures and 
shear forces (Veves, Murray, Young & Boulton, 1992), whilst simultaneously 
diminishing foot sensitivity to trauma.  A breach in the protective epithelium of the 
foot can be the first step towards formation of a diabetic foot wound, and once an 
ulcer is established, it can transform into a chronic, non-healing wound with ease.  
This process is assisted by a prolonged inflammatory response (Stegenga et al., 
2008), decreased perfusion (Apelqvist et al., 2011), and altered immune response 
(Rubinstein, Genaro,Motta, Cremaschi & Wald, 2008). The risk of infection in a 
diabetic foot wound is high at 58%, and infection is often the precursor to lower limb 
amputation (Prompers et al., 2007).  A large prospective study (n=3,018) involving 
97 hospitals across the United States examined risk factors and outcomes in 
patients with a diabetic foot ulcer and identified that over one fifth of these patients 
required a lower extremity amputation (Lipsky, Weiglet & Sun, 2011).  According to 
the National Diabetes Audit (Health and Social Care Information Centre), between 
2010 and 2012, 1.96 million people in the UK were living with diabetes in England 
and Wales.  Major lower limb amputations were carried out for 3,319 of these people 
as a result of their diabetes.  However, type 1 and type 2 diabetes were pooled, and 
there are no statistics available according to type of diabetes.  Nevertheless, given 
such poor outcomes, it is essential to reduce the risk of developing a diabetic foot 
ulcer, which necessitates attempting to interrupt the chain of events that cause 
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ulceration.  Diabetic Peripheral Neuropathy (DPN) is at the centre of the pathway to 
ulceration due to the associated loss of protective sensation, but the peripheral 
nerves of the lower limb are also involved in locomotion.  Sensorimotor function 
enables humans to mobilise whilst remaining upright, and in the absence of this 
information, balance will be lost, which can culminate in a fall.  It is physiologically 
feasible that DPN places patients with diabetes at risk of falls due to the inherent 
loss of sensation.  
 
1.1 The Diabetes Epidemic 
 
According to the World Health Organisation (WHO), in 2013, there were 
approximately 347 million people living with diabetes mellitus worldwide, and this is 
predicted to increase to almost 552 million people by 2030 (World Health 
Organisation, 2013).  Type 2 diabetes mellitus accounts for 85% to 95% of cases in 
high-income regions such as the United States of America (USA) and Europe 
(International Diabetes Federation [IDF], 2013).  Diabetes is characterised by 
sustained elevation of blood glucose levels, as measured by glycated haemoglobin, 
or HbA1c, but, with strict glycaemic control, type 2 diabetes can be reversed (United 
Kingdom Prospective Diabetes Study, UKPDS, 1990; Dufor, Befroy, Lehrke & 
Schulman, 2005).  Type 1 diabetes requires treatment with regular replacement of 
insulin, usually in the form of sub-cutaneous injection. However, achieving stable 
blood glucose is notoriously difficult (Govan, Wu & Brigg, 2011).  This is largely 
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attributable to pharmacological limitations that result in highly variable rates of 
absorption, in addition to peaks and troughs in insulin levels leading to hypo- and 
hyperglycaemic episodes (Heinemann, 2002). 
 
Sustained and uncontrolled fluctuations in blood sugar levels are at the centre of 
diabetes-related complications such as retinopathy, neuropathy and nephropathy.  
This relationship was demonstrated in the European diabetes (EURODIAB) study of 
Insulin Dependent Diabetes Mellitus (IDDM) by Tesfaye et al. (1996), whereby 
diabetic peripheral neuropathy was linked to glycaemic control and duration of 
disease.  This is one of the largest prospective, longitudinal studies available, and 
included health centres across European countries. Hence, the data is highly 
relevant to the current study.  Over a seven-year follow-up period from baseline 
measurements, almost one quarter of patients developed diabetic peripheral 
neuropathy, or DPN (Tesfaye, 2005). 
 
People with diabetes are estimated to have a twofold excess risk of developing 
cardiovascular complications such as ischaemic heart disease, cerebrovascular 
disease, peripheral arterial disease, and heart failure.  Cardiovascular disease is the 
most common cause of death in individuals with both type 1 and 2 diabetes mellitus, 
suggesting an inextricable link between the two diseases (Buse et al., 2007; Sarwar 
et al., 2010).   
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Medical management of this array of conditions is costly. In 2011 the global spend 
for the provision of diabetes-related healthcare amounted to $465 billion, constituting 
a considerable financial burden (IDF, 2013).  The projected estimates of increases in 
world population and diabetes prevalence will see this magnified in future years, and 
the IDF have calculated a global spend of $595 billion for the year 2030 (IDF, 2013).  
The effects of the increased demand will be felt by all healthcare providers, including 
the National Health Service (NHS) in the UK. Increased prevalence of diabetes has 
been mirrored by increased expenditure in European countries such as France, Italy, 
Germany and Spain.  A report from the London School of Economics (Kanavos, van 
den Aardweg & Schurer, 2012) calculated that total healthcare expenditure between 
2004 and 2008 had increased by 49% in France, 22% in Germany, 48% in Italy, 
111% in Spain, and 45% in the UK.  These increases in expenditure correlated 
strongly with increased prevalence of diabetes in each country, most notably Spain. 
Within the UK, expenditure on type 2 diabetes far exceeds that of type 1, 
expenditure on the former being £11.9 billion per year versus £1.8 billion per year on 
the latter.  The National Diabetes Audit, 2012 - 2013, (Health and Social Care 
Information Centre [HSCIC], 2014) found the majority of this spending went on in-
patient care due to diabetes-related complications, including diabetic foot disease.  
 
The need to deliver high quality care with maximum efficiency has prompted 
fundamental changes in practice in many aspects of medicine, and diabetes is no 
exception (Department of Health, [DoH], 2001; 2010).  The range of complications 
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associated with diabetes, and the interactions between them, can produce a 
complex clinical picture making it difficult to determine the specific influence of any 
contributing factors. However, an appreciation of the metabolic processes driving the 
physiological changes helps to illustrate how and why DPN might be linked with gait 
disorders.  The following section will explore the physiology underlying DPN whilst 
also examining the molecular and cellular level changes that produce neuropathy.  
The effects on nerve function will be considered with a view as to how this may link 
to gait changes.   
 
1.2 The Pathophysiology of Diabetes Mellitus 
 
The aim of this section is to demonstrate how the molecular changes that arise as a 
result of diabetes disturb cell function throughout the human body.  Diabetes mellitus 
is an endocrinological disease characterised by abnormal glucose metabolism.  Type 
1 diabetes accounts for between 5% and 10% of all cases worldwide, and usually 
presents in childhood or early adolescence (WHO, 2013).  It is an auto-immune 
regulated disease, resulting in the targeted destruction of pancreatic beta (β) cells, 
the cause of which is a complex interplay between genetic and environmental 
factors.  There are a number of immunological indicators of type 1 diabetes, 
including the presence of islet cell antibodies, auto-antibodies to insulin, glutamic 
acid, decarboxylase, and tyrosine phosphates (Pfluger et al., 2011).  At the point 
where insulin secretion is minimal or absent, levels of plasma c-peptide become 
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undetectable. However, at this stage in the disease process, the patient will have 
clinical signs of uncontrolled diabetes that are life-threatening, such as ketoacidosis.  
Long-term insulin therapy is essential for the health and survival of patients with type 
1 diabetes, but glycaemic control can be difficult to achieve due to hypoglycaemic 
responses (Perez-Maraver et al., 2013).  In contrast, type 2 diabetes is an obesity-
driven abnormality in glucose metabolism (Khan, 2006) resulting in increased 
resistance to insulin activity, and subsequent inadequate insulin secretory response.   
 
1.2.1 Glucose Homeostasis 
In healthy humans, plasma glucose is derived from two main sources: through diet 
via ingestion, and through metabolism of glycogen in the liver. Ingestion of glucose 
results in increased plasma glucose levels which initiates the release of insulin by 
pancreatic β cells (Henquin, 2000).  Normal levels of blood glucose before a meal 
should be between 3.5 and 5.5 millimoles per litre (mmol/l), and less than 8 mmol/l 
after a meal (WHO, 2006).  Staying within these parameters is dependent upon 
maintaining a balance between insulin action and insulin secretion.  Healthy β cells 
are highly flexible and adapt to altered insulin levels accordingly. Thus, a decrease in 
insulin action can be balanced by an upregulation of insulin secretion.  
 
Insulin plays a major role in glucose regulation through the acceleration of glucose 
transport to insulin sensitive cells, and by facilitating glycogenesis and lipogenesis 
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for energy storage (Wright et al., 2007).  In addition to insulin, the hormone glucagon 
is involved in glucose homeostasis, as it is secreted in response to hypoglycaemia.  
Glycogenesis and glucogenesis are both enhanced by glucagon, thereby increasing 
glucose levels and returning to normoglycaemia.  After a meal, glucagon secretion is 
inhibited under normal conditions by hyperinsulinaemia, which assists in suppressing 
hepatic glucose production (Ramnanan, Edgerton, Kraft & Cherrington, 2011), 
thereby assisting in maintaining normal glucose levels.  Target sites for glucose 
transport include adipose, muscle, cardiac, brain and liver tissues.  Permeability of 
target cell membranes is achieved with the assistance of glucose transporter 
molecules (GLUTs) (Baloh, 2008), which allow the passage of glucose via an 
aqueous pore into the cytoplasm (Joost & Thorens, 2001).   
 
Utilisation of glucose begins with the enzyme-mediated reduction of glucose to 
pyruvate via glycolysis.  Oxidative phosphorylation sees pyruvate oxidised to acetyl 
coenzyme A, which then enters the Krebs cycle to combine with oxaloacetate 
forming citrate.  Throughout the process, a series of redox reactions generate 
Adenosine Triphosphate (ATP), Nicotinamide Adenosine Dinucleotide Phosphate 
(NADH), Flavin Adenine Dinucleotide (FADH2), and carbon dioxide (CO2). Electrons 
are then transported down the electron transport chain via an energy gradient until 
accepted by oxygen, which is the terminal acceptor of electrons.  As electrons move 
down the chain, four protein complexes (Sperlagh & Vizi, 1996) assist in the 
donation and acceptance of electrons, which creates a proton gradient of potential 
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energy.  The relative impermeability of the cell membrane maintains stability of the 
gradient whilst the enzyme ATP synthase allows protons to flow back down the 
gradient and cross the membrane, thereby generating ATP (Starkov & Fiskum, 
2003). 
 
Nerve cells have high requirements for ATP in the formation of cell units, and 
maintenance and generation of action potentials (Viader et al., 2011).  The 
propagation of electrical signals along the length of axons is driven by the sodium 
and potassium ion pump.  The pump builds up a concentration gradient, thus 
creating the resting potential of the cell and, when stimulated, an action potential is 
generated allowing the inflow of sodium across the cell membrane.  This opens a 
gated channel for potassium ions (K+) to leave the cell. The sodium in-flow also 
stimulates the opening of sodium channels on the next axon thereby propagating the 
signal.  This pattern of neuro-electrical signalling underpins the peripheral and 
central nervous systems both of which utilise glucose for energy generation.  
 
1.2.2 Glucose Metabolism in Diabetes Mellitus 
 
Diabetes mellitus is characterised by hyperglycaemia, which initiates the diversion of 
glucose away from glycolysis towards alternative metabolic pathways with noxious 
implications for nerve cells.  The polyol pathway was first described by Hers (1956, 
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cited in Oates, 2002,) as the enzymatic reduction of glucose to sorbitol, producing 
fructose as the end product.  Glucose is converted to sorbitol in nerve cells, leading 
to the accumulation of sorbitol in the cytoplasm.  Sorbitol synthesis assists cells in 
buffering high interstitial osmotic pressures, but in the presence of high levels of 
glucose, the accumulation alters osmolarity in the cytoplasm, which in turn drains 
other osmolytes normally involved in regulating cell osmolarity (Kinoshita & 
Nishimura, 1988).  The consequences for cells involved in this process are direct 
tissue toxicity or a rapid increase in cell volume due to water influx (Suzuki et al., 
1999).   
 
The enzyme Aldose Reductase (AR) plays a key role in the polyol pathway, and high 
levels of AR have been found in Schwann cells of myelinated nerve fibres (Brownlee, 
2005), percicytes, and smooth muscle cells.  Increased AR activity, and subsequent 
increased flux through the polyol pathway, utilises and reduces levels of co-enzyme 
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) whilst increasing nitric 
oxide synthase (Kamiya et al., 2003), as this would normally combine with NADPH 
under normoglycaemia.  The resulting decrease of nitric oxide in nerve tissue 
disturbs endothelial function, thus reducing perfusion of nerve tissue (Tomlinson et 
al., 1998).  The polyol pathway is also implicated in reduced neurotrophin secretion 
leading to degeneration of nerve cells (Suzuki et al., 2004).  Aldose reductase is 
challenged by the enzyme glutathione reductase under normal physiological 
conditions. However, increased levels of AR result in over-use of glutathione, whose 
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subsequent inhibition leads to increased free radical generation and oxidative stress 
(Yagihashi, Mizukami & Sugimoto, 2011). 
 
Oxidative stress is a further glucose-driven mechanism promoting cell toxicity 
through the generation of free radicals and reduced free radical scavenging.  
Increased hydrogen peroxide levels, due to polyol-related activities, allow hydrogen 
peroxide to join a reaction that produces superhydroxyl radicals, thus increasing free 
radicals and oxidative stress.  Glycolysis is slowed down due to oxidative stress-
induced DNA strand breakage and activation of poly polymerase, which reduces 
NAD concentration to drive glycolysis.  The metabolism of glucose via glycolysis is 
therefore slowed, the electron chain becomes inefficient and ATP is reduced, as 
observed in Schwann cells by Obrosova and colleagues (2005).  Oxidative stress 
can also cause decreases in nerve conduction velocity, and decreased nerve blood 
flow (Cameron, Cotter, Archibald, Dines & Maxfield, 1994).  Axonal regeneration of 
peripheral nerves can be disrupted by oxidative stress with the degree of impairment 
being inversely proportional to length of time with diabetes (Kennedy & Zochodne, 
2000).  Biopsies of sural nerves have shown virtually no regeneration (Malik, 2005).  
Advanced Glycation End Products (AGEs) are formed by non-enzymatic protein 
glycation via the Maillard reaction, resulting in a group of molecules that can disturb 
the structure, function and integrity of a cell (Munch & Westcott, 2012).  Amino acids 
of proteins with side chains of lysine or arginine react with carbonyl compounds 
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whose reactivity has been enhanced by increased levels of glucose.  A Schiff-base is 
formed and rearranged into a protein-bound Amadori product which undergoes a 
series of oxidations and dehydrations until a broad range of fluorescent and yellow-
brown molecules result.  AGE products can form irreversible cross-links with 
neurofilament proteins involved in axonal regeneration leading to atrophy of axons 
(Duran-Jimenez et al., 2009).  Activity of Na2+K+ ATPase is impaired by AGE 
products, resulting in axonal dysfunction, but more direct nerve fibre loss can be 
initiated by AGE product-activated apoptosis (Ota et al., 2007).  Basement 
membrane hypertrophy is influenced by AGE products’ interaction with extracellular 
matrix proteins (collagen, fibronectin and laminin) and endothelial cells, thereby 
disturbing microvascular structure and function at the blood-nerve barrier (Yao et al., 
2010).   
RAGE is the receptor for AGEs and is classified with the immunoglobulin family of 
cell surface receptors.  It has been identified as present in dorsal root ganglion, 
Schwann cells and peripheral nerves of diabetic mice (Toth et al., 2008).  Cell 
damage arises from the activation of nuclear factor kappa beta (NF-kB), stimulation 
of NAD(P)H oxidase and protein modification.  Activation of NF-kB increases gene 
expression of cytokines, which can prolong and maintain the pro-inflammatory 
response, whilst sustained activation irreversibly alters gene expression and causes 
upregulation of RAGE (Haslbeck et al., 2007). 
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1.3 Diabetic Peripheral Neuropathy 
 
The consequences associated with the metabolic processes instigated by 
hyperglycaemia are diverse, and are implicated in diabetes-related complications 
such as retinopathy, nephropathy and cardiovascular dysfunction (Goh & Cooper, 
2008). DPN encompasses the clinical manifestations of the processes that drive 
changes in nerve cell structure and function.  Electromicroscopy of neuropathic 
peripheral nerves demonstrates axonopathy of small distal unmyelinated fibers 
(Ørstavik et al., 2006) with skin denervation, reported as the DPN progresses (Shun 
et al., 2004). Wallerian degeneration and segmental demyelination are also 
characteristic of DPN (Kennedy & Zochodne, 2005) and can affect larger fibres 
which already demonstrate segmental demyelination (Malik, 2005).  Axon loss and 
axon thinning are associated with reduced nerve conduction velocity, which is 
frequently reported on nerve conduction studies of patients with DPN.  Altered heat 
perception and decreased sensation as a whole is due to c-fibre dysfunction.  
Impaired axon regeneration prevents fibre re-growth and, hence, an overall loss of 
nerve fibre density (Kennedy & Zochodne, 2005).  Nerve cells undergo a variety of 
transformations as a result of hyperglycaemia, direct tissue damage secondary to 
glucotoxicity, exposure to noxious metabolic by-products, and altered gene 
expression at the mitochondrial level.  This culminates in progressive and irreparable 
damage to peripheral nerves accompanied by clinical symptoms of DPN.   
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1.3.1 Prevalence of Diabetic Peripheral Neuropathy 
 
Three major studies have investigated the prevalence of peripheral neuropathy in the 
diabetes population. Young et al. (1993) recruited 6487 patients from 118 hospital 
based out-patient diabetes clinics across the UK.  Of these, 2414 (37.0%) were 
diagnosed with type 1 diabetes, and 3949 (61.0%) had type 2 diabetes, whilst 124 
(2.0%) were of unknown aetiology.  The overall prevalence of DPN in the study 
population of patients with diabetes attending a hospital-based clinic was 28.5% 
(95% confidence interval 27.9%-29.6%).  Prevalence of DPN was significantly higher 
in type 2 diabetes (32.1%) than in type 1 diabetes (22.7%) (p<0.001).  The sample 
size of 6487 patients should imply a reasonable reflection of the diabetes population 
as a whole. However, the distribution of type 1 and type 2 diabetes within the sample 
does not concur with current knowledge of approximately 5% for the former and 95% 
for the latter. The difference has arisen due to the authors’ diagnostic criteria for type 
1 and type 2 diabetes.  The methods state that type 2 diabetes mellitus, previously 
also known as Non-Insulin Dependent Diabetes Mellitus (NIDDM), was used to 
describe patients either  not on insulin treatment or those that did not start insulin 
within 2 years of diagnosis (Young et al.1993).   In 1993, when the study was 
published, these criteria were widely used, but, in 1999, WHO recognised they were 
no longer appropriate, as classification was based on patients’ treatment regime 
rather than pathogenesis and was, thus, open to misinterpretation.  WHO 
determined that type 1 diabetes should describe patients with autoimmune beta-cell 
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destruction and type 2 diabetes should be used for defects in insulin secretion, 
always with major insulin resistance. Young et al. (1993) classified subjects taking 
insulin treatment as type 1 diabetes. However, insulin can be required for type 2 
patients unable to achieve satisfactory glycaemic control through dietary and lifestyle 
changes.  Significantly, this would lead to an over-diagnosis of type 1 diabetes, 
which is likely to explain why 37% of the study population were classed as type 1 
diabetes, and 61% as type 2, in contrast to the 95% type 2 and 5% type 1 division 
observed globally when pathogenesis is used (WHO, 2013).  As a result of this 
design limitation, some of the data has to be disregarded, including the reported 
correlation between disease duration and DPN.  Nevertheless, the study population 
is likely to be a reasonable representation of the UK diabetes population overall.   
 
The European Diabetes Study (EURODIAB), by Tesfaye et al. (1996), recruited 3250 
type 1 diabetes patients randomly selected from diabetes clinic attendees in 16 
European countries.  In contrast to the study of Young et al. (1993), diagnosis was 
based on an HbA1c of 6.7%+/-1.9%.  Patients were assessed for a variety of 
microvascular complications associated with diabetes, including DPN.  Of the 3250 
patients assessed, 28% of these tested positive for DPN, which concurs with results 
from Young et al. (1993).   
 
The Diabetes Control and Complications Study (DCCT) (1993) was a controlled 
clinical trial conducted between 1989 and 1993. The study investigated the effect of 
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strict glycaemic control, through intensive treatment, on the development of 
complications associated with type 1 diabetes.  Subjects were randomised to receive 
either intensive or conventional therapy.  Intensive intervention consisted of insulin 
delivered by an external pump, or three or more insulin injections per day.  Frequent 
glucose monitoring was used to guide treatment regimes.  Conventional therapy 
involved 1-2 insulin injections per day.  The prevalence of DPN at 5 years was 
16.1% for those receiving intensive insulin therapy and 23% for subjects in the 
conventional treatment group.  The results are similar to those reported by Tesfaye 
et al. (1996) and Young et al. (1993).  The DCCT spawned a second observational 
study, Epidemiology of Diabetes Interventions and Complications (EDIC) (EDIC 
research group, 1999), which began in 1994 and followed the surviving 95% of 
members of the original cohort. Data collection has continued since 1994 to the 
present with 93-96% participant retention and this remains ongoing.  
 
The three studies above are the largest studies of diabetes-related complications to 
date and have yielded a vast amount of data.  However, the focus on type 1 diabetes 
makes it difficult to draw conclusions regarding the type 2 diabetes population. The 
prevalence of DPN in type 2 diabetes is unlikely to be as high as in type 1 diabetes 
due to essential differences in the underlying disease processes.  As an auto-
immune disorder, in the majority of cases, type 1 diabetes is diagnosed in early 
childhood, making it a lifelong disease and subsequently associated with more 
severe complications.  People with type 1 diabetes tend to be motivated to attend 
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appointments regularly, possibly due to the early exposure to medical management 
of their diabetes in the context of having a life-threatening disease.  As regular clinic 
attendees, adults with type 1 diabetes are likely to feature heavily in studies of 
diabetes that do not specify type of diabetes for inclusion.  Although the DCCT 
recruited subjects from age 13 to 39 years old, each group contained only 9% to 
19% of adolescents aged between 13 and 18 years old, constituting a small 
proportion of the study as a whole. It is highly unlikely the teenage cohort were non-
attendees to clinic appointments due to legal parental responsibility for their care. 
DPN prevalence may have also been influenced by recruitment sites chosen for the 
studies, as all were hospital-based clinics, and, therefore, more likely to include a 
higher proportion of patients at the severe end of the disease spectrum. Other 
patients would be treated by their General Practitioner.  
 
There have been no attempts to replicate these studies, possibly due to the 
extensive size and cost, but also because the data is widely acknowledged and 
accepted as reliable by clinicians and physicians, whilst international and national 
guidelines continue to include them to support clinical practice. Young and the DCCT 
study group’s (Young et al.,1993) results underpin NICE clinical guideline 10, 
Prevention and management of foot problems (2004), which has not been updated 
as of 2014, but is anticipated to be released into the public domain by July 2015.  
The EURODIAB study features heavily in the International Working Group on the 
Diabetic Foot (IWGDF) guidelines: Practical guidelines on the management and 
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prevention of the diabetic foot (Bakker, Apelqvist & Schaper, 2011).  New data is 
emerging from the rapidly expanding diabetic populations in India and Saudi Arabia, 
but given the significant differences in diet, lifestyle and obesity between these and 
Western European countries, they may not be applicable to Western European 
diabetes populations (International Diabetes Federation, 2013). 
 
1.3.2. Clinical Characteristics of Diabetic Peripheral Neuropathy 
 
 
Clinically, DPN describes a symmetrical alteration in sensorimotor function 
associated with metabolic and microvascular changes arising from chronic 
hyperglycaemia exposure.  There is a pattern of nerve length dependence, i.e., the 
smallest fibres are more susceptible initially (Sumner, Sheth, Griffin, Cornblath & 
Polydefkis, 2003), and thus the process begins in the toes.  DPN progresses 
proximally, thereby affecting nerve function in the foot, ankle and lower limb.  The 
clinical symptoms of DPN vary from patient to patient, but many share similar 
themes in their description of symptoms, such as burning sensations, which may be 
hot or cold, shooting pains, and electric shock-like sensations.  Other abnormal 
sensations reported by sufferers include skin crawling and tingling.  Hyper- and 
hypo-sensitivity can co-exist in patients with DPN, whereby pain is evoked by non-
nociceptive stimuli, or the response to nociceptive stimuli is sensitized to such a 
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degree that extreme pain ensues, yet other areas of the lower limb can be so 
desensitized that direct injury can go unnoticed (Tesfaye & Selvarajah, 2012).  
 
The symptoms of DPN correlate with small or large fibre involvement.  Abnormalities 
in the structure or function of thick, myelinated A-beta (Aβ) fibres may cause 
numbness, pins and needles, and tingling sensations.  Burning, ice-cold shooting 
pain, and stabbing pain sensations are related to A-gamma (AƔ) and unmyelinated 
c-fibre damage (Callaghan et al., 2012).  When patients do complain of symptoms, 
this usually correlates with an advanced neuropathy.  
 
Given the paradoxical symptoms and probable patient reluctance to report such 
inconsistencies, self-reporting may not be the most reliable source of diagnostic 
information.  Assessment and diagnosis of DPN can also be problematic due to wide 
variability in diagnostic criteria and selection of assessment tools (Dyck, Overland, 
Low, Litchy, Davies & O’Brien, 2010).  There have been attempts to address this 
issue by developing explicit guidance such as the Diagnostic Criteria and Definitions 
of DPN (Tesfaye, 2010), and structured, composite assessments, for example, the 
Neuropathy Impairment Score plus nerve conduction tests (Dyck, Davies, Litchy & 
O’Brien, 1997). The gold standard for assessing sensory nerve function is via nerve 
conduction studies which yield qualitative as well as quantitative data (Arimura et al., 
2013).  Needle electrodes are applied to cutaneous tissue above the target nerve 
and deliver electrical stimulation to generate a response in the form of an action 
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potential.  The velocity of the action potential is measured at a further point along the 
nerve.  Conduction velocity is indicative of the speed at which action potentials are 
propagated along large myelinated axons in the peripheral nerve (Kane & Oware, 
2012).  Nerve conduction studies have been utilised to characterise nerve function in 
patients with DPN and assist in diagnosis. Findings include decreased velocity, 
amplitude and/or latency in conduction of action potentials (Dyck et al., 2010). 
However, activity in c-fibres cannot be detected by this method due to the small 
diameter of fibres and slow conduction speed, making the action potentials almost 
impossible to detect.  In the early stages of peripheral neuropathy, the unmyelinated 
c-fibres are the first group of nerves affected by diabetes and a means of 
determining their integrity could assist in early diagnosis of DPN.  Epidermal skin 
biopsy, using a 3-4 mm punch and immunochemical staining, has been used to 
highlight c-fibres that penetrate the epidermis.  Morphological analysis of stains 
provided data on nerve structure, including features characteristic of DPN. Lauria, 
DeVigili (2007) and Arimura et al. (2013) utilised skin biopsies to identify intra-
epidermal nerve fibres through a fluorescent confocal scanning laser microscope.  
Nerve fibre density was then quantified by computerised image analysis.  Changes 
in fibre density correlated with the degree of reduction in sensory action potentials 
recorded by Nerve Conduction Studies (NCS).   
 
Both these techniques for small nerve fibre assessment could represent a means of 
identifying DPN before larger fibres have been affected.  Anecdotal evidence from 
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studies carried out in Manchester identified that patients felt generally reluctant to 
undergo skin biopsy, with many feeling it is too invasive.  Other factors that may 
deter biopsy usage include increased expense of materials and processing, delays in 
processing times for samples, and a high number of patients accessing diabetes 
clinics.  Currently, NCS is used to assist in the diagnosis and management of DPN 
associated with severe pain sensations, whilst other tools, such as skin biopsy, are 
providing valuable data to increase the academic knowledge-base.  However, within 
the clinical environment, assessment tools need to readily assimilate into the running 
of busy, multi-disciplinary diabetes clinics and, perhaps, most importantly, be 
acceptable to patients.  Corneal, Confocal Microscopy (CCM) is a non-invasive 
instrumental assessment for the diagnosis of peripheral neuropathy which can detect 
even small fibre changes.  It involves laser scanning and image capture of the 
cornea on the hand-dominant side which is processed by nerve analysis software to 
provide a measure of corneal fibre length in mm/mm2, corneal nerve branch density 
(number/mm2), and nerve fibre tortuosity measured in tortuosity units (Edwards et 
al., 2012).  In DPN subjects, corneal fibre length and density are reduced and these 
changes are evident even in newly diagnosed patients (Ziegler et al., 2014).  CCM 
also correlates with the severity of intra-epidermal fibre loss (Quattrini et al., 2007), 
making it a viable option for investigating early peripheral neuropathy.   
 
National and international guidelines on management of diabetic foot complications 
(2012; American Diabetes Association, [ADA], 2014; Infectious Diseases Society of 
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America, [IDSA], 2012; International Working Group on the Diabetic Foot, [IWGDF]; 
CG10, [NICE] 2004;) recommend the structure and content of assessment for 
diabetic peripheral neuropathy to promote a consistent evidence-based approach.  
Assessment is similar to lower limb examination during a standard neurological 
medical examination and follows the anatomical and physiological pathways of the 
peripheral nervous system (Wills, 2012).  Patients are tested at specific points along 
the neurological pathway, and the response elicited provides evidence to support or 
exclude a specific diagnosis.  Assessment for DPN is focused on the lower limb and 
afferent pathways for sensing pain and pressure.  The corresponding neuronal 
receptors are the small, unmyelinated c-fibres, which detect temperature difference 
(Schepers & Ringkamp , 2010) rather than hot versus cold.  An inability to identify a 
change in temperature during testing is likely to indicate impaired nerve function.  
Patency of small fibre function can also be elicited through assessment of pinprick 
sensation.  Detection of small fibre changes in the initial asymptomatic stages of 
DPN cannot be achieved clinically. However, nerve conduction studies may also fail 
to identify altered function.  The integrity of large nerve fibres can be determined 
through vibration perception tests and ankle reflex testing (McGlone, 2010).  Inability 
to determine pressure sensation in one or more sites on the foot is indicative of large 
fibre involvement.   
 
To summarise the sections above: the processes involved in the destruction of 
sensory nerve fibres in the foot commence due to excess blood glucose.  Chronic 
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hyperglycaemia disrupts mitochondrial function, increases reactive oxygen species, 
promotes the formation of advanced glycation end products, and alters gene 
expression, culminating in direct damage to nerve fibres and cessation of axon 
regeneration.  This results in altered sensation or loss of protective sensation, the 
implication of which is an increased risk of developing an associated foot ulcer.  The 
next section will briefly explore the management of diabetic foot ulcers and the 
financial cost to complete the clinical pathway from diabetic peripheral neuropathy.   
 
1.3.3. Diabetic Peripheral Neuropathy and Lower Limb Complications 
  
DPN increases the risk of foot ulceration through the loss of protective sensation, in 
the absence of which patients become vulnerable to trauma (Reiber et al., 1999). 
Soft tissue trauma is a major causative factor in the development of diabetic foot 
ulceration in patients with DPN (Boulton et al., 1998). Falls are associated with soft 
tissue trauma and, unlike their healthy counterparts, people with DPN are less likely 
to notice cuts, grazes, puncture wounds etc. in the lower extremities due to the loss 
of protective sensation. If DPN increases the risk of falls which often result in soft 
tissue trauma, an increased risk of foot ulceration is highly likely.  
In the UK, the annual incidence and prevalence of foot ulceration in patients with 
diabetes was calculated at 2.2% and 1.7% respectively in 2002 (Abbott et al., 2002). 
According to Kerr (2012), data on foot ulcer incidence is not collected in the UK and 
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so more recent data is not available.  Scotland does extract data from GP databases 
and identified that 2.5% of the diagnosed diabetes population had an active foot 
ulcer at the beginning of December 2010 (Leese et al., 2011).  Diabetic foot disease 
is associated with a risk 23 times that of a person without diabetes (Holman, Young 
& Jeffcoate, 2012).  A study by theEuropean Study Group on Diabetes and the 
Lower Extremity (Eurodiale) (Prompers et al. 2008)followed 1232 diabetes patients 
with a foot ulcer, and found that 5% of these went on to require major amputation 
(above or below knee) during the 12 month follow-up period (Prompers et al., 2008), 
Krishnan, Nash, Baker, Fowler & Raymen (2008) reported an amputation rate of 
16.5 per 10,000 people with diabetes in the UK.   
Estimates of costs of treating Diabetic Foot Ulcers (DFUs) have demonstrated 
inconsistencies in calculations between countries, and within different regions of the 
same country.  Prompers (2008) used data from the Eurodiale study to calculate an 
average cost of €10,000 for treating a non-infected ulcer.  An infected ulcer with 
concurrent peripheral arterial disease was calculated to cost €17,000 to treat.  All 
centres involved (14 in 10 countries) followed the same assessment and 
management protocols as detailed in clinical guidelines from the International 
Working Group on the Diabetic Foot.  Despite this, there were wide variations in 
treatments provided between countries and centres. For example, use of casting 
varied from 0% to 68% despite clinical guidelines recommending it as the most 
efficacious treatment for plantar ulcers.  The authors reported similar variation in 
imaging techniques employed for ulcers with additional ischaemia. Resource 
  
25 
 
allocation by Clinical Commissioning Groups (CCGs) and health care trusts can 
have a profound effect on DFU management due to workforce numbers, staff skill 
mix, and accessibility of modern, effective treatments. There is an associated risk 
that out-dated treatments may be retained by healthcare providers due to the high 
costs associated with obtaining and implementing more advanced alternatives.  
Cavanagh et al. (2012) examined costs of treating a hypothetical DFU with severe 
infection which was unresponsive to treatment.  The pre-defined outcome was below 
knee amputation.  Estimated costs of treating such an ulcer incorporated several 
failed antibiotic regimens, hospital admission for intravenous antibiotics, 
management of sepsis, attempted limb salvage and, finally, a major limb amputation 
with associated aftercare.  Total costs amounted to $188,645 based on USA 
insurance billing receipts.  Similar calculations have not been forthcoming using UK 
data, which is likely due to differences in the nature of data collected.  USA 
healthcare bills capture details of treatments to ensure every intervention is paid for.  
The focus of UK data collection for the NHS is driven by service planning and 
improvement - prevalence data for specific conditions is compiled in the Public 
Health Observatories prevalence model, for example.  The Quality Outcomes 
Framework and reference costs provided to Clinical Commissioning Groups also 
provide data, but often this is somewhat generic.   
There are few databases that capture diabetic foot ulceration as a distinct entity. 
Diabetes UK analysed data from the Public Health Observatory and National 
Diabetes In-patient Audit to produce “The Cost of Diabetes” report (Diabetes UK, 
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2014), which explored the cost of specific diabetes-related complications to the NHS. 
Diabetic foot conditions were grouped with amputations, and, together, they cost the 
NHS £300 million in 2010/2011.  Amputations are expensive due to surgical and in-
patient bed use, but financial models of total treatment costs for DFU management 
versus amputation management have demonstrated that complex DFUs are 
substantially more expensive than amputations (Kerr, 2012). 
 
Treatment of the majority of uncomplicated diabetic foot ulcers consists of 
debridement of non-viable tissues and an appropriate dressing tailored to the 
requirements of the individual wound, followed by a degree of offloading (IWGDF, 
2011).  This is, perhaps, the key to healing diabetes-related foot ulcers, and 
outcomes are often positive when offloading advice is followed.  Total contact casts 
are the gold standard for offloading, based on evidence of a 90% success rate for 
ulcer healing, as supported by several randomised controlled trials (Armstrong et al., 
2001; Armstrong, Lavery, Kimbriel, Nixon & Boulton, 2003; Armstrong, Lavery, Wu & 
Boulton, 2005; Katz et al., 2005; Piagessi et al., 2007).  Other offloading devices, 
such as a removable cast walker or adapted footwear, have not demonstrated the 
same degree of success.  The reason for the variation in healing rates was revealed 
in a study by Armstrong et al. (2003) who covertly recorded the activity levels of 
patients whilst they wore a prescribed removable cast walker as treatment for 
neuropathic foot ulcers.  Findings demonstrated that patients only wore the 
offloading device for 72% of their total daily activity.  Persistence with weight bearing 
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on a diabetic neuropathic foot ulcer will undoubtedly prevent healing and, in most 
cases, promotes further deterioration.  A total contact cast, on the other hand, 
provides the foot with an alternative means of protection in the absence of normal 
sensation.  Total contact casting is contraindicated for use with ischaemic ulcers, 
and osteomyelitis, due to the risk of additional complications such as ulcer 
deterioration due to poor arterial inflow and the difficulty in prompt detection with a 
non removable cast (Walker, Helm & Pulliam, 1987). 
 
1.3.4 Prevention of Diabetes-Related Foot Complications 
 
The ideal intervention for diabetic lower limb complications should be prevention. 
One of the key messages in the National Institute for Health and Care Excellence 
(NICE) guidelines on Type 2 diabetes (NICE, 2008) is self-management, whereby 
patients are educated regarding specific aspects of their condition, thus empowering 
them to share in the responsibility for their health through self-monitoring.  The aim is 
to achieve an increased awareness, facilitating improved compliance with 
professional advice, which should ultimately lead to a reduction in complications. 
Education programmes, as recommended in the National Service Framework (NSF) 
for Diabetes (Department of Health, 2001) and NICE (2008), have attempted to 
achieve patient self-management through education sessions from the diabetes 
multi-disciplinary team.  The DESMOND programme (Diabetes Education and Self-
Management for Ongoing and Newly Diagnosed) offers education sessions for 
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patients as part of a highly structured training programme.  In 2008, the efficacy of 
the DESMOND programme was investigated via a cluster randomised controlled trial 
in England and Scotland (Davies et al., 2008). The intervention group (receiving the 
DESMOND programme) consisted of 437 newly diagnosed type 2 diabetes subjects, 
and the control group consisted of 387 newly diagnosed type 2 diabetes subjects. 
Outcomes included a 1% improvement in HbA1c, weight and psychosocial beliefs 
relating to their diagnosis. Results were adjusted for a clustering effect, but failed to 
demonstrate a statistically significant change at the 5% level for changes in HbA1c 
(p=0.52).  However, a significant improvement in weight (p=0.02) was identified at 
four-month and twelve-month follow-up, with DESMOND participants losing a mean 
of 2.98 kg versus the control group weight loss of 1.86 kg.  Improved depression 
scores (p=0.03) of intervention group participants were also observed at twelve-
month follow up.  The positive outcomes were not maintained after study completion, 
and a three-year follow-up period failed to show any differences in biomedical 
outcomes between the control and intervention groups (Khunti et al., 2012).   
 
To date, the only intervention proven to halt or reduce diabetes-related complications 
is strict glycaemic control, as reported in The Diabetes Control and Complications 
Trial (DCCT, 1993).  No other treatment has demonstrated such a profound impact 
on clinical diabetic complications, and, as a result, glycaemic control remains at the 
forefront of diabetes management (Inzucchiet al., 2015).  The DCCT recruited 1441 
subjects in a multi-centre, randomised controlled trial to investigate the effects of an 
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intensive insulin regime and stringent blood glucose monitoring on diabetes-related 
complications.  The intensive regime was defined as pre-prandial ranges of 3.9 – 6.7 
mmol/l and post-prandial of less than 10 mmol/l, plus 3 injections per day or the use 
of an insulin pump, combined with regular glucose monitoring.  Subjects on the 
intensive regime demonstrated a 76% reduction in the onset of retinopathy (p=0.04), 
a 39% reduction in nephropathy (p=0.02), and a 60% reduction in neuropathy over 
6.5 years (p=0.006). Furthermore, glycaemic control over the duration of the study 
was significantly better in the intensive group versus the conventional cohort 
(8.6+1.7SD (standard deviation) versus 12.8+3.1SD mmol/l, p<0.001).   
 
Diabetes-related complications can be prevented and even reversed, but, in practice, 
DPN remains a major cause of diabetic foot ulceration.  Treatment of DFUs is based 
on a sound understanding of the physiological changes that occur in the lower limb 
as a result of diabetes.  However, prevention is always more preferable than 
attempting to heal an acute or chronic ulcer.  Targeting prevention through daily self-
inspection of feet for signs of injury is just one example of trying to reduce risk. 
Falling in the home or outside, and an associated soft tissue injury could be the 
catalyst for foot ulceration. Ulcers can have a devastating impact on a patient’s 
quality of life and psychological profile, not to mention the economic considerations 
to the healthcare provider.  
 
  
30 
 
To summarise, the previous sections have explored diabetes physiology and the 
development of DPN, followed by the clinical consequences of DPN, including DFUs. 
However, the peripheral nerves of the lower limb are not restricted to a purely 
protective function; they also play a huge role in sensory feedback during 
ambulation.  The next sections will present the physiological evidence for the role of 
the peripheral nerves during gait, and the rationale for proposing DPN disturbing 
gait.  
 
1.4 Normal and Ageing Gait 
 
The lower limb provides body weight support and assists in mainlining equilibrium, 
but its principal role is locomotion.  Peripheral neuropathy and gait are linked by 
shared physiology.  Normal human locomotion involves a complex interplay between 
the peripheral and central nervous systems to enable movement of the human body 
through its centre of gravity.  Simultaneously, information from the external 
environment is collected, processed and assimilated, so that any necessary 
adaptations can be initiated as quickly and efficiently as possible.  The foot and 
ankle possess an array of sensory receptors that contribute to the processes 
involved in maintaining safe, effective locomotion.  Cutaneous receptors are involved 
in the detection and transmission of information received from the external 
environment.  Meisseners corpuscles are located in the dermis of the foot and 
consist of encapsulated nerve endings.  These receptors generate rapidly adapting 
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action potentials to convey information about the “dynamic” low frequency vibration 
(levels less than 100Hz) (Brodal, 2004).   
 
Pacinian corpuscles are another type of encapsulated afferent receptor, and are 
located at the dermis-subcutaneous border. They are rapidly adapting in the 
generation of action potentials similar to Meisseners corpuscles, but, in contrast, 
have a lower response threshold, thus detecting high frequency vibration (above 
100Hz) (McGlone, 2010).  In the epithelial tissues of the foot, Merkels discs convey 
touch sensation, specifically that of form and surface judgement.  Ruffini corpuscles 
are present in the dermis, parallel to the skin surface, but can also be found in 
ligament and tendon. They may detect position sense. Temperature sensation is 
conveyed by receptors specifically designated for cold or hot stimuli using A-delta (δ) 
fibres and c-fibres (Schepers & Ringkamp, 2010).  
 
Beyond the foot, moving to the ankle joint and lower limb, peripheral receptors are 
embedded in the joint capsules and connective tissues receiving information via 
small afferents from group III and group IV fibres.  Group III are very thinly 
myelinated and Group IV fibres are unmyelinated (Gilman & Cooper, 2002).  The 
receptors within the joint capsule and connective tissue are essentially free nerve 
endings interspersed with encapsulated endings which are similar in structure and 
function to the Pacinian and Ruffini endings of the dermis.  Spindles are housed 
within a capsule containing intrafusal fibres and sensory dendrites from the muscle 
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spindle afferent.  The capsules are interspersed throughout the body of the muscle 
so that alterations in muscle length are accompanied by a corresponding spindle 
stretch (Kumar & Clarke, 2002). This information is communicated to the spinal cord 
via grade Ia and grade II afferent fibres.  Type Ia fibres are heavily myelinated, and, 
as such, exhibit rapid conduction velocities necessary to relay information about 
muscle stretch (Proske, 2005).  Group II fibres are myelinated, but not to the same 
degree as Ia fibres, and their slower conduction velocity means they are suited to 
conveying information on static muscle position.  
 
Receptors in the Golgi tendon organs are responsible for monitoring and signalling 
forces, whilst receptors within the muscle spindles relay and receive signals 
regarding alteration in muscle length and velocity (De Carlos & Borrell, 2007). 
 
During limb loading, a number of receptors are activated, including the pressure 
receptors in the foot, Golgi tendon organs within the ankle, and spindles within 
stretched muscles.  Further information is transmitted from the vestibular system.  
Force is sensed by the Golgi tendon organs, and this in turn modulates muscle 
activity in the leg (Wakeling, von Tscharner, Nigg & Stergiou, 2001).  Position of the 
body and limbs, and subsequent movement is sensed by the muscle spindles. 
Sensory integration of the information occurs in the thalamus.  Neurological control 
of locomotion is complex, and, in order to function effectively, the components need 
to be intact.  It follows that a disturbance in the core parts of the system is likely to 
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result in a degree of malfunction.  Peripheral neuropathy increases the vulnerability 
of the lower limb to trauma and ulceration.  It is logical to assume that peripheral 
neuropathy also increases the possibility of gait disturbance. 
 
1.4.1 The Gait Cycle in Level Walking  
 
The normal gait cycle broadly consists of two phases, stance and swing, which are 
sub-divided to capture the specific constituents of each phase.  The stance phase 
consists of initial contact, a loading response, mid-stance, and terminal stance, plus 
the first half of pre-swing.  During level walking, heel strike represents initial contact 
at which point the toes of the contralateral limb are still in contact with the ground 
pending swing. This creates a position of double limb support, which provides 
maximum stability and shock absorption into the loading response. At the same time, 
knee flexion is achieved, controlled by the quadriceps, and hip extension begins as 
the trunk moves forward, regulated by eccentric contraction by gluteus maximus and 
the hamstrings (Anderson & Pandy, 2003).  Plantar-flexion of the ankle occurs with 
eccentric contraction of anterior tibialis, and the lesser dorsiflexors produce a 
smooth, controlled descent of the foot.  Mid-stance is marked by the plantar surface 
of the foot having achieved full contact with the ground.  The heel will be 
approximately three degrees inverted in relation to the supporting surface in order to 
lock the sub-talar and mid-tarsal joints (Root et al., 1977).  Once the medial and 
lateral columns of the foot make contact with the ground, plantar-flexion allows the 
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mid and anterior foot to follow, having become compressed and fixed to provide 
maximum stability (Lafortune, Cavangh, Sommer & Kalenak, 1994).  Muscles active 
during this phase include gluteus medius, hamstrings, quadriceps, and pretibial 
muscles. Lengthening of the quadriceps during knee flexion provides shock 
absorption for the foot, whilst triceps surae, tibialis anterior and the plantar fascial 
band promote a smooth, controlled foot descent.   
 
During mid-stance, body weight is supported by a single limb, causing the 
longitudinal arch of the foot to flatten in order to increase stability.  Additional support 
from the plantar fascial band and full plantar contact with the ground provide 
maximum stabilisation.  Forefoot loading and supination of the sub-talar joint move 
the sub-talar joint into a neutral position, whilst the mid-tarsal joint locks.  At the point 
of maximum forefoot loading, the “windlass mechanism” (Hicks, 1954) assists with 
“toe off”, and subsequent limb propulsion.  The tightening of the plantar fascial band 
was likened to a windlass by Hicks, mimicking a rope-and-pulley system to pull the 
calcaneous forwards, simultaneously raising the medial longitudinal arch.  This 
promotes elevation of the heel and compression of the foot joints. Heel elevation 
signifies the start of terminal stance, during which body weight moves forward over 
the supporting foot and becomes concentrated at the metatarsal heads.  The 
metatarsal and phalanges spread to give additional support.  Throughout mid and 
terminal stance, stability is maintained by the soleus and gastrocnemius (Leardini et 
al., 2007). 
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The swing phase consists of a portion of pre-swing, initial swing, mid swing and 
terminal swing.  Pre-swing begins when the foot on the contralateral limb enters 
initial contact to create a second period of double support.  Body weight is 
transferred to the other limb, whilst the pre-swing limb flexes at the knee and hip to 
support the trunk and limb. During initial swing, “toe off” occurs as described above. 
Ankle dorsiflexion and contraction of the lower limb muscles assist in achieving 
ground clearance for the foot.  As advancement of the limb continues, the tibia 
assumes a vertical position, and ankle dorsiflexion prevents the forefoot from 
dragging on the surface below (Mills & Barrett, 2001).  The knee is extended in 
preparation for heel strike, and the foot assumes a neutral position.  The point at 
which the same limb achieves heel strike for the second time constitutes the end of 
one gait cycle.  
 
1.4.2 The Gait Cycle During Stair Negotiation 
 
The gait cycle for stair ascent and descent differs substantially from level walking 
(McFadyn & Winter, 1988).  Some of the differences reported include greater 
maximum angles for hip and knee flexion and ankle plantar/dorsiflexion during the 
swing phase (Lark, Buckley, Jones, & Sargeant, 2004).  Mean maximum angles for 
ascent show a greater amount of knee and hip flexion in comparison to descent 
(Andriacchi et al., 1980).  Ankle joint ascent requires less dorsiflexion and plantar 
flexion than during descent (Protopapadaki et al., 2007).  Reiner, Rabuffetti and 
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Frigo (2002) found stair negotiation required approximately 12-20 more flexion at 
the knee, and 15-20 more hip flexion than level walking. Temporo-spatial gait 
parameters also differ for stairs versus level walking, with gait during stair negotiation 
being associated with lower cadence, shorter stance, and longer cycle duration in 
healthy adults (Nadeau, McFadyen & Malouin, 2003).   
 
In addition to the different characteristics of gait for stair negotiation versus level 
walking, the structure of the gait cycle is altered.  The first stage is weight 
acceptance, proceeding into the pull-up phase, followed by forward continuance, foot 
clearance and foot placement (McFadyn & Winter, 1988).  During weight 
acceptance, initial foot contact with the ground is made by the forefoot whilst the hips 
and knees move into flexion with the ankle on the leading limb slightly dorsiflexed.  
Double support provides assistance with stability and weight bearing at this point.   
 
The pull-up phase of stair ascent requires significant power generation from the 
ankle, knee and hip, primarily in the extensor muscle group, to lift the swing limb 
from one step to the next.  The greatest muscle activity is generated by the knee 
during this phase, but the ankle assists with vertical lift.  During weight acceptance, 
the knee and hip provide support for full body weight in single support, whilst also 
moving vertically.  This is achieved by the extensor muscles of the knee and ankle.  
The hip flexors play a dominant role during swing for the limb to progress anteriorally 
before the extensors open the knee, and dorsiflexors lift the toe in preparation for 
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foot clearance, with hip extensors assisting in final foot placement (Graci, Elliott & 
Buckley, 2009).   
 
The phases of stair descent begin with weight acceptance by limb loading in the 
direction of gravity, and thus requiring greater control from the muscles.  During 
weight acceptance, the lateral border of the foot makes contact with the step below, 
and ankle stability is maintained by the plantar flexors as body weight shifts forwards 
and down.  By the time “toe-off” occurs in the contralateral limb, the body will have 
dropped to the level of the stair below, which requires significant dorsiflexion at the 
ankle.  The travelling leg is pulled through by the hip flexors with only slight flexion 
needed at the knee.  Between leg pull-through and final foot placement, the hip and 
knee move into extension, and the ankle joint is plantar flexed in preparation for 
contacting the step below.  The process of descending from one step to the next 
(step over step) is described by McFadyn and Williams (1988) as being a process of 
“controlled lowering”, whereby eccentric muscle activity dominates to maintain 
posture and stability.  
 
1.4.3 Alterations in Gait  
 
Changes in the gait cycle are visibly apparent in neurological disease states, for 
example, the shuffling gait associated with Parkinson’s disease (Plotnik, Giladi & 
Hausdorff, 2007), the asymmetrical hemiparetic limb of cerebrovascular accident 
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(Patterson et al., 2008), and the dyskinetic, ataxic gait of Huntington’s disease 
(Hausdorf, Cudcowicz, Firtion, Wei & Goldberger, 1998).  Gait alterations also occur 
in healthy, elderly individuals as a result of the normal ageing process, but the 
changes are not instantly visible to the naked eye as they are with neurological 
disorders. Specific characteristics associated with elderly gait have been established 
via gait analysis, and comparisons have been made with the gait of younger people.  
Ferrandez, Pailhous and Durup (1990) studied gait in 67 adults aged between 60-92 
years, labelled in the study as the elderly group, plus 9 males with a mean age of 25 
years as controls.  Data were collected for temporo-spatial gait parameters whilst 
subjects walked the width of a six-metre room.  Subjects from the elderly group 
walked at a lower velocity and used a shorter stride length than the younger group 
(p<0.001) in the walking task.  This could not have been an intentional modification, 
as the overall cycle duration did not change and these findings have been reflected 
in later studies (Grabiner, Biswas & Grabiner, 2001). 
 
Maki (1997), like Ferrandez (1990), reported reduced gait speed in a study of 72 
healthy adults (mean age 82 years) during level walking.  A follow-up interview 
twelve months later was used to determine if patients had experienced falls in that 
time. Results indicated that parameters such as gait speed and time spent in double 
support were predictive of fear of falling, but not actual falling.  The best independent 
predictor of falling was stride-to-stride variability in speed, which Maki proposed 
could be useful in predicting falls.  
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Other age-related alterations to gait have been observed when the stability of 
walking is challenged by an unexpected physical disruption during walking.  Studies 
have utilised a variety of methods to achieve this effect, including pulling at the 
ankle, and pop-up pieces of metal in the floor.  These techniques are termed, in the 
field of gait analysis, gait perturbations.  Eng, Winter and Patia (1994) established 
that healthy, young (19-29 year old) subjects responded to perturbations presented 
early in the swing phase by either elevating or lowering the perturbed leg to maintain 
stability.  A combination of both strategies was demonstrated by Cordero, Koopman 
and van der Helm (2003), whereby elevation of the perturbed leg is attempted but 
abandoned, and the leg is lowered at a shorter step length (Cordero et al., 2003). 
Krasovsky et al. (2012) reported a different response to unexpected perturbations in 
older subjects (mean age 68 years) characterised by a lowering strategy, i.e., the 
perturbed leg was lowered to the ground in combination with a reduction in step 
length and step time.  Utilising this gait strategy results in a prolonged Centre of 
Mass (COM) displacement, thereby producing a period of destabilisation (Krasovsky, 
2012).  The reasons why older subjects utilise a gait strategy that is likely to increase 
the risk of falling is unclear.  Older people take longer to respond to perturbations 
and require more time to recover central stability in comparison to younger people 
(Krasovsky, Lamontagne, Feldman & Levin, 2014).   
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Responses to perturbations in older people demonstrate increased vulnerability to 
destabilisation due to prolonged recovery time after perturbation and prolonged COM 
displacement.  The method of sabotaging a subject’s stability on a treadmill is the 
closest investigators can get to assessing changes in gait when stability is 
challenged.  The aim is to work towards understanding the underlying gait changes 
that increase the risk of falls in older adults.  However, applying these findings to the 
elderly population as a whole is difficult due to perturbations presented at different 
points in the gait cycle across different studies which could influence the gait 
response.  Furthermore, there is the possibility of a priming effect if subjects are 
exposed to multiple perturbations: if gait disturbances are anticipated, then the 
results are not representative of a normal gait response.  However, Hernandez, 
Slider and Herderscheit (2009) addressed some of these issues by demonstrating 
that healthy, elderly subjects (mean age 72 years) controlled COM differently during 
level walking than young subjects, and also displayed reduced medio-lateral COM 
acceleration, thereby increasing lateral instability.   
 
Walking is influenced by many health-related factors such as orthopaedic health, 
vascular health, cardiac health, Body Mass Index (BMI), muscle strength, joint range 
of motion and joint strength, cognition, motivation, mood, and fear (Maki, 1997).  It is 
difficult to separate these components and determine which has the greatest 
influence on gait.  Nevertheless, clarification of whether diabetes changes gait would 
be beneficial in the battle to reduce DFUs. 
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1.4.4 Gait Changes Associated with Falls 
 
The literature demonstrates that gait patterns alter with ageing, but the nature of the 
relationship with falls is less clear, largely due to practical difficulties associated with 
obtaining data about an event that is not predictable and, therefore, cannot be 
observed.  As a result, data regarding fall frequency either has to be collected 
retrospectively using medical records or through questionnaires.  This relies heavily 
on memory, recall and the honesty of the individual to report if and how a fall 
occurred.  The admission of a fall carries many negative connotations for elderly 
people, and it is possible that people avoid reporting a fall when it occurs.  The 
attitudes and belief systems elderly people hold about falls was investigated in a 
qualitative study by Yardley, Donavan-Hall, Francis & Todd (2006).  Data were 
generated in focus groups consisting of 3-6 people with a facilitator to assist in 
promoting discussion.  Follow-up one-to-one sessions also took place at participants’ 
houses in case of information being withheld due to confidentiality concerns.  Sixty-
six healthy, independently living people aged between 61 and 94 years of age took 
part in the study.  The results revealed some interesting attitudes, with falls being 
associated with loss of independence and loss of control over the environment, and 
falls were seen as an indicator of having become “old”.  It is necessary, therefore, to 
consider that the answers of older people, when questioned about falls history, may 
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be coloured by their beliefs about what a fall represents, rather than representing an 
accurate reflection of falls frequency.   
 
The influence of emotional state on falls risk was reported by Maki et al. (1997), who 
demonstrated that changes in temporo-spatial gait parameters, such as decreased 
stride length and speed, together with prolonged double support time, were 
independently associated with fear of falling rather than falling per se.  In calculating 
falls frequencies from information obtained via questions and answers, the 
influences of individuals’ belief systems needs to be considered as a possible 
confounder.  An alternative to obtaining temporo-spatial data is the assessment of 
gait variability.  Gabell et al. (1984) proposed that the gait characteristics of healthy 
adults were subject to small fluctuations between strides, and the magnitude of the 
fluctuations could be used to determine the degree of falls risk.  Support for this 
came from Maki (1997), who reported increased stride-to-stride variability among 
subjects despite all other gait parameters being normal.  Hausdorff et al. (2001) 
explored the possibility of gait variability as a predictor of falls in a prospective one-
year study of 52 healthy elderly (over 70 years of age) subjects.  Results indicated 
approximately 40% of the subjects suffered a fall in the 12-month follow-up period. 
Those that fell demonstrated greater stride-to-stride fluctuations than non-fallers 
(p<0.05), including increased stride time variability (p=0.04), and swing time 
variability (p=0.02).  Greater variability in these parameters was predictive of falling 
(increased stride time variability, OR ((odds ratio) = 5.3, p=0.04), (increased swing 
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time variability, OR=2.2, p=0.02)).  The findings, however, need consideration in the 
context of the methods used for collecting data on falls frequency. Subjects were 
interviewed weekly, by telephone, and, as such, objective data or evidence of a fall is 
lacking, opening up the possibility of falls being under-reported due to 
embarrassment or fear of social consequences.  Other possible confounders were 
minimised through detailed assessments of cognition using the mini-mental status 
examination (Folstein, Folstein & McHugh, 1975), the geriatric depression scale 
(Yesavage, Lum, Heersema, Adey & Rose, 1982), and functional assessment of 
balance (Berg & Norman, 1996), all of which disturb gait.   
 
Although the methods employed to obtain information on falls occurrence in studies 
of older people is limited to the individuals’ subjective report, the strength of 
Hausdorff’s study lies with the extensive efforts to reduce confounders to a minimum.  
This is not seen in other studies investigating gait and falls.   
 
Variability in temporo-spatial gait parameters, such as double support time, step 
length, and step time, was demonstrated by Callisaya et al. (2010).  Their sample 
size was 412, and ages of participants ranged from 60 to 86 years old.  Gait analysis 
demonstrated falls risk was greater in subjects with increased double support time 
(variability (p=0.01), and increased step length variability (p=0.02)).  Furthermore, 
increasing age was associated with greater variability across all gait measures.  This 
provides data that supports the findings of Hausdorff (2001), but there are two 
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factors that need to be addressed: firstly, a proportion of the subjects recruited had 
co-morbidities that would influence gait parameters, for example, 12.5% had 
diabetes, 7.8% had cerebrovascular accident, and 44.3% had arthritis. Secondly, 
subjects were contacted about previous falls after a full twelve months had elapsed, 
with no reference made by the authors to any interim reminders or liaison to prompt 
subjects’ ongoing monitoring of falls.  There is no evidence that the self-reported falls 
are accurate, but there is evidence to suggest that older people under-report falls 
(Mackenzie et al., 2006). However, the falls incidence in the study may be over-
estimated due to the presence of co-morbidities that significantly increase the risk of 
falling.  It is difficult, therefore, to draw accurate conclusions about the relationship 
between gait variability and falls from this study.   
 
Consensus regarding specific gait variables most predictive for falls has not been 
achieved to date, and investigation into the value of standard temporo-spatial 
parameters versus gait variability is ongoing.  The Hausdorff study (2001) perhaps 
comes closest to achieving validity due to the depth and breadth of baseline data 
obtained in order to reduce as much as possible the confounding variables inherent 
in falls research.   
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1.4.5 Summary  
 
The introductory chapter has presented the anatomy and physiology underlying 
DPN, falls, and human gait thus illustrating the underlying links between the three. 
DPN and gait are connected through shared anatomy of the lower limb and also 
through shared neurology. DPN impairs sensory function whilst gait relies on intact 
sensory function for feedback to enable continual refinements and adjustments 
during walking. It is logical, therefore, to question whether the impairments in 
neurological function associated with DPN might also have a negative effect on gait 
and, if so, would this place people with DPN at risk for falling? Should this be the 
case, the implications for patients and service providers would be far-reaching. Gait 
disturbances inevitably increase the risk for falls, which are associated with high 
levels of mortality and morbidity. If DPN disturbs gait to an extent that this risk is 
increased, it may also be necessary to review current Podiatry practice in diabetes to 
determine if there is an unmet need.  
In considering a possible relationship between DPN, gait and falls, a number of 
questions emerge: firstly is there any evidence in the current knowledge base that 
illustrates DPN gait characteristics that differ significantly from healthy gait? Is there 
general agreement between authors regarding the nature of gait alterations for 
patients with DPN? What, specifically, links DPN gait with falls?  The answers to 
these questions have been generated through the literature search and 
accompanying search results.  
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1.5 Literature Review  
 
Search Strategy 
 
The literature search was initiated using a PICO framework (Population, 
Intervention,Contol, Outcome) to guide the search strategy. However, the focus of 
the current work was not related to an intervention but rather the effect of DPN on 
joint range of motion. As a result a PECO framework (Population, Exposure, 
Control,Outcome) was used to represent the key areas of interest (Richardson, 
Wilson, Nishikawa & Hayward, 1995).  The study population (P) was concerned with 
people with DM, who were exposed (E) to DPN. Participants included controls (C) 
with DM but no PN and healthy, non-diabetic people. Outcomes (O) of interest were 
alterations in kinematic gait parameters. 
 
MEDLINE, CINAHL, Embase, and Pubmed databases were searched for the 
timeframe 1990 to June 2013 using MeSH terms and text word searches.  Terms 
used were: diabetes mellitus, gait, gait variability, gait kinematics, gait kinetics, and 
peripheral neuropathy. Only English articles were included. Further articles were 
generated through hand searches of reference sections in articles generated from 
the electronic databases.   
416 papers were generated from the search, of which 109 were excluded by title 
alone as being not relevant, leaving 307 abstracts. 40 exclusions were due to a 
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range of lower limb amputations or deformities.  A total of 146 papers either lacked 
any gait analysis data, or only collected kinetic data, also resulting in exclusion. 17 
studies were either single case reports or reviews of collected works, thus providing 
no new data. Studies that did not have a DPN group of subjects amounted to 15, and 
a further 15 studies included peripheral neuropathy of multiple neurological causes. 
Examination of full texts allowed the exclusion of 53 studies due to no comparison 
group with the DPN/DM groups. 5 studies were excluded due to poor methodology, 
leaving 9 for the literature review. 
An additional 7 studies were included, having been obtained as cross-references 
appearing in the 9 studies identified by the literature search.  
 
1.5.1 Gait Alterations Associated with Diabetic Peripheral Neuropathy 
 
An association between diabetic peripheral neuropathy and an increased risk for falls 
was initially identified by Cavanagh, Derr, Ulbrecht, Maser and Orchard (1992). In a 
study of type 1 diabetes patients with and without peripheral neuropathy, it was 
found that there was an increased tendency for falls in those with peripheral 
neuropathy (OR 15.0; 95%CI 1.04-216.6).  The data for this study was obtained, 
prospectively, via questionnaires completed fortnightly over the telephone, whereby 
participants were asked if they had fallen since the previous telephone call.  The 
subject groups had mean ages of 31.9 years (diabetes with Peripheral Neuropathy 
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[PN]) and 32.9 years (diabetes without PN), with all subjects part of a larger 
epidemiological study of diabetes complications, having undergone testing for DPN. 
This study became the foundation upon which future research in diabetes and gait 
abnormalities would be based, with Cavanagh et al. (1992) and, later, Mueller, 
Minor, Sahrmann, Schaaf and Strube (1994) cited by the majority of authors included 
in this current literature review.  However, there are significant limitations in the 
study’s methodology that need exploration before accepting this as a seminal piece 
of work.  There was no face-to-face assessment of subjects engaged in locomotion, 
and falls data was collected via telephone interviews only and, therefore, objective 
confirmation of falling events through medical records or medical examination is 
lacking.  The mean age of subjects was between approximately 32 and 33 years old, 
which is not an age group associated with falls, which is due to a lack of identifiable 
risk factors for falling.  In addition, self-reporting of falls has been found to be 
inaccurate in older patients (over 65 years of age) in terms of both fall severity and 
frequency of falling (Mackenzie, Byles & D’Este, 2006).  Furthermore, the phrasing of 
questions put to individuals can influence their responses. For example, the Centre 
for Disease Control (CDC) analysed data on falls via telephone surveys conducted in 
2006 for the Behavioural Risk Factor Surveillance System (BRFSS) (CDC, 2008).  
Individuals over the age of sixty-five were asked if they had fallen and suffered a 
related injury in the three months prior to the telephone contact. Results found 
approximately 5.8 million people, over the age of sixty-five, had fallen at least once in 
the previous three months. A similar study was conducted by Boyd and Stevens 
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(2009) who identified 3.5 million older adults as having fallen in the same time frame.  
The disparity in results, after exclusion of other possible influences, was attributed to 
the content of the questions asked.  The CDC had provided individuals with clear 
definitions of what constituted a fall and/or injury at the time of questioning, thereby 
establishing a shared semantic framework to assist responses.  In contrast, Boyd 
and Stevens (2009) asked participants only if they had fallen in the last three 
months, leaving it to the individual to determine what constituted a fall. The 
relevance of this to Cavanagh et al. (1992) and other studies of falls is the fact that 
self-reporting may not be a reliable method of obtaining data on falls frequency and, 
therefore, results of studies utilising this method to investigate falls and DPN should 
be considered in this context.   
 
Mueller et al. (1994) carried out gait assessments on ten people with DPN and ten 
healthy, age-matched controls. Kinematic and kinetic data were generated as 
subjects walked along a 6.8 metre walkway.  Results indicated that people with DPN 
had a lower walking velocity (p=0.031) and shorter stride length (p=0.004) than 
healthy age-matched controls.  Significant differences between groups were 
demonstrated for reduced ankle joint motion, peak ankle moment, and peak ankle 
power during walking.  Ankle range of motion during gait was significantly reduced in 
DPN subjects (p=0.001), and this was also observed for plantar-flexor peak torque 
(p=0.001).  The authors suggest that the differences in gait parameters between 
groups could be indicative of weakness in the plantar flexors of the DPN subjects, 
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which would decrease the potential for developing plantar flexor moments during 
terminal stance.  DPN subjects also illustrated a gait pattern which favoured the use 
of the hip flexors to pull the leg forward during terminal stance (hip strategy) rather 
than making use of the weaker plantar flexors (ankle strategy) to push the leg 
forward and propel body weight.  Reduced plantar flexion strength during terminal 
stance may also account for the shorter step length observed due to insufficient 
power generation during “toe off”.  
 
The clinical implication of these data is related to the destabilising effect of a hip 
strategy, which could increase the risk for falls, and some of the issues identified by 
Mueller have continued to be researched today.  However, there are methodological 
issues in this study that limit the conclusions that can be made: firstly, the sample 
size was small with only 10 subjects in each group.  Secondly, the diagnostic criteria 
for peripheral neuropathy were not sufficiently specific to exclude ulcers of other 
causes that would influence results, e.g. non-neuropathic vascular ulcers.  A history 
of a diabetic neuropathic ulcer is not a suitable diagnostic parameter for a clinical 
setting, or research.  Although subjects were recruited from a diabetic foot centre, it 
could be assumed that all DPN subjects had previously undergone appropriate 
assessment as part of their care, but, unfortunately, this information is not provided.  
Furthermore, the timeframe for a “history of a neuropathic ulcer” is unclear. A very 
recently healed plantar ulcer would be likely to influence pressures generated during 
“toe off”, or any kinematic parameters.  Additionally, foot ulcers are usually treated 
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with some degree of offloading, which, if an individual is immobilised for a protracted 
period, could lead to disuse atrophy in the plantar flexors.  Based on the issues 
above, it is difficult to generalise the results to DPN patients as whole. However, the 
authors claim to have identified the reason for gait differences, focusing on a 
reduction in ankle strength and range of motion.  Despite methodological shortfalls 
and over-generalisation of results, both studies are frequently cited in relation to 
diabetes and gait abnormalities, and are valuable from a historical perspective.  A 
literature review could be construed as incomplete without Cavanagh et al. (1992) 
and Mueller et al. (1994) but, nevertheless, neither study provides conclusive 
evidence for diabetes-related gait alterations.  
 
Significant differences in the gait characteristics of DPN subjects and healthy 
controls were identified by Courtemanche et al. (1996) as part of a study (total 
sample n= 21) investigating the influence of attention diversion on gait.  The authors 
hypothesised that the decreased proprioception associated with DPN would increase 
the demands on cortical processing in an attempt to compensate for reduced 
sensory information.  During walking tasks simultaneously accompanied by auditory 
distracters, DPN subjects demonstrated shorter cycle amplitude (the distance 
travelled between successive heel contacts of the same foot) and slower cycle 
speed (amplitude divided by cadence).  Increased time spent in double support and 
longer reaction times to diversion stimuli were also recorded.  Although 
Courtemanche et al. (1996) only had a total of 21 subjects, the results illustrate the 
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potential for DPN to increase risk factors for falling when cognitive load is increased.  
In everyday life, locomotion occurs amidst a vast range of sensory distractors. How 
well older individuals with DPN adapt to environmental and cognitive demands in the 
context of impaired proprioception could assist in identification of those most at risk 
of falling.  
 
Richardson, Thies, DeMott and Ashton-Miller (2004) continued on a similar theme to 
Courtemanche by challenging the locomotion system of subjects with peripheral 
neuropathy and observing the effect on gait.  Subjects with peripheral neuropathy 
(n=12) were compared with healthy controls (n=12) whilst walking over a variety of 
different surfaces.  A textured and uneven walkway consisted of carpet flooring with 
pieces of wood protruding from underneath with the aim of exploring whether or not 
the reduced proprioception in the peripheral neuropathy group reduced their ability to 
negotiate the walkway.  In order to decrease the amount of support from the visual 
system, the experiment was conducted under dim lighting.  This is more reflective of 
the everyday environment than previous studies, and places a greater load on 
proprioceptive processing.  On a flat walkway, the neuropathic subjects displayed 
slower speed, shorter step length and longer step time when compared to the 
controls. However, there were no significant differences between the two groups on 
the parameters of step width, step width variability or step time variability.  The 
authors suggest that neuropathy does not destabilise subjects when mobilising on a 
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flat surface.  The challenge of the uneven surface for the neuropathy group elicited a 
wider, more temporally variable gait.   
 
The findings imply that subjects with neuropathy can maintain a relatively normal gait 
pattern until challenged by uneven surfaces and reduced lighting, at which point gait 
alterations can occur that reduce the speed and efficiency of mobilisation.  It is 
possible that subjects with peripheral neuropathy were unable to meet the sensory 
demands of a more challenging environment due to a reduction in sensory receptors 
in the foot. However, a wide range of aetiologies for peripheral neuropathy are 
included such as connective tissue disease, chemotherapy-induced neuropathy, and 
idiopathic neuropathy, and these in addition to DPN. Whilst all of these conditions 
ultimately reduce lower limb sensation, other medical symptoms associated with 
each of these diagnoses may have also influenced the results. Other confounding 
variables include duration of neuropathy, type of diabetes, and duration of diabetes. .  
The strength of this study is the departure from standard gait analysis on a flat 
surface to a variety of surfaces similar to those experienced in everyday life.   
Katoulis et al. (1997) used a greater number of subjects (n=80) for a study of gait 
characteristics in people with diabetes.  Four study groups were formed as follows; 
20 healthy controls, 20 non-neuropathic diabetes subjects, 20 with diabetes and 
peripheral neuropathy, 20 with diabetes, peripheral neuropathy plus a history of 
previous diabetic foot ulceration. All groups were matched for age, sex, and BMI.  
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Robust inclusion and exclusion criteria reduced the possibility of confounding 
variables to a minimum whilst also maintaining external validity.   
 
Results illustrated that subjects with DPN and a history of foot ulceration 
demonstrated a significantly slower gait speed than the healthy controls or diabetic 
non-neuropathic group (p<0.02).  Smaller joint angles were observed at the knee 
and ankle, whilst joint moment was higher in the DPN group than the diabetes and 
control groups.  This study provided joint angle and moment measures, which other 
studies did not assess.  These are particularly valuable, as they equate to muscle 
strength, which can decrease in the presence of DPN.  
 
Few studies have explored whether the gait patterns demonstrated by subjects with 
DPN are attributable to peripheral neuropathy or the condition diabetes mellitus. 
Petrofsky, Lee and Bweir (2005) reported the results of their study investigating gait 
changes in people with diabetes but no peripheral neuropathy.  In comparison to 
healthy controls, the diabetes subjects walked more slowly (p<0.01) and used more 
steps to complete the linear walking course.  Swing width was altered in that the 
diabetes subjects kept their legs wider than their shoulders at the widest point during 
gait (p<0.001).  For the turns at the end of the path, the diabetes group 
demonstrated a lower velocity (p<0.01), and required longer to execute the turn 
(p<0.05).  Petrovsky et al. (2005) reported increased gait variability in the diabetes 
subjects, especially at the hip and knee.  Almost all of the findings above have been 
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reported previously by other authors and attributed to DPN rather than diabetes per 
se, but based on the data of Petrovsky et al., subsequent studies would need to 
match DPN, diabetes but no peripheral neuropathy, and healthy controls in order to 
establish which condition was producing the gait alterations.   
 
Both Mueller et al. (1994) and Katoulis et al. (1997) report similar gait changes 
across kinematic and kinetic parameters.  This could be a reflection of their inclusion 
criteria in that the more severe presentations of neuropathy were represented in both 
studies.  Katoulis et al. (1997) included DPN subjects with a history of foot ulceration, 
whilst Mueller et al. (1994) used history of a neuropathic foot ulcer as the diagnostic 
criteria for DPN.  The ideal groups would be healthy subjects, diabetes but no 
neuropathy, and DPN but no history of ulceration.   
 
Given that the main features of DPN gait appear to be reduced velocity and shorter 
stride length, Dingwell et al. (1999) investigated the effects of removing speed as a 
variable to determine the nature of any gait alterations remaining.  Three groups of 
17 subjects were assembled and consisted of individuals with DPN, those with 
diabetes and minimal/absent peripheral neuropathy, and healthy controls.  Data was 
captured during the last minute of a fifteen-minute treadmill walk at a speed of 1 m/s.  
The timeframe for data capture was based on a pilot study conducted by the authors 
that demonstrated stable state locomotion is not achieved until 15 minutes of walking 
has been completed (Cavanagh et al., 1993), which is optimum timing for 
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assessment of variability.  No significant differences were identified between the 
groups for average stride time, minimum toe clearance, and coefficient of variation in 
knee angles or coefficient of variation in ankle angles.  The authors suggest that gait 
changes identified in subjects with DPN could be the product of reduced speed 
rather than adaptations to reduced proprioception.  However, the fact that Dingwell’s 
subjects could have been vulnerable to a fatigue effect because of the duration of 
the treadmill task also needs to be considered when appraising this study.   
 
Altered temporo-spatial gait parameters were also reported by Menz et al. (2004) 
specifically in relation to head and pelvis accelerations in subjects with diabetes and 
peripheral neuropathy in comparison to healthy, age-matched controls (total sample 
size=60).  Accelerations at the head and pelvis were measured during a walking task 
on regular and irregular surfaces.  In contrast to many of the studies in this clinical 
field, subjects completed a thorough battery of tests prior to walking.  Assessments 
included electromyographic studies of major leg muscles, a reaction time test, and 
tests of sensation, balance, and visual acuity.  This provided a method for diagnosis 
of neuropathy, exclusion of other subjects with non-neuropathic neurological or 
circulatory symptoms, plus sufficient baseline information to observe any 
confounding variables.  Results showed that diabetic subjects with peripheral 
neuropathy demonstrated smaller accelerations at the head and pelvis in vertical 
anterior-posterior and medio-lateral planes during gait tasks in comparison to their 
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healthy counterparts.  Indeed, accelerations were reduced even further for walking 
on an irregular surface.   
 
These data suggest that patients with diabetes and peripheral neuropathy use small 
accelerations in an attempt to maintain stability during gait, as any larger 
acceleration would be likely to have the opposite effect.  On balance, the results 
indicate that this patient group have a tendency towards instability during gait and 
the small accelerations may counteract the instability, but further investigation into 
these key areas is required.   
 
1.5.2 Gait Variability in Diabetic Peripheral Neuropathy 
 
Studies of gait variability in people with diabetes and peripheral neuropathy have 
identified a number of parameters susceptible to increased variability.  Menz (2004) 
described increased step-time variability in older (age range: 51 to 91 years) 
diabetes patients with peripheral neuropathy in comparison to healthy controls 
(p=0.003).  Richardson et al. (2004) also calculated gait variability in older women 
(mean age 67.1 years old, standard deviation 7.9 years) with peripheral neuropathy 
versus healthy age-matched controls, but only found a trend towards increased step-
width variability and increased step-time variability.  DeMott (2007) reported 
increased step-time variability in patients with diabetic peripheral neuropathy (of 
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multiple causes) when walking on a regular surface in comparison to controls.  This 
was not statistically significant, and the total sample size was only 20 subjects.  
Dingwell (1999) calculated the coefficient of variation of the knee angle and ankle 
angle over the whole stride during treadmill walking in subjects with diabetes and 
neuropathy (n=17), diabetes and no neuropathy (n=17), and healthy controls (n=17). 
Differences between the three groups for the above angles only approached 
significance for the coefficient of variation of knee angle (p=0.082), and failed to 
reach significance for the coefficient of variation for ankle angle.  Kinematic variables 
measured at 10% stride intervals showed no tendency towards significant variability.  
However, as discussed in the previous section, this study was carried out using a 
treadmill, and the imposition of constant speed and incline may have reduced the 
amount of variability in gait.   
 
Increased variability in gait cycle time of subjects with DPN (p=0.002) was identified 
by Allet et al. (2009).  Gait analysis was carried out on three groups of 15 subjects 
categorised by DPN, diabetes but no neuropathy, and healthy controls.  No 
differences for the coefficient of variation were found for stride length.   
 
Measures of gait variability have proven efficacy as a predictor for falls in the elderly, 
as demonstrated in an earlier section of this document.  Dingwell (1999) and DeMott 
(2007) failed to demonstrate a significant difference in gait variability for subjects with 
DPN, whereas Allet (2009) did.  Dingwell’s results may have been affected by 
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inclusion of people with “minimal neuropathy” whilst De Mott used subjects with a 
variety of different aetiologies for the peripheral neuropathy.  Allet used a range of 
assessments to diagnose neuropathy, which was either present or absent, and 
excluded any foot-related history that could influence results.  As a consequence, 
her group of subjects is most likely to reflect the population of patients with diabetic 
peripheral neuropathy because she has excluded everyone else..    
 
The literature describes a variety of alterations in gait associated with diabetic 
neuropathy, although the nature and extent of these remains undefined due to 
limitations in study design.  A tendency towards increased variability in gait 
parameters such as step-time, step-width, step-length and joint angles has been 
documented, in addition to an exacerbation of variability during challenging gait 
tasks. Step-to-step variability is reportedly associated with an increased risk for falls, 
which could equate to people with DPN becoming a high-risk falls group.   
 
Many studies of gait variability, as cited above, relate to temporo-spatial aspects.  
The majority have assessed gait during level over-ground walking, with only a few 
investigating more challenging environments such as uneven surfaces (Allet et al, 
2009).  Given that ambulatory humans negotiate complex internal and external 
environments on a daily basis, the results from studies concentrating on level ground 
walking may not be representative of “real life” and its daily environmental 
challenges.  The implications of this are: firstly, that research to date may have 
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underestimated the degree of vulnerability to falls among diabetes patients with 
neuropathy and, secondly, there is a need to ascertain the specific changes in gait 
that occur during highly challenging gait tasks. This approach may provide data that 
is a more accurate reflection of the challenges encountered in everyday life and may, 
therefore, assist in the identification of patients most at risk of falls.   
 
The focus and novelty of the research presented for the current thesis lies with the 
combination of parameters for analysis.  Firstly, lower limb joint range of motion will 
be assessed to determine whether any restricted motion is contributing to the gait 
changes observed in people with DPN to date.  Secondly, the study will analyse 
whether there is evidence of variability in joint range of motion, as this could 
represent a risk for falling.  Data for the parameters described above will be obtained 
during three different gait tasks that aim to increase the demands made on the 
sensori-motor contribution to locomotion and, thus, representing the challenges of 
locomotion in daily life.  These tasks include level walking, stair ascent and stair 
descent.   
 
1.5.3 Research Aims  
 
1. To examine joint range of motion in the lower limb during a range of gait tasks 
executed by individuals with diabetes mellitus combined with peripheral neuropathy. 
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2. To establish the degree of gait variability, and determine the risk of falls for 
individuals with diabetic peripheral neuropathy.   
 
1.5.4 Hypothesis 
 
People with diabetic peripheral neuropathy will exhibit differences in lower limb joint 
range of motion and increased kinematic variability during selected gait tasks in 
comparison to healthy controls.  The degree of variability will increase as gait tasks 
become more challenging.   
 
1.5.5 Ethics Approval  
 
The study was presented to the National Research Ethics Service North West, 
Greater Manchester West review panel and the University of Huddersfield, 
Manchester Metropolitan University, and Manchester University ethical review 
panels, and was assigned REC reference number 11/NW/0686 upon approval. 
Central Manchester Foundation Trust, Research and Development approved the 
research (reference number R01772) 
IRAS (Integrated Research Application System) number – CSP 85837/GM 
REC (Research Ethics Council) reference number – 11/NW/0686  
NRES (National Research Ethics Service,  Northwest, Greater Manchester West). 
REC approval was granted on 25/10/2011 
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CMFT R&D approval was granted on 31/10/2011 
Pan Manchester approved on 01/04/2012 
Chapter Two  
Methods  
The hypothesis of the current study is based on data that suggest people with DPN 
express kinematic gait parameters and variability that are different to those people 
without DPN.  The literature review provided information that allowed the formulation 
of the hypothesis, which will be tested using an analytical study design.  A 
descriptive study is not appropriate, as the current study is not investigating 
prevalence.  A diagnostic study design is also not appropriate, as diagnostic tests 
are not the focus of the investigation (Mann, 2003).   
 
The current study is a prospective, observational study.  As no intervention is being 
tested, it cannot be classed as experimental. Rather, subjects are being observed 
over the duration of the study period, and parameters of interest measured.  Types 
of observational study include cross-sectional, case series, case control, and cohort 
studies.  A cross-sectional study would not be suitable for the current investigation, 
as the characteristics being observed in the current study are not limited to one point 
in time.  Data is not generated from retrospective sources either.  Case series look at 
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specific diseases or individual characteristics that are not part of the current study 
remit (Koretz, 2007).   
 
The design selected for the current investigation is a cohort study, which is 
characterised by observing a group of people with defined characteristics whom are 
followed to determine incidence, mortality or outcome from a specific disease.  
Cohort studies are described in terms of exposure, or disease status, and outcome, 
and these are related to the independent and dependent variables (Levin, 2006).  
Disease status in the current study is divided into DM, DPN, and healthy (non-
diseased), and these constitute the independent variables.  The dependent 
variables, or outcomes, are ROM and variability. The dependent variables are being 
compared between the groups to infer an association, but not as part of an attempt 
to establish or define causality.  This is the study type that is most suitable for 
comparing the three groups to be studied.   
 
The hypothesis of the current study requires a comparison of three groups: DPN, DM 
and control to ensure that any differences between groups are due to different group 
characteristics, and not just related to the shared diagnosis of diabetes, or being 
sampled from the wider population.  The three groups constitute three levels of an 
independent variable or exposure in relation to the cohort study design.   
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The defined population of interest consists of people attending the Manchester 
diabetes centre for their diabetes care.  The healthy group is drawn from the same 
geographical population, but they are disease free.  A sample size calculation is 
required to promote generalisability to the wider population of people with diabetes 
and ensure a sufficient power to detect any differences between the groups.  Losses 
are anticipated, and are factored into the sample calculations.  
 
The group of people with diabetes will be subdivided at the point of initial 
assessment, in the current study, into those with symptoms of peripheral neuropathy 
and those free of neuropathy.  This will assist in differentiating between outcomes 
associated with the disease state per se, and those that are specific to diabetes-
induced sensory dysfunction.  All assessment tools used to determine the presence 
or absence of neuropathy will be selected based on validity or accepted best 
practice, whilst also being highly reproducible (see sections below).  All the non-
diseased people will also be tested for neuropathy to reduce the likelihood of any 
undiagnosed individuals entering the study, as this would be likely to skew results for 
the healthy control group.  
 
Data related to outcome will be measured using specialist gait assessment tools and 
associated software.  The total number of people placing markers on individuals 
involved in the study will be restricted in order to reduce performance bias. 
Confounding variables will be minimised as much as possible through exclusion 
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criteria which also incorporate any factors with the potential to influence gait 
patterns, for example, reduced vision, inner ear disorders, and neurological 
disorders.  The risk of compromising external validity (Rothwell, 2005) is 
acknowledged. However, the inclusion of such clinical groups in the current study 
has the potential to increase the risk of collecting data that is skewed by the outcome 
of the additional disease or exposure. Furthermore, it would be difficult to determine 
which exposure was associated with the differences observed between groups.   
The outcomes being measured are joint range of motion, measured in degrees, and 
stride-to-stride variability in joint range of motion measured as standard deviation in 
degrees.  These parameters relate to the underlying disease characteristics of 
interest upon which the hypothesis is based, i.e., that DPN alters sensation and 
alters gait.  Given that the joints of the lower limb are anatomically associated with 
one another in their different planes of movement (Hoy, Zajac & Gordon, 1990), it is 
appropriate to measure ROM and variability at each joint in each plane of movement. 
Restricting this to one plane of movement will limit the possibility of finding any 
associations between the outcome and exposure.     
 
The current study was part of a larger piece of research by S.Brown and 
J.Handsaaker at Manchester Metropolitan University investigating kinetic 
biomechanics in subjects with DPN, including joint moments and centre of mass-
centre of pressure separation during stair negotiation. The methodology and data 
analysis for the current study examining gait kinematics and variability were 
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independent of the larger study, but the current author was responsible for DPN and 
DM recruitment to both. The kinetic data generated was utilised for two separate 
PhD studies, and constituted baseline data for comparison with post-intervention 
data after a short period of targeted rehabilitation. The kinematic data was the focus 
of the current study, and the kinetic data was not available to the author. The 
sections that follow provide details of the methods used to carry out the study. 
 
2.1 Recruitment to the Study 
Sample size was based on the assumption of a treatment effect of 20%, and 23% 
data variability. Given this is a cohort study investigating the effect of disease state 
on specific gait parameters, treatment effect is synonymous with disease effect, that 
is, the effect of DPN on ROM/ROM variability.  Therefore a study of 17 participants 
per group (i.e. 51 in total for a 3-arm study) would be adequately powered to detect a 
significant difference between groups at standard levels of power and significance 
(van Belle, 2002). Hence, the current study, in which 90 participants were recruited, 
should be adequately powered to detect any existing effects with allowance for a 
certain level of attrition loss. Furthermore, all available consenting patients were 
recruited to the study. Hence, the study sample size is substantiated on pragmatic as 
well as theoretical grounds.  
The size of the data set is such that the sampling distributions of the data will 
approach Normality regardless of the distribution of the population the sample was 
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taken from, according to the Central Limit Theorem. Hence, the relevant assumption 
is met for the ANOVA procedure, which, in any case, is robust to violations of 
Normality (Glass, Peckham & Sanders, 1972). The sample size for each of group in 
the study, n, is calculated using a formula based on estimated proportionate change 
in means (PC) and the coefficient of variation (CV) quoted by van Belle (2002):  
     
Healthy control subjects were recruited from the staff and student population at 
Manchester Metropolitan University via radio announcements, pamphlets, and word 
of mouth.  The diabetes subjects were sourced from patients attending the 
Manchester Diabetes Centre (Central Manchester Foundation Trust) for 
management of type 1 or 2 diabetes mellitus, i.e., they were active patients.  All staff 
working within the diabetes centre were educated regarding the study, and asked to 
notify the investigator when suitable patients arose.  A laminated poster of inclusion 
and exclusion criteria was displayed in all clinic rooms used by physicians, nurses 
and allied health professionals.  All patients were consented by the investigator 
following discussion and provision of written literature.  Patients from ethnic 
minorities who could not speak or understand English due to the wide variation in 
ethnicity in central Manchester consented via an interpreter from the Trust’s 
Interpretation and Translation Service. 
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2.2 Inclusion and Exclusion Criteria 
Inclusion into either of the diabetes groups required a diagnosis of Type 1 or Type 2 
diabetes, which was established from participants’ individual medical case notes. 
These were actively open to the diabetes team at the diabetes centre.  
 
Those recruited to the healthy group were questioned regarding their diabetes 
status, and consented to correspondence being sent to their general practitioner 
(GP) for clarification of whether they had any conditions listed as part of the 
exclusion criteria. Responses from GPs were received by letter, but in the event of 
no response, the investigator made a telephone call and spoke directly with the 
doctor.  Letters were sent to the GPs of all subjects informing them of their patients’ 
involvement in the study as a matter of courtesy.  
 
Subjects were excluded from the study in the presence of the following conditions: 
unstable ischaemic heart disease, neurological impairments (apart from diabetic 
peripheral neuropathy), rheumatic disease, recent or past history of cerebral “injury”, 
disorders of the vestibular system, musculoskeletal injury, recent surgery to the foot, 
ankle, lower limb, hip or back, lower-limb amputation, open foot ulcer, visual acuity 
measured on the Snellen scale <6/18 (of any aetiology), or excessive alcohol intake 
(>30 units per week), as the above conditions may impact on a person’s ability to 
undertake the required set of tasks that lay ahead.   
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2.3 Assessment for DPN:  Neurodisability Score   
 
Assessment for DPN was conducted according to methods recommended by 
Boulton et al. (2005) for clinical trials and epidemiological studies. There is a 
distinction between the aims of assessing DPN as part of clinical practise versus 
assessing for research. In the former, it is important that assessment is pragmatic, 
rapid, practicable, and as accurate as possible within the clinical environment.  NICE 
guidelines (CG10, 2004) recommend foot sensation is tested with a 10 g 
monofilament, or a test of vibration perception such as a biothesiometer or calibrated 
tuning fork. According to the guidelines, patients will be tested for pressure 
perception or vibration perception, but not both. This is sufficient within the context of 
screening for loss of protective sensation in the foot to identify risk factors for foot 
ulceration. For the purposes of research, a more detailed, highly objective 
assessment, such as nerve conduction studies or intra-epidermal nerve fibre density, 
is required, but these are invasive and therefore inappropriate for research purposes. 
The Neuro-Disability Score (NDS), (Boulton et al., 2005) is a multiple modality 
assessment tool for the purpose of testing a range of nerve functions, and is 
validated for use specifically in research of the diabetic foot.  
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2.3.1 Vibration Perception 
 
The neuro-disability score incorporates multi-modality testing, the results of which 
are amalgamated to obtain a single score, with a score of ≥6 indicative of DPN 
(Boulton, 2005).  Patients were seated on a hard medical couch with legs out-
stretched so that the whole lower limb and heels were supported.  The 
neurothesiometer (Diaped®, distributed by Algeos, Algeo Ltd) is an electrical device 
that produces vibration which terminates in a probe that is easily applied to the apex 
of the hallux.  Commencing at zero volts, the amplitude is increased by adjusting the 
dial until the vibration is perceived by the patient.  This is repeated three times to 
produce a mean reading, which constitutes the vibration perception threshold (VPT).  
A threshold of ≥ 25Hz is required for a diagnosis of DPN (Boulton, 2005).  The 
assessment and marking is summarised in Table 1.   
 
2.3.2 Pin-prick Sensation 
 
This was assessed using the Neurotip (Owen MunfordTM), which consists of a 
disposable pin.  The sharp point was placed proximal to the toenail on the dorsal 
hallux, and sufficient pressure applied to indent but not break the skin (Paisley, 
  
71 
 
Abbot, van Schie, & Boulton, 2002).  Failure to identify the sharp sensation scores a 
one, while a normal response scores zero. 
 
2.3.3 Temperature Perception 
A Tip-therm® device (Bailey Instruments Ltd) was used to determine sensitivity to 
changes in temperature.  The device has two pointers of different temperatures 
which are applied to the tip of hallux in succession.  The patient is required to identify 
which is the warmer of the two (Viswanathan et al., 2002). Failure to identify the 
temperature difference scores a one, and normal would score zero. 
2.3.4 Achilles Reflex 
 
Patients were instructed to lie in a supine position with ankles and heels hanging 
loosely over the edge of the examining table.  The foot was placed in neutral position 
90 degrees to the leg, thus placing a stretch on the Achilles tendon.  The tendon 
body was then tapped with a tendon hammer to elicit a response.  A normal 
response is rapid plantar-flexion of the foot. 
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Table 1. Score sheet for the neurodisability score.  
 
Intact sensation should have a total score of zero.  The higher the score, the greater 
the degree of pathology.   
 
Neuropathy Disability Score 
 Scoring Right foot score Left foot score 
Vibration Perception  
Threshold 
 
Normal = can 
distinguish between 
vibration/no vibration 
 
 
Normal = 0 
 
Abnormal = 1 
  
Temperature 
Perception 
Normal = differentiates 
between warm/cold 
  
Pin-Prick Sensation 
Normal = differentiates 
between sharp/not 
sharp 
  
Achilles Reflex 
Normal = reflex 
response 
Present = 0 
Present with 
reinforcement = 1 
Absent = 2 
  
 
Total =                 /10 Total =                 /10 
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2.4 Gait Assessment 
Data were generated from three gait tasks completed by all participants.  The tasks 
consisted of level walking, stair ascent, and stair descent.   
2.4.1 Level Walking 
A 10-metre walkway was used for level walking tasks.  This was constructed from 
concrete to represent a normal external walking surface.  Two white lines marked out 
the start and finish.  The width was set at a regular pavement width of 1 metre. 
Participants were fitted with retro-reflective markers and requested to stand at the 
beginning of the walkway with feet together, looking straight ahead.  They were 
instructed to walk at a pace which felt comfortable to them, and to stop where the 
walkway terminated at 10 metres.  This was repeated three times per limb to 
generate sufficient data to obtain a mean value for each parameter being measured, 
and to produce a sufficient number of strides to observe any stride-to-stride 
variability.   
2.4.2 Stair Negotiation 
 
Stair ascent and descent was carried out using a seven-step stair, constructed by 
Manchester Metropolitan University School of Healthcare Science.  Seven steps 
were selected to capture two-and-a-half gait cycles during ascent and descent to 
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mimic normal stair negotiation.  The stairs were designed with each step measuring 
175mm high, 1050mm wide and 275mm deep, which is broadly representative of 
household stair measurements.  The frame was metal, whilst tread and kicker plates 
consisted of a wood composite similar to medium density fibreboard (MDF).  
Smooth, metal handrails on both the right and left were included running along the 
full length of the stair.  To obtain a starting position and posture consistent across 
trials, participants were instructed to focus their vision onto a target picture of three 
concentric circles printed onto plain white paper and positioned at eye level, placed 
10 metres in front of them.  The aim was to control for downward gaze being used as 
a strategy to aid foot placement.  Once in position at the base of the stairs, 
participants were requested to ascend and descend the stairs as comfortably as 
possible using the handrails as required.  Upon reaching step seven, where there 
was ample room to turn around, participants were instructed to descend the stairs.  A 
minimum of three ascents and three descents were recorded for each participant to 
obtain mean values for each parameter. Gait speed was measured as the horizontal 
velocity of participants’ centre of mass.  
2.4.3 Marker Set and Data Capture 
Data was obtained for each participant engaged in (i) level walking, (ii) stair ascent, 
and (iii) stair descent.  Data was captured using the Vicon®  three-dimensional (3D) 
motion capture system (Vicon Motion Systems, Oxford, UK), and Vicon Plug-in-gait 
kinematic model with the modified Helen Hayes marker set. Vicon MX40 (4 
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megapixel) cameras were used at 100Hz, and positioned around the walkway to give 
the best possible view of the walkway area and stairs.  
Visual 3D TM (C-motion Inc, Maryland, USA) is a multiple modelling software 
package, compatible with a wide range of motion capture systems. It measures and 
quantifies movement from these systems. This is not restricted to any one gait 
model, allowing greater system flexibility, especially for research.  
The full body marker set was used as part of an additional study collecting gait 
related data. The current study generated and analysed data for joint range  of 
motion and gait speed during the three gait tasks. The descriptions for marker 
protocol, segment and tracking definitions, and subsequent figures are presented for 
full body application for completeness. To determine joint angles, the model gains 
information on the position and orientation of each segment (i.e., foot segment, 
shank segment, thigh segment), and examines each segment’s position in relation to 
the proximal segment. This provides the joint angle in all three planes. To provide 
this information, each segment needs to have a minimum of 3 non-collinear markers. 
Modifications included the use of additional tracking markers to provide redundancy 
from occlusion due to the structure of the stairs, and medial ankle and knee markers 
to improve joint centre definition at those joints. The protocol for marker placement is 
given in Table 2 as per the Vicon Plug-in-gait manual. Additional information 
regarding placement was utilised from the work of Davis (1991), and the Helen 
Hayes model.  
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The current study’s markers were placed by two Biomechanists and a Podiatrist. The 
current author had received training in marker application by one of the 
aforementioned Biomechanists.  
 
Vicon Plug-in-gaitTM is an addition to the original software for the 3D motion sensor, 
and uses a full body set of retro-reflective markers, the placement of which is 
illustrated in figure 1.  The body is divided up into segments containing different 
markers to track position and orientation of each segment.  Placement of most 
markers relates to a particular bony landmark on the body. However, the mid-shank 
markers were positioned to define segment rotation in relation to joints or other 
markers.  Joint centres were calculated from the markers.  Tracking markers were 
used to define the position of a marker relative to a specific body segment during 
software model calibration, thus providing better tracking of segments during trials. 
Reliability and accuracy of placement was increased by ensuring that investigators 
had achieved competency in placement under the supervision of a senior 
biomechanist with extensive experience in marker application.  The exact placement 
of markers is shown as an illustration in Figure 1.     
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Table2. Protocol for marker placement. 
 
 
 
Marker placement for Plug-in-gait: Upper Body 
 
Marker Landmark for placement 
 
HD_TOP 
 
Top of head 
LFHD 
RFHD 
Headband:  Left front/Right front 
LBHD 
RBHD 
Headband: Left back/Right back 
C7 
 
7th cervical vertebra 
RBAK 
 
Middle of right scapula 
T10 
 
10th thoracic vertebra 
CLAV 
 
Jugular notch, between the clavicle at meeting point with sternum 
STRN 
 
Xiphoid process 
LSHO 
 
Left Acromio-clavicular joint 
LUPA 
 
Left upper arm between elbow & shoulder markers 
LELB 
 
Left lateral epicondyle 
LWRA 
 
Styloid process of Left Ulna 
LWRB 
 
Styloid process of Left Radius 
LFIN 
 
Left hand proximal to the 2nd metacarpal head 
RSHO 
 
Right Acromio-clavicular joint 
RUPA 
 
Right upper arm between elbow & shoulder markers 
RELB 
 
Right lateral epicondyle 
RWRA 
 
Styloid process of Right Ulna  
RWRB 
 
Styloid process of Right Radius 
RFIN 
 
Left hand proximal to the 2nd metacarpal head 
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Marker placement for Plug-in-gait: Lower Body 
 
Marker Landmark for placement 
LASI Left anterior superior spine –placed directly over pelvis 
RASI Right anterior superior  iliac spine – placed directly over pelvis 
LPSI Left posterior superior iliac spine – placed on the bony prominences below the sacro 
iliac joints at the point where the spine joins the  pelvis  
RPSI Right posterior iliac spine – see above 
SACR_INF Sacral marker – placed midway between LPSI & RPSI markers & slightly inferior 
L_PEL Left side of pelvis level with & between LPSI & LASI markers 
R_PEL Right side of pelvis level with & in between RPSI & RASI markers 
LTHI Lateral thigh approx ½ way between hip centre & knee centre. Align anteroposteriorally 
with the knee & hip extension/flexion axes 
LKNE Left lateral femoral epicondyle – lateral side of knee flexion/extension axis: flex & 
estend knee & use most constant axial point 
LKNE_MED Left medial femoral epicondyle – medial mirror of LKNE marker so that the line 
connecting the two approximates the flexion/extension joint axis 
LTIB_SUP Left leg, top 1/3rd of shank, medial to tibia 
LTIB Left leg, lateral edge of shank, same plane as the knee & ankle flexion/extension axes 
LTIB_INF Left leg, bottom 1/3rd of shank just lateral to the sagittal plane 
LANK Left leg, medial malleolus 
LANK_MED Left leg, lateral malleolus 
LHEE  On the calcaneous, at same height as LTOE marker (left foot) 
LFT_MED On foot band, medial side of left foot -  position so that band is approx midway between 
toe markers and ankle, ensure ankle motion wont disturb band. 
LFT_LAT On foot band, lateral side of left foot - position so that band is approx midway between 
toe markers and ankle, ensure ankle motion wont disturb band. 
LTOE 2nd metatarsal head, left foot 
LMT5 5th metatarsal head, left foot 
Table 3. Description of Plug-in Gait marker placement for the lower body. 
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Marker placement for Plug-in-gait: Lower Body (continued) 
 
Marker Landmark for placement 
RTHI Lateral side of right thigh approx ½ way between hip centre & knee centre. Align 
anteroposteriorally with the knee & hip extension/flexion axes 
RKNE lateral femoral epicondyle of right leg – lateral side of knee flexion/extension axis: flex 
& extend knee & use most constant axial point 
RKNE_MED  
RPSI Right posterior iliac spine – see above 
SACR_INF Sacral marker – placed midway between LPSI & RPSI markers & slightly inferior 
L_PEL Left side of pelvis level with & between LPSI & LASI markers 
R_PEL Right side of pelvis level with & in between RPSI & RASI markers 
RTHI Medial femoral epicondyle right leg – medial mirror of RKNE marker so that the line 
connecting the two approximates the flexion/extension joint axis 
RTIB_SUP Top 1/3rd of shank, medial to tibia of right leg 
RTIB Lateral edge of shank, same plane as knee & ankle flexion/extension axes of right  leg 
RTIB_INF Bottom 1/3rd of shank just lateral to the sagittal plane, right leg 
RANK Medial malleolus, right leg 
RANK_MED Lateral malleolus, right leg 
RHEE  On the calcaneous (right leg), at same height as LTOE marker  
RFT_MED On foot band, medial side of right foot -  position so that band is approx midway 
between toe markers and ankle, ensure ankle motion wont disturb band. 
RFT_LAT On foot band, lateral side of right foot - position so that band is approx midway 
between toe markers and ankle, ensure ankle motion wont disturb band. 
RTOE 2nd metatarsal head, right foot 
RMT5 5th metatarsal head, right foot 
R2ND Tip of 2nd toe, right leg 
Table 3 (continued) Description of Plug-in Gait marker placement for the lower body 
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Figure 1. Positions for Plug-in-gait anatomical markers 
Key: red - tracking marker, yellow – calibration marker,  red and yellow – tracking 
and calibration marker. 
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Segment Definition Tracking 
Head HD-TOP + LFHD + RFHD + LBHD + 
RBHD 
LFHD + RFHD + LBHD + RBHD 
Thorax RSHO + LSHO + Pelvis LSHO + RSHO + C7 + T10 + CLAV + 
STRN + RBAK 
Pelvis LASI + SACR + RASI LASI + RASI + L_PEL + R_PEL + LPSI 
+ RPSI + SACR_INF 
Upper arms Left LSHO + LELB + LUPA LSHO + LUPA + LELB 
Right RSHO + RELB + RUPA RSHO + RUPA + RELB 
Fore-arms Left LELB + LWRA + LWRB LELB + LWRA + LWRB 
Right RELB + RWRA + RWRB RELB + RWRA + RWRB 
Hands Left LWRA + LWRB + LFIN LWRA + LWRB + LFIN 
Right RWRA + RWRB + RFIN RWRA + RWRB + RFIN 
Thighs 
Left 
HH_LEFT_HIP + LKNE + LKNE_MED HH_LEFT_HIP + LTHI + LKNE + 
LKNE_MED 
Right 
HH_RIGHT_HIP + RKNE + 
RKNE_MED 
HH_RIGHT_HIP + RTHI + RKNE + 
RKNE_MED 
Shanks 
Left 
LKNE + LKNE_MED + LANK + 
LANK_MED 
LANK + LANK_MED + LKNE + 
LKNE_MED + LTIB + LTIB_SUP + 
LTIB_INF 
Right 
RKNE + RKNE_MED + RANK + 
RANK_MED 
RANK + RANK_MED + RKNE + 
RKNE_MED + RTIB + RTIB_SUP + 
RTIB_INF 
Feet 
Left 
LANK + LANK_MED + LMT5 + LTOE LANK + LANK_MED + LFT_MED + 
LFT_LAT + LTOE + LMT5 
Right 
RANK + RANK_MED + RMT5 + RTOE RANK + RANK_MED + RFT_MED + 
RFT_LAT + RTOE + RMT5 
Table 4. Segment and tracking definitions. 
Table 4 describes the markers used to define each segment, and which markers are 
then used in order to track the segment.  Markers were kept in place with a low tack 
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tape (3MTM) to prevent skin abrasions.  The double-sided tape was attached to the 
flat surface of the retro reflective marker for fixing onto patient skin or clothing, 
depending upon their attire. The used tape was hygienically disposed of and fresh 
tape applied for every subject.  On completion of data capture the markers were 
removed and used tape  hygienically disposed of. Each subject had markers applied 
with fresh tape thus, the markers were never in direct skin contact so that the risk of 
contamination with colonised or infecting bacteria could be reduced.  
2.4.4 Clothing and Footwear 
Participants were instructed to wear tight-fitting clothing such as leggings, cycling 
shorts and non-baggy T-shirts to improve the accuracy of marker placement.  To 
counteract the possibility of variability arising due to differences in footwear, all 
participants were fitted for a pair of Darco MedSurgTM shoes, which are used in post-
operative care.  The upper is fabricated from a lightweight breathable mesh, and the 
sole from an ultra-high density composite rubber.  Heel grips reduce slippage, and 
Velcro straps hold the foot firmly in place. The MedSurgTM shoe is available in sizes 
small, medium, large, and extra-large for men.  Retro-reflective markers were placed 
on the shoe itself as instructed in the plug-in-gait marker set.  Stair ascent and 
descent included use of a body harness to ensure safety of the patient in the event 
of a fall.  The gait laboratory was equipped with a Petzl full body harness made from 
high strength, flexible polyester webbing accompanied by the appropriate safety 
certification (CE, EN 12 277 type A, UIAA 105).  Fully adjustable shoulder straps and 
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leg loops ensured suitability for a full range of subject heights and weights whilst also 
being easy to put on.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Marker placements in lateral and anterior views. The current study utilised 
the lower limb only.  
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Figure 3. Marker positions from a posterior view and during level walking (lower limb only).  
 
  
85 
 
 
Figure 4 . Stair ascent and descent with harness and markers attached. 
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 Figure 5. Over-head harness 
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2.5 Data Analysis 
 
Kinematics were generated and processed using visual 3D (C-motion, Inc., MD, 
USA).  All signals were filtered using a Butterworth filter (6Hz low-pass).   
The sample was summarised descriptively by group.   
Variability was measured using the standard deviation of the joint ROMs obtained 
from the right and left limb, over two full gait cycles, under each walking condition 
(level, stair ascent and stair descent), for each joint in each plane (sagittal, frontal 
and transverse), which allowed the calculation of the mean standard deviation per 
group.  
Analyses of Variance (ANOVAs) were conducted on the data to identify significant 
differences in range of motion and gait variability between the control, DM and DPN 
groups (following verification of key assumptions of homogeneity of variance (using 
Levene’s test) and independence of data).  Normality of the sampling distribution 
could be assumed due to the sample size.  Where statistical significance was 
indicated, post hoc testing was conducted using the Newman-Keuls multiple 
comparison procedure.  Effect sizes were reported in all cases identified as showing 
statistical significance.   
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The number of outcome measures was considered in the inferences of statistical 
significance or otherwise.  To avoid over-conservatism arising from likely correlations 
between different outcome measures, an amendment to the usual Bonferroni 
correction was applied such that the method adopted was to consider any p-value 
arising from a post-hoc test to be significant if it was substantially under the usual 
threshold of 5%, for example under 0.01.  Statistical analyses were carried out using 
Graphpad Prism 6 © 2013 (Graphpad Software, Inc.).   
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Chapter Three   
Results 
A total of 90 subjects were recruited: 30 in the control group, 30 in the diabetes 
group, and 30 in the DPN group. Between the start and completion of the study, 
losses occurred in both the DM and DPN groups as follows: two from the DM group 
due to diabetic foot sepsis and drop out, 11 from the DPN group, comprising of two 
drop-outs, one incomplete data set due to technical failure, one fall, four due to 
additional hospital appointments, one parking issue, and two unable-to-contact.   
 
3.1 Demographic and Baseline Observations 
Groups were approximately evenly matched in terms of age.  The mean BMI across 
the groups placed all three groups in the overweight category. Group means for the 
Neuropathy Disability Score (NDS) and Vibration Perception Threshold (VPT) 
demonstrated parity with clinical and study inclusion criteria for the diagnosis of 
diabetic peripheral neuropathy.  The divisions between the groups, based on clinical 
assessments, are also evident in the increasing VPT from controls to DMs, with the 
DPNs having the highest threshold.      
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CHARACTERISTICS 
Control Diabetes mellitus Diabetes mellitus & 
peripheral neuropathy 
Gender 
Male 16 Male 14 Male 13 
Female 14 Female 14 Female 6 
Descriptive 
statistics 
Mean SD Range Mean SD Range Mean SD Range 
Age (years) 51.1 16.1 26-84 58.1 11.7 27-78 57.6 9.1 41-68 
Weight (kg) 74.6 13.0 50-105 79.5 12.0 55-99 86.6 19.5 61-140 
Height (cm) 170 9.0 147-186 170 10.0 162-197 170 90 157-190 
BMI (kg/m2 ) 25.6 3.7 21-37 28.0 3.3 21-34 29.1 5.1 22-39.9 
NDS * 0.8 1.0 0-4.0 1.6 1.7 0-6.0 7.1 3.0 1.0-10.0 
VPT ** 6.9 4.9 2.0-15.4 10.3 5.6 3.7-23.2 30.8 9.6 13.0-
46.6 
Table 5. Demographics for groups. 
Table 5 shows the mean values for baseline characteristics of the subjects by group, 
including standard deviation and range values.   
The healthy controls had the youngest mean age, whilst the DM and DPNs were 
relatively close to each other in mean age. The DPN group had the smallest range in 
ages (27 years) in comparison to the other groups; DM age range 51 years and 
control age range 58 years. In most cases the upper and lower limits of the data 
presented above are equally far away from the mean values suggesting similar 
distributions without outliers. The ranges are fairly similar to each other as a 
proportion of the corresponding mean to which it is attached.  
There is no definitive age at which gait becomes characteristic of being elderly, but 
the majority of the DPNs lie between 48.5 and 66.7 years of age, which is insufficient 
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to impose the changes associated with being elderly on the results. According to the 
SD, the healthy group age majority lies between 35 and 67.2, and the DMs lie 
between 46.4 and 69.8. There are studies where subjects younger than 65 were 
included in elderly groups, but there is no evidence to suggest that subjects at this 
age demonstrate abnormal gait due to aging alone.  
In terms of gait speed during the walking and stair tasks, the DPNs were consistently 
slower than the DM and control groups. For level walking, the control group were 
fastest with a mean speed of 1.36 metres per second (m/s) (range 0.83-1.71 m/s), 
followed by DMs at 1.26 m/s (range 0.98-1.61), then the DPNs at 1.18 m/s (range 
0.71-1.88). Similarly, during stair ascent, the controls were fastest with a mean 
speed of 0.56 (range 0.39-0.82), DMs at 0.51 (range 0.33-0.77), and DPNs’ mean 
speed was 0.44 (range 0.24-0.61). For stair descent, again, the controls were fastest 
at 0.6 m/s (range 0.44-0.93), followed by DMs 0.52 m/s (range 0.31-0.81), and DPNs 
at 0.47 (range 0.22-0.76).  
The DM & DPN groups’ average BMI was 28.0 kg/m2 and 29.0 kg/m2 respectively, 
neither of which equates to obesity. The healthy subjects in the current study had an 
average BMI of 25.6 kg/m2, placing them in the overweight category. This is in 
keeping with the national trend of rising levels of overweight people in the UK 
population (HSCIC, 2012 health survey).  
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3.2 Results for Joint Range of Motion 
 
One-way analyses of variance (ANOVAs) identified statistically significant 
differences between the group means during stair ascent for range of motion at the 
ankle joint in the frontal and sagittal planes, the knee in the frontal and sagittal 
planes, and the hip in the sagittal and transverse planes.  A statistically significant 
difference in means was also identified during stair descent affecting ankle range of 
motion in the sagittal plane, the knee in the frontal plane and the hip in the frontal 
and transverse planes.  In level walking, a difference between group means was only 
identified for ankle range of motion in the sagittal plane.  
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Table 6 illustrates the results from the one-way ANOVAs of the three groups for 
range of motion during all three gait tasks.  Significant relationships are highlighted 
by bold typeface.  df – degrees of freedom.  F – F statistic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Results of ANOVA, for joint range of motion during three gait tasks. 
Joint & plane 
 
df F p value 
Stair ascent 
Ankle frontal 2,77 2.57  0.08 
Ankle sagittal 2,77 5.47  0.006 
Ankle transverse 2,77 0.30  0.74 
Knee frontal 2,77 8.48 <0.001 
Knee sagittal 2,77 3.91  0.02 
Knee transverse 2,77 0.71  0.49 
Hip frontal 2,77 0.85  0.43 
Hip sagittal 2,77 5.59  0.005 
Hip transverse 2,77 3.07  0.05 
Stair descent 
Ankle frontal 2,73 5.63 0.006 
Ankle sagittal 2,73 10.3 <0.001 
Ankle transverse 2,73 0.71 0.49 
Knee frontal 2,73 8.11 <0.001 
Knee sagittal 2,73 3.04 0.05 
Knee transverse 2,73 3.02 0.05 
Hip frontal 2,73 9.21 <0.001 
Hip sagittal 2,73 2.52 0.08 
Hip transverse 2,73 11.5 <0.001 
Level walking 
Ankle frontal 2,77 0.33 0.72 
Ankle sagittal 2,77 6.28 0.003 
Ankle transverse 2,77 0.44 0.65 
Knee frontal 2,77 0.15 0.85 
Knee sagittal 2,77 1.13 0.32 
Knee transverse 2,77 2.10 0.13 
Hip frontal 2,77 0.58 0.56 
Hip sagittal 2,77 0.89 0.41 
Hip transverse 2,77 0.79 0.45 
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The Newman-Keuls post-hoc procedure identified statistically significant differences 
between groups for parameters.  Twenty-seven “test triplets” were conducted on 
each outcome, i.e., DPN versus control, DPN versus DM, and DM versus control.   
 
 
 
Group mean Ankle ROM 
(degrees) 
Newman-Keuls MCT 
 
 
 
A 
S 
C 
E 
N 
T 
 
Plane of 
motion 
Ctl DM DPN Group comparison Q value p value 
 
Frontal 
 
8.9 
 
10.4 
 
10.6 
   
 
Sagittal 
 
37.1 
 
37.0 
 
32.5 
DPN v DM 
 
DPN v Ctl 
4.24  
 
4.08 
p<0.05* 
 
p<0.01* 
 
Transverse 
 
9.4 
 
9.0 
 
9.1 
   
 
D 
E 
S 
C 
E 
N 
T 
 
 
Frontal 
 
8.9 
 
10.4 
 
10.6 
DPN v Ctl, 
 
 
Ctl    v  DM 
3.95   
 
3.94   
p<0.05* 
 
p<0.01* 
 
Sagittal 
 
58.8 
 
58.0 
 
51.0 
DPN v Ctl 
 
DPN v DM 
6.09  
  
5.40   
p<0.001 
 
p<0.001 
 
Transverse   
 
8.6 
 
8.9 
 
9.4 
   
 
L 
E 
V 
E 
L 
 
Frontal 
 
8.1 
 
8.1 
 
8.6 
   
 
Sagittal 
 
27.8 
 
26.5 
 
24.3 
DPN v Ctl 
DPN v DM 
4.98 
3.21 
p<0.01* 
p<0.05* 
 
Transverse   
 
11.4 
 
10.9 
 
10.7 
   
 
Table 7. Ankle joint ROM during stair ascent, stair descent, and level walking. 
Significant Newman-Keuls multiple comparisons test (MCT) results are also shown. 
Table 7 illustrates that subjects in the DPN group had significantly reduced mean 
range of motion at the ankle during stair descent in the sagittal plane when 
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compared with the Ctl and DM groups.  (*) denotes statistical significance not directly 
inferred due to correction for multiple comparative testing. 
 
 Group mean Knee  ROM (degrees) 
 
Newman-Keuls MCT 
 
 
 
A 
S 
C 
E 
N 
T 
 
Plane of 
motion 
Ctl DM DPN Group comparison 
 
 
Q value p value 
 
Frontal 
 
11.5 
 
14.6 
 
16.9 
DPN v Ctl 
 
Ctl v DM 
5.72 
 
3.69 
p<0.001 
 
p<0.05* 
 
Sagittal 
 
85.3 
 
90.5 
 
87.8 
Ctl v DM 
 
 
3.95 
 
p<0.05* 
 
 
 
Transverse 
 
13.2 
 
12.7 
 
13.6 
 
 
 
  
 
D 
E 
S 
C 
E 
N 
T 
 
 
Frontal 
 
9.2 
 
12.3 
 
12.6 
DPN v Ctl 
 
 
Ctl    v  DM 
 4.77 
 
4.93   
p<0.01 
 
p<0.001 
 
Sagittal 
 
84.5 
 
87.8 
 
85.5 
 
 
 
  
 
 
 
 
 
Transverse   
 
11.2 
 
12.0 
 
13.2 
 
 
 
  
 
L 
E 
V 
E 
L 
 
Frontal 
 
8.1 
 
8.5 
 
8.6 
 
 
 
  
 
Sagittal 
 
69.4 
 
67.4 
 
67.5 
 
 
 
 
 
 
 
Transverse   
 
12.1 
 
11.16 
 
13.46 
 
 
 
  
 
Table 8. Knee joint ROM during stair ascent, stair descent, and level walking. 
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After adjustments for multiple comparisons, the DPN subjects showed increased 
mean knee joint range of motion in the frontal plane, during stair descent, in 
comparison to the Ctl group. The DM group showed significantly greater range of 
motion during stair descent in the frontal plane, when compared with the other two 
groups.  (*) denotes statistical significance not directly inferred due to correction for 
multiple comparative testing. 
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 Group mean Hip ROM (degrees) 
 
Newman-Keuls MCT 
 
 
 
A 
S 
C 
E 
N 
T 
 
Plane of 
motion 
Ctl DM DPN Group comparison 
 
 
Q value p value 
 
Frontal 
 
14.6 
 
15.1 
 
15.7 
  
 
 
 
 
 
 
Sagittal 
 
55.37 
 
59.19 
 
58.33 
DPN v Ctl 
 
Ctl v DM 
3.21 
 
4.58 
p<0.05* 
 
p<0.01* 
 
 
Transverse 
 
11.57 
 
12.64 
 
14.28 
 
 
 
  
 
D 
E 
S 
C 
E 
N 
T 
 
 
Frontal 
 
11.2 
 
13.3 
 
15.2 
DPN v Ctl 
 
DPN v DM 
 5.97 
 
 2.86 
p<0.001 
 
p<0.05* 
 
Sagittal 
 
28.0 
 
30.0 
 
29.4 
 
 
 
  
 
 
 
 
 
Transverse   
 
14.4 
 
16.0 
 
20.2 
DPN v Ctl 
 
DPN v DM 
6.7 
 
4.9 
p<0.001 
 
p<0.001 
 
L 
E 
V 
E 
L 
 
Frontal 
 
12.3 
 
11.4 
 
12.2 
 
 
 
  
 
Sagittal 
 
46.8 
 
46.7 
 
44.9 
 
 
 
 
 
 
 
Transverse   
 
12.7 
 
12.4 
 
11.4 
 
 
 
  
 
Table 9. Hip joint ROM during stair ascent, stair descent, and level walking.  
Significant differences were identified for mean hip range of motion during stair 
descent; ROM in the frontal plane was greater in the DPN group than the controls, 
and in the transverse plane, DPN ROM was greater than the control and DM groups.  
(*) denotes statistical significance not directly inferred due to correction for multiple 
comparative testing. 
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3.3 Results for Gait Variability 
Standard deviation was chosen as the measure of variability in keeping with previous 
studies by Brach (2008, 2010), and Paterson (2009). The coefficient of variation has 
also been used in studies to measure variability, which results in a final figure 
expressed as a percentage. However, as this lacks any unit of measurement, it 
bears little resemblance the original clinical data. The standard deviation retains this 
information, which is clinically more meaningful to healthcare professionals involved 
with this patient group. For the purpose of this study, range of motion was measured 
in degrees.  
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Table 10 illustrates results from the one-way ANOVAs of the three groups for gait 
variability during all three gait tasks.  Significant relationships are highlighted by bold 
typeface.  df – degrees of freedom.  F – F statistic.  
Joint & plane 
 
df F p value 
 
Stair ascent 
   
Ankle sagittal 2,77 2.41 0.09 
Ankle frontal 2,77 2.659 0.07 
Ankle transverse 2,77 0.56 0.56 
Knee frontal 2,77 0.06 0.94 
Knee sagittal 2,77 2.70 0.07 
Knee transverse 2,77 0.36 0.69 
Hip frontal 2,77 1.77 0.17 
Hip sagittal 2,77 1.30 0.27 
Hip transverse 2,77 0.24 0.78 
 
Stair descent 
   
Ankle frontal 2,73 1.99 0.14 
Ankle sagittal 2,73 2.15 0.12 
Ankle transverse 2,73 0.77 0.46 
Knee frontal 2,73 1.45 0.24 
Knee sagittal 2,73 0.70 0.49 
Knee transverse 2,73 3.25 0.04 
Hip frontal 2,73 0.88 0.42 
Hip sagittal 2,73 0.34 1.25 
Hip transverse 2,73 3.85 0.02 
 
Level walking 
   
Ankle frontal 2,77 0.23 0.79 
Ankle sagittal 2,77 1.66 0.19 
Ankle transverse 2,77 1.84 0.16 
Knee frontal 2,77 0.73 0.48 
Knee sagittal 2,77 2.67 0.07 
Knee transverse 2,77 2.07 0.13 
Hip frontal 2,77 2.7 0.07 
Hip sagittal 2,77 0.9 0.4 
Hip transverse 2,77 1.02 0.36 
 
Table 10. ANOVA results for gait variability in joint range of motion during  three gait tasks 
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 Gait variability standard deviation    
(degrees) 
Newman-Keuls MCT 
 
 
D 
E 
S 
C 
E 
N 
T 
 
Plane of 
motion 
Ctl DM DPN Group comparison 
 
 
Q value p value 
 
Knee 
transverse 
 
2.2 
 
2.6 
 
3.2 
DPN v Ctl 3.6 
 
 
 
p<0.05*  
 
 
Hip 
transverse 
 
30 
 
32 
 
43 
DPN v Ctl 
 
DM  v DPN  
 
3.8 
 
3.2 
p<0.05* 
 
p<0.05* 
 
Table 11. Mean variability by group and multiple comparisons results.Comparisons initially 
appeared significant, but after adjustments for multiple comparisons this was no longer the 
case.  
ANOVA identified only two parameters where a statistically significant difference 
between the groups occurred for gait variability: at the knee joint in the transverse 
plane during stair descent, and at the hip joint during stair descent in the transverse 
plane.  Newman-Keuls multiple comparisons testing established that the DPN group 
demonstrated greater variability in knee joint motion versus the control group, but 
after corrections for multiple comparative testing, this was no longer significant.  The 
significance of between-group differences in hip variability was not maintained after 
correction for multiple comparative testing.   
To summarise, the ANOVAs illustrated a significant difference in means between the 
three groups studied for specific gait parameters.  This implies the null hypothesis, 
that all means are equal as they originate from the same population, can be rejected.  
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The post-hoc Newman-Keuls test identified which groups and parameters 
specifically were associated with the statistically significant differences.  For the most 
part, this arose from comparisons between the DPN and control groups, although a 
small number of significant differences emerged between the DM and controls, and 
DM versus DPN.   
The  dot plots illustrate intra-group distribution of results, in relation to the group 
mean, for the three subject groups where Newman-Keuls identified significant 
differences between the groups.  The dot plots in figure 6 illustrate the DPN groups’ 
significantly reduced ROM at the ankle (sagittal plane) during stair descent.  The 
pattern of distribution around the mean is fairly symmetrical for each group.   
Figure 7 is a dot plot for knee ROM (frontal plane) during stair ascent in which the 
DPN group showed a significantly increased ROM compared to controls, but not to 
DM subjects.  Figure 8 illustrates knee ROM in the frontal plane during stair descent.  
DPN ROM was significantly greater than the control or DM groups.  In figure 9, the 
DPN group demonstrated significantly increased ROM at the hip (frontal plane) 
during stair descent compared with the other groups.  The majority of the DPN 
subjects had hip ROM above the mean, and the subjects with hip ROM below the 
mean appear comparable with the lower ranges of the corresponding DM group.  In 
figure 10, hip ROM in the transverse plane illustrates the increased ROM at the hip 
in the DPN group, which was significantly different to both results for the DM and Ctl 
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groups.  The DM and Ctl groups have a wide spread in their group data with some 
values at the extreme ranges for the group.  
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 Figure 6. Ctl, DM and DPN results for ankle ROM (sagittal) during stair ascent. 
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  Figure 7. Knee ROM (frontal) for stair ascent.                                                           Figure 8. Knee ROM (frontal) stair descent.                                                   
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. 
Figure 9. Hip ROM (frontal) for stair descent.                                                                           Figure 10. Hip ROM (transverse) for stair descent. 
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Chapter Four  
Discussion 
The purpose of the current study was to determine whether people with DPN 
demonstrate gait kinematics that are significantly different to people with DM and 
healthy controls.  To recapitulate, joint range of motion in the lower limb and stride-
to-stride fluctuations in joint range of motion were observed under three different 
walking conditions: level walking, stair ascent, and stair descent.  Significant 
differences between groups were identified in gait kinematics, but to a lesser degree 
for measurement of stride-to-stride variability.  The implications of the results will be 
discussed relative to each gait task.    
Demographic data confirmed that the three groups were similar in terms of baseline 
characteristics in all but the disease-dependent parameters such as the 
neurodisability score, and vibration perception threshold.  For a study of this size, 
imbalances in some of the measured variables at baseline are to be expected.  
There is no evidence that the measured imbalances will have any bearing on the 
measured outcomes. For example, it is highly unlikely that the gait characteristics of 
the DM and DPN groupsin the current study were due to obesity given the small 
magnitude of differences between their mean BMI. According to the National Clinical 
Guidelines for the assessment of obesity (NICE CG189, 2014), a BMI between 30 
and 34.9 kg/m2 is classed as obese. The DM & DPN groups’ average BMI was 28.0 
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kg/m2 and 29.0 kg/m2 respectively, neither of which equates to obesity.” Overweight “ 
corresponds to  a BMI between 25-29.9 kg/m2, and the healthy subjects in the 
current study had an average BMI of 25.6 kg/m2, also placing them in this 
category.The fact that all groups have a mean weight in the overweight range is in 
keeping with the national trend of rising levels of overweight individuals in the UK 
population (HSCIC, 2012 health survey). Within the DPN group itself, 32% of 
subjects had a BMI concurrent with obesity. In the DM group, 37% were obese, and 
in the healthy control group 14.3% were obese although all the groups had a large 
range of BMI values.  
Studies of gait in obese subjects often include subjects with BMI values in excess of 
30 kg/m2. For example, in Lai (2007), mean BMI was 33.6 for 14 individuals, whilst in 
DeVita and Hortobagyi (2003), mean BMI for the obese group was 42.3 kg/m2. This 
is reflective of the heterogeneity in data for gait and obesity, and, in a systematic 
review by Runhaar, Koes, Clockderts and Bierma-Zenstra (2011), lack of agreement 
between studies featured heavily. Nevertheless, the main characteristics of gait in 
healthy, obese people include slower velocity, shorter and wider steps, longer stance 
duration, and greater toe-out angle than non-obese individuals. It is also proposed 
that spending longer time in double support and assuming a wider base of support 
was part of a strategy aimed at increasing balance and stability. A simpler 
explanation was put forward by Browning (2012), who proposed gait changes to be 
the result of physical changes arising from obesity such as increased thigh diameter. 
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There is also the possibility that some gait changes are the manifestation of 
underlying poor cardiovascular function.  
 Katoulis et al (1997) recorded the following mean BMI values for their study groups; 
controls  25.5 kg/m2, non-neuropathic diabetes25.1, kg/m2  ,diabetic peripheral 
neuropathy 27.0 kg/m2 and diabetic peripheral neuropathy with a history of foot 
ulceration  27.0. kg/m2 . These are similar to the results for the current study. 
Participants for the Katoulis et al. study were taken from the same geographical 
catchment area as the current study, which suggests the current study’s data may be 
reflective of the local population.  
Age is unlikely to have influenced the results of this study due to the mean ages of 
the three groups: control 51.1, DMs 58.1, and 57.6 for DPNs, none of which concurs 
with other studies of “elderly” or “ageing” gait, which often make age 63 the starting 
age for inclusion. There is no definitive age at which gait becomes characteristic of 
being elderly, but the age ranges for each of our study groups are comparable with 
others such as Ferrandez (1990), Gomes et al. (2011),  Katoulis et al. (1997) and 
Mueller (1994). Changes in gait kinematics associated with ageing include 
decreased gait speed, and impaired responses to perturbations. Age can affect 
velocity and normal gait velocity for over 65s is between 1.00 m/s (Ferrandez, (1990) 
and 0.89 m/s (Himann, 1988).  
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Gait speed for level walking in the current study for the healthy subjects was 1.36 
metres per second (m/s), which concurs with other studies of healthy level-walking 
data. DPNs walked at 1.18 m/s, and DMs at 1.26 m/s. It is difficult to make 
comparisons with other studies, as most compare young versus old, and the age 
ranges in the current study fall into neither category. Lusardi, Pellecchia and 
Schulman (2003) divided their results according to age, and found subjects between 
the ages of 50 and 59 whowere healthy had a gait velocity over level ground of 1.43 
m/s. The non-DMs assessed by Mueller (1999) were a similar age to the current 
study groups at 56.8 years old, and had a velocity over level ground of 1.26 m/s.  In 
terms of DM and DPN, Mueller recorded 1.06 m/s for DMs. Katoulis et al. (1997) 
found DMs walked at 1.1 m/s, and those with a previous ulcer history at 1.07 m/s. 
Sawacha (2009) identified DMs at 1.10 m/s, DPNs at 1.2 m/s, and controls at 1.27 
m/s. These are fairly similar results to those obtained in the current study.  
The exact nature of the relationship between gait speed and gait variability has been 
difficult to establish, and there are many inconsistencies in the evidence base. Menz 
(2004) is one of few that identified increased variability in DPNs versus healthy 
controls, whereas other authors have failed to find any significant differences 
between DPN and healthy controls in terms of temporo-spatial gait variability in 
DPNs (DeMott et al. 2007; Dingwell 1999; Richardson 2004). Allet (2009) reported 
increased variability, but only when patients walked on an irregular surface. Perhaps 
increased gait variability only becomes apparent when the locomotor system is 
challenged.  
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4.1 Level Walking 
During level walking, subjects with DPN displayed a reduction in ankle range of 
motion (24.3°) in the sagittal plane, compared to DM subjects (26.5°), and healthy 
counterparts (27.8°), although this was not statistically significant.  There were no 
significant differences between the groups for gait variability during level walking.  
The findings are in keeping with previous studies that have examined joint range of 
motion in DPN subjects.  Similar changes in ankle joint range of motion in subjects 
with DPN have been described by Mueller (1994), Sawacha et al. (2009), and Sacco 
et al. (2009).  
 
The clinical significance of reduced ankle range of motion is related to the functional 
role of the ankle during the gait cycle.  The sagittal plane is the plane of flexion and 
extension, which is controlled by the ankle plantar flexors and dorsiflexors.  It is also 
the plane of forward progression, and the ankle makes significant contributions to 
many aspects of the gait cycle, including forward propulsion, body weight support 
(Keppel et al., 1997), vertical acceleration of COM (Wilken, Sinistski & Bagg, 2011), 
and maintenance of knee stability (Jonkers, Stewart & Spaepen, 2003).  Thus, 
reduced dorsiflexion and plantarflexion during level walking has the potential to 
disrupt the normal gait cycle from the onset of heel strike through to heel strike of the 
contralateral limb.  Initial foot contact requires the ankle to be dorsiflexed with the 
plantar surface of the foot just above the ground.  The foot should be lowered 
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smoothly and steadily through eccentric contractions of the dorsiflexors, but if this is 
impaired, foot slapping can result when contact is made.  This type of gait is 
associated with pathologies such as peroneal nerve injury, lumbar spine (L4/L5) disc 
herniations, and unilateral hemiparesis arising from CVA rather than DPN.  However, 
it is likely that DPN produces a slow, progressive reduction in dorsiflexion.  Although 
this gait pattern was not assessed as part of the current study, it is unlikely to have 
been overlooked during the locomotion tasks, given that it is highly audible and 
visually obvious.  Nevertheless, reduced plantarflexion-dorsiflexion has the potential 
to cause gait changes with the potential for negative functional consequences.   
 
Reduced plantarflexion is likely to result in excess sagittal plane tibial rotation as the 
eccentric contraction of plantar flexors required to control forward rotation of the tibia 
may be decreased.  The outcome could be that the centre of mass overshoots the 
base of support leading to a moment of instability when the subject becomes at risk 
of loss of balance (Sutherland, Cooper & Daniel, 1980).  Reduced dorsiflexion, at the 
point of weight transfer, mid-stance, would reduce the capacity of the supporting limb 
to bear body weight during swing, and could result in premature “toe off”, which will 
create a further vulnerability to instability. This can be related to Winter’s (1995) 
inverted pendulum hypothesis, whereby the body is envisaged as a pivot on the 
ankle joint and, in the absence of the pivot, balance can be lost.  A reduction in 
sagittal plane range of motion at the ankle could increase vulnerability to balance 
disturbances and unsteadiness during level walking.  This is also in keeping with 
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studies that have reported that people with DPN spend increased time in double 
support to assist in maintaining balance (Mueller, 2000; D’Ambroghi et al., 2005).  
  
4.2 Stair Ascent 
 
As discussed in the introduction of this document, few studies have examined 
kinematics in stair negotiation. Those that have investigated joint angles have 
focused almost exclusively on the sagittal plane. Furthermore, there is no 
consistency in approach regarding specific measurements utilised to determine joint 
angle motion in terms of mean peak angle, total range of motion, and angular 
displacement angle. The current study shares similarities and differences in 
methodology with others. The current study used a seven-step staircase to obtain 
two-and-a-half full gait cycles, whereas others use only four steps. Due to the wide 
range of methodologies available, the number of variables under investigation, and 
methods of measuring gait kinematics, it is not possible to ascertain from the 
literature what the “normal” range of motion for the hip, knee and ankle joints is 
during SA or SD in healthy, age-matched individuals.  
As observed in the level-walking task, ankle joint range of motion during stair ascent 
was reduced in the DPN subjects (32.5°) compared with DMs (37.0°) and controls 
(37.1°) in the current study. Although not statistically significant, the results are 
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similar to the findings of Onodera, Gomes, Pripas, Mezzarane & Sacco (2011), who 
reported a decrease in maximum ankle dorsiflexion during stair ascent towards the 
end of forward continuance.  Additionally, Onodera et al (2011) found theDPN 
subjects showed a decrease in maximum plantarflexion at the end of forward 
continuance compared to controls 
The task of stair ascent is biomechanically demanding due to the increased range of 
motion required in the joints of the lower limb, and the increased strength necessary 
to bear body weight whilst also allowing vertical displacement of body mass 
(McFadyn & Winter, 1988).  As illustrated in the discussion of level walking above, 
there are specific points during stair ascent when reduced ankle range of motion 
could increase the risk of tripping or falling.  As weight acceptance begins, the hips 
and knees move into flexion and the ankle on the leading limb is dorsiflexed, the 
angle of which increases when single support is initiated, and the supporting limb 
bears full body weight whilst also being raised vertically through the ankle.  Reduced 
dorsiflexion will impact on available knee flexion and restrict forward progression of 
the tibia, resulting in a posterior shift in the centre of mass, which will compromise 
balance and stability (Zietz, Johannson & Holland, 2011).   
Decreased ankle range of motion, as identified in the DPN group of the current 
study, may also disrupt the pull-up phase of stair gait.  This phase requires 
considerable power generation from the ankle, knee and hip to lift the swing limb 
from one step to the next.  Although the greatest magnitude of muscle activity is 
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generated by the knee during this phase, the ankle also assists with vertical lift.  
There is the potential for reduced ankle joint motion to compromise vertical lift and 
prevent the foot from clearing the next step (Hamel, Okita, Higginson & Cavanagh, 
2005).  A collision between the swing limb and stair beneath is even more likely in 
the presence of decreased dorsiflexion as well.  It is reasonable to speculate that 
reduced range of motion at the ankle during stair ascent has the potential to increase 
the risk for falls in people with DPN by undermining balance and stability.   
 
A significant increase in knee ROM in the frontal plane was demonstrated by the 
DPN group during stair ascent (16.9°) in comparison to DM (14.6°) and control 
(11.5°) groups.  Knee abduction-adduction is associated with the frontal plane of 
motion, but does not usually feature in normal gait due to anatomical restrictions 
imposed by the hip and ankle.  However, the current study also illustrated increased 
flexion-extension at the hip during stair ascent, which could assist the knee in 
achieving this abduction-adduction position.  The changes at the knee and hip could 
also compensate for the reduced ankle range of motion, as greater hip flexion-
extension would assist with foot clearance and foot placement during stair ascent 
(Graci, Elliott & Buckley, 2009).  There would be a beneficial effect on stability as a 
greater degree of flexion-extension at the hip could increase the base of support, 
thus increasing stability. (The combination of increased knee abduction-adduction 
with increased hip flexion-extension appears to represent a gait adaptation to 
compensate for reduced plantarflexion-dorsiflexion at the ankle.)  
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Increased range of motion in the sagittal plane at the hip was observed, with the 
DPN subjects achieving a mean range of motion of 58.3°, the DM group 59.2°, and 
controls 55.4°.  Although the DM group appears to have a range of motion that is 
greater than the DPN group, multiple comparison testing did not identify a significant 
difference between the means of the DM and DPN groups.  The dot plots show the 
distribution as similar between the groups, so hip range of motion appears to be 
similar whether there is peripheral neuropathy or not.  This suggests that the 
increased hip ROM occurs as a result of the diabetes rather than the PN, or, it may 
be indicative of alterations in sensation which are occurring before clinical PN 
emerges, and subsequent compensatory strategies are initiated.   
This is in keeping with Mueller (1997) who also found increased range of motion at 
the hip and assumed it to be a compensatory strategy for reduced ankle range of 
motion.  However, it would be necessary to confirm such a supposition with more 
data, i.e., a larger study.   
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4.3 Stair Descent 
 
Stair descent is more demanding than ascent due to the requirements of greater joint 
angles, and control of body weight against gravity (Protopapadaki et al., 2007), 
which could result in more exaggerated gait disturbances.  The DPN group in the 
current study achieved a mean ankle range of motion in the sagittal plane of 51.1°, 
the DM group achieved 58.0°, and controls 58.8°.  Reduced plantar flexion and 
dorsiflexion during stair descent has been reported in one other study of stair 
negotiation, and the authors found this to be most evident in the weight acceptance 
phase (Odonera et al., 2011).  
Limited ankle range of motion is likely to have significant repercussions on the safety 
of stair descent, as large dorsiflexion angles are required to complete the task.  
During forward continuance, balance relies heavily on ankle stability to bear the 
weight of the contralateral limb and, thus, reduced range of motion could disturb 
stability and compromise balance.  The controlled lowering phase requires significant 
ankle dorsiflexion in the stance limb and plantar flexion in the swing limb in 
preparation for foot placement.  Reduced ankle range of motion at this point in the 
stair descent process could result in loss of balance during controlled lowering, or 
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insufficient lowering for the foot to contact the step below.  As the swing leg is pulled 
through, foot clearance may be compromised by reduced plantar flexion.  The 
phases of the stair gait cycle described above represent the points at which falls risk 
will be increased due to altered balance and/or stability.  Insufficient range of motion 
to move the lower limb and body weight from one step to the next will also limit stair 
descent.   
The current study demonstrated increased frontal plane ankle range of motion during 
stair descent in the DPN group (10.6°) versus DM (10.4°) and controls (8.9°).  
Additionally, the DPN group showed increased frontal plane movement at the hip 
(DPN 15.2°, DM 13.5°, controls 11.2°) and knee (DPN 12.6°, DM 12.3°, control 9.2°) 
when compared with the DM and control groups.  Transverse plane hip range of 
motion was also significantly increased in the DPN subjects (20.2°) in comparison to 
DMs (16.0°) and controls (14.4°).   
The data demonstrate a statistically significant difference in joint ROM between the 
DPN and control groups obtained during stair descent. Specifically, there is a 
reduction in ankle ROM in the sagittal plane accompanied by increased hip ROM in 
the frontal and transverse planes. The features observed at the hip are equivalent to 
abduction-adduction and external-internal rotation, both of which would also facilitate 
a more abducted position at the knee. The alterations in DPN joint ROM may 
represent a gait strategy to compensate for the limitations imposed by reduced 
plantarflexion-dorsiflexion at the ankle. Furthermore, increased abduction-adduction 
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of the hips accompanied by additional rotation will reduce the overall angle of 
descent for the swing limb during forward continuance to the step below. Utilising the 
lateral thigh muscles and knee flexors should aid foot clearance, providing further 
compensation for reduced ankle joint ROM.  Increased hip rotation and frontal plane 
movement during stance may also assist the ankle in supporting body weight during 
single stance.  
Stair descent requires the absorption of kinetic energy through eccentric muscle 
contraction at the ankle, knee and hip (McFadyn & Winter, 1988). The beginning and 
end of single support are high demand periods for the ankle and knee specifically. 
Peak energy absorption at the knee occurs during weight acceptance and controlled 
lowering in stair descent.   The increase in knee range of motion in the frontal plane 
observed during the current study may be part of load redistribution to compensate 
for impairment at the ankle. This has also been reported in a study by Reeves, 
Spanjaard, Mohaghegi, Baltzopoulos and Magnaris (2008), whereby  older people 
compensated for reduced ankle and knee ROM by increasing activity from the hip 
extensors. The redistribution of joint moments allowed subjects to operate at their 
moment reserve rather than at their moment limits in order to keep energy costs 
within safe parameters. It is possible that the DPN group in the current study is 
utilising a similar strategy of compensatory load redistribution. In conclusion, the 
current study of stair negotiation in subjects with DPN has demonstrated that DPNs 
have reduced range of motion at the ankle joint, which is compensated for by 
alterations in joint angles in other planes of motion, suggestive of a compensatory 
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gait strategy . To the best of this author’s knowledge, a compensatory stair gait 
strategy in people with DPN has not been reported in the literature before.  
 
4.4 Gait Variability 
The hypothesis was based on investigating any significant differences between the 
groups in relation to variability in joint ROM from one gait cycle/stair cycle to the 
next.  No significant differences were identified between the three groups of the 
current study for gait variability (stride-to-stride fluctuations in range of motion) during 
level walking or stair ascent.  However, a trend towards increased variability in the 
DPN group was observed during stair descent in comparison with the DM and 
control groups.  This occurred at the knee and the hip in the transverse plane of 
motion.   
The greater challenge of stair descent may demand less variation in gait patterns 
given the need to work against gravity to maintain an upright position, whereby gait 
patterns need to be precise. In this sense, it would follow that there are no significant 
variations between the groups.  
The absence of a significant difference between the three groups for variability in 
joint range of motion could be attributed to a number of factors. Firstly, there are 
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methodological issues related to parameters selected for measurement and sample 
size, and, secondly, there are physiological/theoretical, and statistical issues. 
Hausdorff (2001) identified gait variability as a marker for falls in a study of 
community-dwelling elderly people. The conclusions were based on a large body of 
data generated from extensive gait testing of up to 6 minutes’ continuous walking to 
obtain kinematic data for several hundreds of strides per subject. These were 
analysed by taking the time series for stride time and calculating the standard 
deviation of the time series for comparison against each subject’s mean stride time.  
Dingwell (2001) measured variability in sagittal plane motion at the hip, knee, and 
ankle. Subjects walked 200 metres at a “natural pace”.  Gait variability was 
calculated from the “average stride times and standard deviations of stride times 
obtained from the individual stride times extracted from the continuous time series 
data”(Dingwell, 2001,p.4) Although the current study has used the standard deviation 
as a measure of variability, it has not been calculated within each time series 
variable, which may contribute to the lack of variability observed in the groups.  
Hausdorff (1996) reported that fluctuations in the time elapsed from one heel strike 
of one limb to the next heel strike of the same limb (the stride interval) demonstrate 
marked similarities with the fluctuations. If gait variability measures are to 
encompass long-range correlations in physiological time series, then calculation of 
time intervals or their demarcation should be an integral part of data management. 
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The calculation of a single value (CV or SD) to indicate variability in the sense that 
Hausdorff intended may be an oversimplification.  
There are obvious limitations in generating data for stair negotiation mainly related to 
fatigue, especially in subjects with medical conditions and co-morbidities. The reality 
of investigating disease state or disease effects is that methodologies used on 
healthy individuals may not transfer seamlessly to those suffering with a chronic 
disease, and the suitability of gait variability measurement may need exploring 
further. Lord, Howe, Green, Simpson and Rochester (2011) conducted a literature 
review of the clinical value of measures of gait variability paying specific attention to 
reliability and validity. The authors’ conclusion is there is a lack of consistency in the 
application and calculation of gait variability.  
The current study has not calculated gait variability in the form described by 
Hausdorff (2001), as the physical limitations imposed by diabetes and the use of 
stairs restricted the volume of gait data generation.  
The lack of significant variability between the groups could also be related to the 
parameters being measured.  Hausdorff et al. (2001) advocated calculating gait 
variability for parameters such as step-length, step-width, and stride-time, which 
were later correlated with falls risk through a prospective one year study of older 
adults living in the community (Hausdorff et al., 2001).  In contrast, there are no data 
to support the reliability or significance of calculating stride-to-stride fluctuations in 
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joint range of motion, and it is possible, therefore, that this measure cannot be 
applied to joint range of motion. Alternatively, given the large number of tests 
conducted, and the fact that the transverse planes in the hip and knee had not been 
identified a priori as planes of specific interest where a significant result was 
expected, the p-values obtained, despite being below 0.05, should not all be 
interpreted as being indicative of a statistically significant difference of gait variability 
in these particular planes.   
The present study found that people with DPN have reduced range of motion at the 
ankle during level walking, in comparison to DM and healthy controls, which may 
compromise balance and stability during gait.  The DPN group also showed limited 
ankle range of motion during stair ascent, but increased knee adduction-abduction, 
together with increased hip flexion-extension as a possible compensatory 
mechanism.  Given that stair descent is more demanding than the previous gait 
tasks, it was not surprising that gait adjustments were more pronounced, resulting in 
subjects utilising a side-stepping strategy to move down the stairs.   
The alterations in knee and hip range of motion observed in the DPN group suggest 
a co-ordinated response to compensate for restricted ankle range of motion.   
 
4.5 Clinical and Research Implications  
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The presence of a gait strategy, as illustrated in this study, would appear to enable 
the subjects with DPN to complete the task of stair negotiation. However, this does 
not necessarily concur with efficiency and safety, which may be compromised due to 
the new strategy. Further data is required to determine the true nature of any gait 
deficit that is prompting the change in underlying gait patterns during stair descent. 
Some authors have suggested that people with DPN generate their muscle moments 
more slowly than healthy counterparts whilst also working almost to their maximum 
capacity (Reeves et al., 2008). This could possibly respond to resistance and 
strength training of muscle groups.   
Fear of falling is inextricably linked to a higher risk of falls, as noted by Maki (1997). 
It is possible that the gait strategy observed in the DPN group is related to fear of 
falling. Herman, Giladi, Gurevich and Hausdorff (2005) reported study results that 
suggested a cautious gait could be a manifestation of such a fear, arising from 
underlying unsteadiness. 
The present study has observed a reduction in ankle range of motion during gait 
among people with DPN, which is unsurprising given the large number of studies 
that have demonstrated this previously.  DPN symptoms begin distally and ascend 
proximally as a result of which, it is highly likely that dennervation also follows this 
pattern.  The low threshold afferents of the sural nerve have demonstrated inhibition 
over tibialis anterior, whilst the afferents of the tibial nerve increased tibialis activity 
(Aniss, Gandevia & Burke, 1992). The results suggest mechanoreceptors in the 
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plantar surface of the foot have multi-synaptic connections with the motor neuron 
pools innervating the muscles at the ankle.  Iles (1996) found that excitation of low 
threshold receptors on skin in humans in the dorsal foot depressed presynaptic 
inhibition of soleus Ia afferents, especially during ankle extension.  Similarly, Nielsen 
and Sinkjaer (2002) performed a series of tested subject responses to unloading or 
stretching the plantar flexors during stance.  Unloading the plantar flexors resulted in 
a drop in soleus activity at a latency of 60 milliseconds, which equates to tendon 
afferent (group II) activity.  Latencies are shortest when the stimulus is closest to the 
efferent, and when fibres are myelinated.  In addition, unloading the plantar flexors 
stretches the dorsiflexors, which probably contributes to inhibition of motor neurones.  
The findings reported by Nielsen and Sinkjaer (2002) demonstrate the 
interconnectivity of neurones involved in gait, and imply that group II afferents 
contribute to the motor neurone drive of the plantar flexors.  In essence, alterations 
in afferent fibres, as in peripheral neuropathy, could reduce motor activity of the 
ankle plantar flexors and dorsiflexors via combined synaptic inputs to interneuron 
pools.   
Another study supporting the results above is that of Fallon et al. (2005) which 
identified 53 afferents in the cutaneous surface of the foot innervating low threshold 
mechanoreceptors.  47% cent of these were rapidly adapting types of afferents 
(respond quickly to stimulus and return to pre-stimulus level of activation quickly), 
and the remaining 53% were slow adapting.  Rapidly adapting type 1 afferents were 
found to be coupled with spinal motor neurones, and stimulation of these afferents 
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modulated EMG activity in tibialis anterior, gastrocnemius and soleus.  The role of 
the small nerve fibres of the foot and ankle can be overlooked in studies of gait, but 
as technology advances, the influence of the peripheral nerves is becoming more 
apparent. Stimulation of the plantar nerve during mobilisation attempts by spinal cord 
injured patients resulted in modification of abnormal gait reflexes to produce a more 
functional gait pattern (Knikou, 2010).The aim of citing the papers above is to 
emphasise that the peripheral nerves in the foot and ankle have a significant 
influence on lower limb muscle function and gait.  Diabetic peripheral neuropathy, 
therefore, can disturb the function of these neurones and, as such, significantly alter 
muscle function in the lower limb.  Plantar, cutaneous afferents and 
mechanoreceptors have a greater role in muscle activity than previously thought, 
which should be incorporated into future investigations of gait function in people with 
DPN.  
The current study has demonstrated several points during stair ascent and descent 
where the risk of falling may be increased due to reduced ankle range of motion. 
Whilst subjects employ an apparent gait strategy to compensate for this, there is no 
evidence that these strategies are successful in reducing the risk of falls.  This would 
require further prospective study of a larger sample of DPN subjects, and gait 
analysis during stair negotiation to determine the nature and frequency of strategies 
used.  Subjects could then be monitored in terms of “time to falling” and compared 
with matched controls.  It would also be useful to investigate inter-subject variability 
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in terms of adaptive gait strategies to determine whether alterations are consistent, 
and whether they are suggestive of an innate adaptive process.   
4.6 Study Limitations 
The current study attempted to minimise confounding factors as much as possible 
and, given the robust inclusion and exclusion criteria, it is likely at least some of the 
findings can be attributed to diabetes with peripheral neuropathy.  The sample size 
appears small from a statistical perspective, with only 19 subjects in the DPN group 
after losses.  This is perhaps reflective of difficulties recruiting and maintaining 
subjects that already carry a heavy appointments burden due to their underlying 
disease.  Furthermore, the sample size in the current study is comparable with other 
studies in this clinical area, for example Dingwell and Cavanagh (2001) had 10 DPN 
subjects and 10 matched controls, and Sawacha et al. (2009) recruited 20 controls, 
26 DPN subjects and 21 DM subjects, but they do not report numbers lost to follow 
up. Rao (2006) recruited 10 DM subjects and 10 DPN subjects, while Sacco (2009) 
used 31 patients divided into two groups to form DPN and control groups, but fails to 
explain which group was the bigger.  Finally, Carter (2009) assessed 39 subjects 
with DPN. Overall, the group sizes are in keeping with this study and are probably 
reflective of the difficulties in recruiting and retaining people with a medical condition 
that is associated with multi-professional care and, therefore, multiple appointments.  
Patients can have a full day of review, out-patient appointments, and fatigue, face 
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transport costs, and experience fluctuations in motivation. All of these can impact on 
whether or not patients arrive for research projects.   
 
The depth and quality of neurological testing carried out is not observed in many 
other studies.  Mueller (1994) did not perform any baseline testing of neuropathy, as 
the inclusion criterion was a history of foot ulceration.  Carter (2009) included 
subjects based on their symptom descriptions plus additional assessment for an 
absent or decreased Achilles reflex, Michigan neuropathy score, and electro-
diagnostic testing of the peroneal or sural nerve.  This represents a good balance of 
neurological tests as they relate to human anatomy and physiology.  Rao (2006) 
used only the monofilament, which, to diagnose neuropathy, is inadequate.  Sacco 
(2009) used the Michigan neuropathy instrument to diagnoses diabetes, and this 
includes an inspection of the foot, ankle tendon reflex test, and monofilament.  This 
is a basic screening tool and, to ensure an accurate diagnosis, it should really be 
carried out alongside other instrumental testing modalities.   
The NDS utilised in the current study has an advantage, as it includes instrumental 
vibration perception testing with the Biothesiometer, used in harmony with the other 
tests.  Sacco (2009) tested every aspect of sensation and structure in the foot, going 
on to test the cardiovascular system for signs of autonomic dysfunction and pelvic 
tilt. Dingwell (2001) utilised VPT with two devices - one custom made, with the other 
being the biothesiometer.  
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The Vicon three-dimensional analysis of gait also has the potential to be a source of 
error, as demonstrated in a study by Gorton, Herbert and Gaunotti (2008). The 
nature of variability in 3D gait analysis was investigated across 12 different 
laboratory sites utilising 24 different assessors measuring one subject. They reported 
that less than 2% of overall variance was due to system inaccuracy. The conclusion 
was that inaccuracies arose from variations in marker placement. However, 5 of the 
12 of the laboratories used in the study did not undergo testing of system accuracy 
prior to assessment due to processing problems and different marker configurations. 
In the absence of this data, it is difficult to conclude, as the authors do, that more 
than 75% of the variation arising in 3D gait analysis originates with examiners and 
their marker placement. Moreover, the examiners came from a wide range of 
professional backgrounds including Orthopaedic surgery, Physiotherapy, Podiatry 
and Orthotics. The average maximum difference between examiners for parameters 
measured was 14.8 degrees and, for joint angles specifically, the difference ranged 
from 1.2 degrees to 7.3 degrees. In the absence of the calibration data for the other 
sites, it is possible that this is not a true reflection of between-examiner differences.   
 
Summary 
To summarise, it is essential for diagnostic criteria to be robust when a study aims to 
compare one group against another, as the disease type forms the basis of all future 
  
129 
 
investigation and analysis.  In the absence of assessments with established reliability 
and validity, it is difficult to extract meaningful information from data.  There is a wide 
variety of equipment available for collecting kinetic and kinematic data for gait 
analysis.  The current study used Vicon motion capture with plug-in-gait, but other 
gait analysis tools reported in the literature include the DataLogger back pack and 
goniometers, as used by Dingwell (2001), the Optotrak 60Hz marker system (Rao, 
2006), and the Pedar-X (Sacco, 2009).  It is difficult to determine how comparable 
these are with each other, however.  
 
In terms of data analysis, a high number of comparisons were made for different 
parameters between the groups.  Range of motion was compared in three different 
joints, in three different planes of motion, for three disease groups, in addition to 
examining variability in range of motion for all of the preceding parameters.  The high 
number of comparisons made between the groups increases the risk of a type 1 
error, which Newman-Keuls post-hoc testing can normally correct for, but this is 
unlikely to be effective with such high numbers and, therefore, results should be 
interpreted with caution.  The number of comparisons could have been reduced by 
selecting only one stair direction to compare with level walking.  The use of three 
groups was important to monitor for a “diabetes effect” versus a “DPN effect”.  It may 
have been more appropriate to use a total range of motion at each joint rather than 
range of motion from sagittal, frontal and transverse planes.  Despite the fact that 27 
“test triplets” were conducted on each outcome, it is reasonable to assume that 
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these triplets are related to some degree, and, hence, applying a Bonferroni 
correction would result in over-conservatism.  The method adopted was thus to 
conduct post-hoc tests within each triplet, and to consider the resulting p-value 
significant if it was substantially under the usual threshold of 5%.  
 
The absence of gait variability across the different tasks could possibly be attributed 
to an insufficient number of steps captured.  Gabell and Nayak (1984), Guimares 
and Issacs (1980), and, later, Hausdorff (1997) have been the main advocates of 
gait variability research and its application to falls risk.  Whilst a multitude of studies 
have identified increased variability in selected parameters between specific healthy 
versus ageing-or-diseased groups, the link with falls is mainly based on inference 
from, albeit large, longitudinal and cross-sectional studies.  There is a lack of data 
concerning the predictive value, validity and reliability of gait variability in predicting 
falls versus other validated assessments.  Available data regarding gait variability 
and falls comes from a vast array of studies that differ significantly in terms of age 
and type of subject groups, measurement tools, processing technology, and type of 
gait task being assessed.  Furthermore, there is no agreement as to whether gait 
variability reflects an abnormal or normal locomotor system (Hausdorrf, 2007).  
Bearing this in mind, it is possible that joint range of motion during stair negotiation 
and level walking is not an appropriate indicator of variability.  This is compounded 
by the lack of agreement in the literature regarding the minimum number of steps to 
use when measuring variability.  Hartmann et al. (2009) advised 20 metres, or 25 
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steps, for assessment of step duration or step length, whilst Dingwell and Cavanagh 
(2001) advocated 10 minutes’ continuous walking.  Paterson, Lythgo and Hill (2009) 
reported that short bursts of interrupted walking do not give sufficient time to 
accurately measure spatiotemporal parameters, as subjects do not achieve steady 
state walking until after 20 to 25 stride cycles.  However, the first 20 to 25 stride 
cycles could also be where the falls risk occurs.  The current study used two-and-a 
half gait cycles, which may be inadequate, but, by the same token, even healthy 
individuals would struggle to perform a high number of stair ascents and descents.  
 
Future investigation of gait in subjects with DPN and the possible relationship to 
falling necessitates a prospective study, whereby baseline data is obtained for gait 
function, and subjects are followed up for a period of 12 months for falls occurrence.  
Given that fallers are not reliable sources regarding their own falls status, utilising 
GP records, diabetes clinic reviews, and Accident and Emergency attendance would 
assist in producing more reliable data.  
4.7 Consideration for Future Work 
Variability is inherent in many aspects of human movement, whether the motion is 
voluntary as with walking, or involuntary like the rhythm of the heart. The underlying 
function of variability in human motor systems is not fully understood, and it is 
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unclear whether variability is related to errors made during the execution of a 
movement, in which case practise should reduce variability (Summers & Anson, 
2009).  Other hypotheses suggests that variability arises due to interference from 
redundant motor systems (Domkin et al., 2002), and there is the suggestion that 
variability is a reflection of a biological system attempting to find a stable solution for 
movement in a given environment (Kamm, Thelan & Jensen, 1990).   
Measures of variability have been accepted and highly utilised for gait analysis in the 
form of the co-efficient of variation and standard deviation.  However, some authors 
report that motor programming and the execution of movement cannot be evaluated 
by linear measures of centrality, as this assumes that any variations in movements 
are random and unrelated to previous or future variations.  Hausdorff (2009) and 
Dingwell (2007) have illustrated that the variations that occur during gait are not 
random “noise”, and have fractal properties.  Non-linear measures of variation in 
motor function may need to be considered as part of future gait research, as 
illustrated in studies by Cavanagh et al. (2010), Meyers et al. (2010), and Stergiou 
and Decker (2011).  The application of variability to gait analysis of people with DPN 
may benefit from the involvement of professions not traditionally associated with 
clinical research such as biophysics and mathematics.  
Researchers that utilise variability as part of gait analysis, such as Hausdorff, have 
expressed the need for agreed protocols on the methods to be used when gathering 
and analysing data on gait variability, as practise differs vastly around the world.  
  
133 
 
One of the significant findings from the current study was the lack of variability in 
range of motion parameters in any of the subjects studied.  This may well be 
reflective of an inappropriate application of variability measurement to this particular 
gait parameter. It would be interesting to explore, using a larger sample size, 
whether non-linear analysis of joint range of motion would illustrate altered patterns 
of variation between the study groups.  
There is insufficient data in the literature to conclude that DPN causes gait 
abnormalities which increase the risk for falls.  However, given the shared anatomy, 
physiology and neurology, it is difficult to dispute that a relationship exists in some 
form.  Data from a large, prospective, well-designed, and objectively measured study 
is required in order to establish the kinematic characteristics of DPN gait, after which 
subjects are monitored for actual falls.   
4.8 Conclusion 
This study has demonstrated that there are significant differences in joint range of 
motion in the lower limb between people with DPN, in comparison to DM individuals 
and healthy controls.  This is characterised by reduced range of motion at the ankle, 
which appears to be offset by a simultaneous increase in knee and hip range of 
motion, and this may represent a strategy to compensate for limitations at the ankle.   
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The differences between the groups were most apparent during stair negotiation due 
to increased biomechanical demands, and, as such, future investigations of DPN gait 
could benefit from assessment of subjects ascending and descending stairs.  
Assessment of gait variability failed to identify consistent differences between the 
groups, but this may have been an inappropriate measure to use with range of 
motion.  
Results from the current study reflect those from previous studies, but it is difficult to 
relate this to an increased risk of falls, as there is no evidence demonstrating a direct 
correlation between reduced ankle range of motion and falling.  Research can 
sometimes be based on assumption and inference rather than evidence. Therefore, 
a strong, reliable evidence base is required to underpin the link between DPN and 
falling.  Promoting real improvements in management of DPN necessitates the 
development of studies with increased sample sizes to provide robust methods and 
generation of clinically relevant, reliable data that answer the question of whether or 
not DPN increases the likelihood of falling.   
Rehabilitation programmes to maintain muscle strength, balance and co-ordination 
may be beneficial at reducing the inferred risk of falling, but positive effects could be 
short-lived given the progressive nature of DPN.  Managing falls risk in the DPN 
population would require considerable financial resources for surveillance, education 
of patients, risk assessment, risk management, and adaptations within the home 
where necessary.  The basis for increased funding in the NHS today is robust 
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evidence, and demonstrating a direct link between DPN and falling should continue 
to be a goal in clinical research.   
 
Chapter Five  
Personal Impact Statement for Frank L. Bowling 
 
The current research originates from patients attending the diabetes clinic in 
Manchester. During Podiatry assessment and treatment sessions, several patients 
complained about difficulties encountered during walking.  
 “I feel like I’m going to trip up on my own feet”, “I don’t know what my feet are doing 
when I’m out, I have to actually look at them”, “I have to concentrate on my feet and 
keep my balance when I’m coming down the stairs”.   
My responses to their complaints were initially constrained by my own lack of 
knowledge in this area and, therefore, little significance was attached to their 
descriptions. Over time, it became apparent that more patients were describing 
similar experiences, which prompted me to question myself; perhaps I had 
overlooked this aspect of lower limb complications associated with diabetes. A brief 
literature search and discussion with colleagues allayed my fears, having discovered 
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there were only a handful of studies linking gait changes with diabetes, and nothing 
at all in associated clinical guidelines. Nevertheless, the combination of patient 
descriptions of walking issues and the identification of a few relevant publications 
was sufficient to motivate me to investigate further.  
Having worked in diabetes for the last 13 years, I have devoted my employed life to 
the pursuit of preventing and managing diabetic lower limb complications. The 
possibility of a gait or balance disorder affecting this client group alarmed me due to 
the potential for increasing falls and soft tissue injuries with a subsequent increased 
risk of foot ulceration. I set out to clarify and characterise the gait patterns of people 
with Diabetic Peripheral Neuropathy (DPN) with a view to determining if there was an 
unidentified need within this patient group. The journey towards this goal has been 
difficult, not least due to working full time, but it has yielded new insights into the 
world of research across higher education institutions, NHS Trusts, and the NHS as 
an organisation.  
The current work has illustrated that people with DPN use what appears to be a gait 
strategy during stair descent tasks, and this is probably the result of reduced range 
of motion at the ankle joint. We can infer that this may increase the risk for falling, 
which has huge implications for DPN patients and service providers. Further 
research is necessary in order to establish how many of these patients go on to fall, 
and a prospective study would be beneficial.  
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Evidence, in the form of research, provides the basis for reallocation of resources, 
re-organisation of clinics, and new strategies to facilitate prevention and 
management of a newly identified risk.  In considering the impact of the current 
thesis on people, there is insufficient evidence here or in the studies cited in the 
literature to inform a change in practise. Research cannot promote change for 
change’s sake. Change in practise should be based on the principles of evidence-
based medicine which incorporate structured and critical appraisal of the evidence, 
clinical knowledge, and experience. Soper and Hanney (2007) conclude that 
implementing research is hugely complex, and has been underestimated.  
 
My vision for this work is that it promotes and inspires further investigation of gait 
alterations in people with DPN, and a prospective study of falls risk in this patient 
group.  The findings have been published in a peer reviewed journal, and presented 
at two European conferences attended by experts in diabetes and lower limb 
complications. It is anticipated that the wider dissemination of the study’s findings will 
sow the seeds of further research questions related to gait changes and falls risk in 
DPN so as to achieve a collective, relevant research base upon which new practise 
guidelines can be built.  
One of the major difficulties encountered during the study became a significant 
learning opportunity for me. The study was conducted between two universities and 
a hospital trust in order to secure appropriate equipment and patient recruitment. 
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The collaboration was not without difficulties, which, on reflection, arose due to 
frustrations based on misconceptions. A lack of exposure to people with chronic 
diseases led to collaborators from a non-clinical background becoming frustrated by 
the constraints associated with this. Moreover, training in the use of equipment 
technology for the study was more time-consuming than first envisaged, increasing 
time pressures on all involved. The net result was a slightly charged atmosphere.  
This situation has illustrated to me, on a personal level, that I need to be more 
descriptive and transparent regarding my own gaps in knowledge. This would have 
probably resulted in training issues being given a higher priority, and reduced 
frustrations on all sides. I also now appreciate that shared knowledge cannot be 
assumed between professionals, and should be clarified.  Advanced communication 
skills are vital if this is to be achieved.  With the benefit of hindsight, this can also be 
relevant when investigators from a non-clinical background are involved in patient-
based study. Observation of patients undergoing a relevant assessment or treatment 
provides an opportunity to familiarise researchers with targeted patient groups, for 
example, spending half a day attending a clinic to observe and build a picture of 
health needs, physical and psychological demeanour, and social issues that may 
influence patients’ attendance/non-attendance. This could also foster an 
understanding of the different roles involved in the research process.   
The lessons learned above are also directly applicable to multi-disciplinary or inter-
disciplinary projects within the NHS Trust. Assumptions breed misunderstandings, 
which can ultimately lead to conflict. One solution is to share the knowledge, 
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experience and perspective of others involved in projects from the outset, which can 
promote mutually agreeable outcomes. This solution can also be utilised to increase 
the understanding of the perspectives of researchers, clinicians, managers, and 
commissioners. 
In conducting this research I have encountered literature regarding the wider role of 
the researcher, and the benefits associated with research within the NHS. This has 
broadened my understanding and enabled me to see the possibility of using my skills 
to actively promote research within my own profession, and in the NHS Trust. I 
envisage my contribution to the next generation of future researchers in DPN and 
gait through inspiring and promoting research originating at the patient/service 
interface. The initial steps towards this require assisting clinical staff to understand 
and interpret the available knowledge. Allied Health Professionals often avoid 
reading studies due to difficulty understanding the statistics (Metcalfe, Lewin, 
Wisher, Perry, & Bannigan, 2001), which can be addressed easily. Journal clubs can 
increase familiarity with data analysis techniques through a group forum, whilst 
Continuing Professional Development (CPD) workshops focused on areas of 
identified learning needs within departments could also be beneficial. More novel 
ideas include a “research surgery” where professionals can drop in and ask for 
advice. Undertaking taught research modules can provide staff with the confidence 
to consider higher-level study.  It is unfortunate that many healthcare professionals 
feel they possess inadequate knowledge and skills to interpret or undertake research 
(Shakeshaft, 2008), but increasing the feeling of confidence among staff is possible.  
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Establishing the nature of the research culture within my own professional 
department can also assist with the dissemination of research by illuminating 
barriers. Obtaining information regarding perceptions of research and roles from 
management level downwards can highlight where specific problems lie, and assist 
in targeting where education and joint working is needed (Perry, Grange, Heyman & 
Noble, 2008).  
I intend to disseminate my experiences of research within the Podiatry department - 
partly to demonstrate the potential impact of successful projects, and partly to dispel 
myths associated with experienced researchers. The aim is to increase familiarity 
with the processes involved in research, address misconceptions, and reduce the 
trepidation with which research is approached by many clinicians.   
At an organisational level, inter-professional research strategy groups can be an 
effective means of increasing professional inclusion and of influencing joint research 
strategy. Such meetings can be intimidating for new or potential researchers, but 
attendance with a mentor may help.  
Engaging patients more by increasing their awareness of good quality care and 
guidelines defining this can also generate research from patients themselves. 
Patients have a different set of experiences, perceptions and motivations related to 
the NHS, and their views can be very different to the professionals’ assumption of 
need (Powell, 2003). After all, the experiences and comments of diabetes patients 
motivated the current work.  
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Research can generate more research, and raising professional profiles can assist 
with obtaining funding (Sopper & Hanney, 2007). Publications stimulate further 
research nationally and internationally whilst also raising the NHS Trust profile. My 
employer, Central Manchester University Hospitals NHS Foundation Trust (CMFT), 
in particular, aims to become a research leader, and individuals possessing a wide 
range of relevant skills can make a significant contribution to this process through 
the flow of information from strategic level to staff/patient level, and vice versa.  
Research implementation is just as much about changing attitudes as it is about the 
facts obtained from the study. Whilst the study findings are insufficient to promote 
changes in practise at present, the research journey and the emphasis on critical 
reflection has revealed to me a means of promoting a new understanding of the 
clinical guidelines that underpin practise through empowering others to develop 
critical thinking and experience the formulation of research ideas.  
Completing the professional doctorate has altered my views on research in relation 
to the overall contribution of findings. In reviewing NHS England’s research and 
development strategy (2013), I was struck by the long-term vision for the future of 
increasing healthcare research through empowering health care staff and, yet, 
research priorities would be set by commissioners and NHS England. Emphasis is 
placed on improving outcomes for patients without considering that many areas of 
research depend on the accumulation and assimilation of multiple works before 
translation to patient outcomes is possible. My work, when considered in a short 
term context, is insufficient to promote a change in practise at present. The longer 
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term impact will be based on the contribution made to the pool of knowledge 
developing on DPN and gait abnormalities. It is important that, in promoting 
research, the value of a piece of work is not restricted to whether it initiates a change 
in practise or not. The true value of a study may not become apparent until related 
works have been completed over time, in which case, the outcome may not become 
apparent for many years and studies later.  
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Introduction 
People with diabetes and neuropathy display gait instability and are, in fact, up to 20 
times more likely to fall compared to aged-matched controls. One of the factors 
thought to contribute to an increased risk for falling is an increase in the variability of 
many parameters of gait such as stride length and stride time (e.g., Richardson et 
al., 2008)  Increased variability in key temporal gait parameters may also become 
more evident between at risk groups when the environment negotiated becomes 
more challenging (e.g., Menz et al., 2004). We will investigate a range of everyday 
gait tasks that vary in the complexity of the environment to be negotiated. Tasks 
investigated will include level walking, stair ascent, stair descent, and stepping over 
an obstacle on level ground. Differences in gait variability will be investigated 
between three separate groups: people with diabetes and no/only mild neuropathy, 
people with diabetes and severe neuropathy, and a matched control group without 
diabetes. 
 
Research Aims 
1. To examine selected kinematic gait parameters in individuals with diabetes 
mellitus and peripheral neuropathy. 
2. To establish the degree of gait variability and thereby determine the risk of falls for 
individuals with diabetic peripheral neuropathy.   
Hypothesis 
People with diabetic peripheral neuropathy will exhibit significant differences in lower 
limb joint range of motion and increased kinematic variability during selected gait 
tasks in comparison to healthy controls. The degree of variability will increase as gait 
tasks become more challenging.  
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Methods 
 
The study population will be (1) patients with diabetes but no/only mild neuropathy, 
(2) patients with diabetes and severe peripheral neuropathy, and (3) age and body 
mass index-matched controls without diabetes. 
 
Inclusion Criteria 
1) Consenting patients with Type 1 or 2 diabetes (for the diabetes patient 
groups). 
2) Male or female, aged 20-80 years. 
3) Presence of significant neuropathy (for the neuropathy group only) as defined 
below. 
4) Absence of diabetes (for the matched control group only). 
 
Exclusion Criteria 
1) Unstable ischaemic heart, neurological (other than diabetic aetiology), or 
rheumatic disease.  
2) Cerebral injury. 
3) Disorders of the vestibular system.  
4) Musculoskeletal injury/recent surgery affecting gait.  
5) Amputation.  
6) Open foot ulcer.  
7) Use of centrally acting medications.  
8) Excessive alcohol intake (>30 units per week). 
9) Unable to speak and comprehend English. 
10) Unreliable, unwilling or unable to comprehend informed consent. 
 
Screening 
1) A detailed medical history will be taken, including questions about typical 
weekly alcohol intake and relevant medications used. 
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2) A visual acuity test will be performed. 
3) Tests to assess the presence/extent of peripheral sensory neuropathy will be 
performed. These tests will assess participants’ ability to detect very small 
applications of force and vibration to different areas of their feet. Neuropathy 
will be defined as moderate/severe according to standard assessments of a 
composite neuropathy disability score (normal = 0, moderate/severe 
neuropathy ≥6) and quantitative sensory testing of the vibration perception 
threshold. All patients allocated into the neuropathy group for this study will 
have a neuropathy disability score ≥6, and vibration perception threshold ≥25. 
 
Procedures 
 
Participants will be assessed in the gait laboratory within the Institute for Biomedical 
Research into Human Movement and Health at the Manchester Metropolitan 
University. The work for this doctoral thesis will link into a larger study on gait and 
diabetes already underway at the Manchester Metropolitan University. The ethical 
permissions and all other relevant approvals are currently in place for this study.  
 
Participants will be provided with standardised specialist diabetic footwear as well as 
other clothing appropriate for gait analysis (non-restrictive, but relatively tight-fitting 
clothing). We will measure participants’ height and weight and some other 
anthropometric measures, such as joint widths, using a measuring tape and 
callipers. Small retro-reflective markers will be placed onto specific parts of 
participants’ bodies to define joint centres of rotation and limb segments. The 
movement of these markers will be accurately tracked using a motion analysis 
system (Vicon system) consisting of ten infra-red cameras surrounding the testing 
area.  
 
Participants will also be asked to walk up and down a custom-built experimental 
staircase in the laboratory a number of times. The staircase is of standard 
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dimensions with handrails present. As an additional safety measure while walking on 
the stairs, participants will be secured in a harness.  
 
During all gait tasks, participants will walk at their self-selected speed and complete 
a number of trials for each task. Key parameters of interest are expected to be 
temporal characteristics such as step width, step length, stride time, and other 
kinematic variables such as centre of mass. The variability of these parameters can 
be evaluated within individuals, between repeated trials. In addition to this, 
participants will also walk on level ground.  
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Participant Code: ………..………….. 
 
PATIENT CONSENT FORM 
 
Title of Project: Factors compromising the safety of gait in people with diabetic peripheral 
neuropathy and the influence of intervention 
 
Chief Investigators: Neil D Reeves & Frank Lee Bowling. Principal Investigator: Andrew 
J M Boulton,  
            
 
I confirm that I have read and understand the information sheet dated 12/07/2011 (version 1) for the 
above study and have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
 
 
I agree to take part in the above study.       
 
 
I agree to my GP being informed of my participation in the study and if severe osteoarthritis is 
identified.  
 
 
 
I agree to members of the research team at the Diabetes Centre looking at my medical notes.           
 
 
 
I agree to my anonymised information being exported to members of the research team at the 
Manchester Metropolitan University. 
  
   
I understand that relevant sections of my medical notes and data collected during the study may be 
looked at by individuals from regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have access to my records. 
 
 
 
 
 
 
 
Please 
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Name of Participant Signature  Date  
 
 
   
 
Name of Person taking consent Signature  Date  
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Participant Information Sheet Generic for all 
Studies Involved in Gait 
  
 
Study title: 
͞FaĐtors ĐoŵproŵisiŶg the safety of gait iŶ people ǁith diaďetiĐ peripheral 
Ŷeuropathy aŶd the iŶflueŶĐe of iŶterǀeŶtioŶ͟ 
 
 
You are being invited to take part in a research study being conducted at the Manchester 
Metropolitan University. Before you decide whether or not to take part it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and ask any questions you may have to the 
research team afterwards. 
 
Why have you been selected? 
Either: 1) you have been diagnosed with diabetes, or 2) you do not have diabetes and are 
being asked to take part as part of a comparison group without diabetes (defined as a 
͚ĐoŶtrol partiĐipaŶt͛). 
 
What is the purpose of the study? 
Some people with diabetes may have problems when they do everyday tasks such as 
walking and going up and down stairs. These problems may cause some people to fall and 
injure themselves. A lack of sensation in the feet and also weakness of the muscles that help 
us to walk may be two possible reasons as to why some people with diabetes may have 
problems with these everyday things. We want to understand exactly why some people 
with diabetes may have problems with these everyday tasks. We also want to try to improve 
certain things that may cause problems for some people with diabetes by carrying out a 
training program that targets muscles and walking ability. By doing this we hope to reduce 
unsteadiness during walking and improve the safety of everyday tasks for some people with 
diabetes.   
 
What will I have to do if I take part? 
You will be asked to sign a consent form to show that you understand what is involved in 
taking part. If you are a control participant you will be asked to attend the laboratory at the 
Manchester Metropolitan University on 3 separate occasions (described below). If you are a 
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participant with diabetes you will be asked attend the laboratory at the Manchester 
Metropolitan University on 3 separate occasions before and 3 separate occasions after the 
intervention programme. It may be possible to combine some of these test visits so that you 
can attend on fewer occasions if you prefer. The time commitment for each session is 
indicated below. 
The intervention programme is only intended for people with diabetes and will last between 
4-6 months, requiring one visit to the Manchester Metropolitan University each week. There 
is a chance that you may not actually receive the intervention and will instead go into a 
comparison group who do not receive any intervention, but are tested before and after the 
same period of time that the intervention lasts for. The purpose of this is so that we can see 
the true effect of the intervention, in comparison to a group that does not receive the 
intervention (i.e., the comparison group). We will randomly allocate people to one of these 
two groups by giving everyone a number; putting these numbers into a computer and using 
a computer programme to randomly pick out the number of people we need in the 
intervention group. 
 
We can reimburse your travel expenses to attend the university (we will just need a public 
transport receipt, details of car mileage etc.). 
  
During the first laboratory visit we will ask about your medical history, test your vision and 
perform some simple non-invasive tests to check for nerve damage (peripheral neuropathy) 
in your feet. Tests for peripheral neuropathy will involve pressing on different areas of your 
feet and also placing a vibrating device on your feet to see if you can detect these 
sensations.  
 
We ǁill also take a ͚fiŶger-priĐk͛ ďlood saŵple to ŵeasure ďlood gluĐose leǀel. If you are a 
control participant and we identify that you may have peripheral neuropathy or a 
particularly high blood glucose level, we will not include you within the study and with your 
consent will notify your GP who may then suggest following an appropriate course of action 
with you.  
 
Gait laboratory visit 1: [This visit will last approximately 2
1
/2 hours]  
We will provide you with non-restrictive, but relatively tight-fitting clothing and velcro-strap 
sandals for this test and simply observe and measure as you walk naturally in our testing 
area.  
 
We will place small reflective markers onto different parts of your upper and lower body. 
The movement of these markers will be measured by a number of cameras and will allow us 
to assess the ŵoǀeŵeŶt of your ďody as you ǁalk. These Đaŵeras ǁill oŶly ͚see͛ the 
reflective markers. In a few cases, we may also use a video camera to record how you walk 
and help us further understand the data – if we do so, you will be notified of this and we will 
ask for your consent. 
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Small sensors will be placed onto the surface of your skin over the muscles on your legs to 
measure the activity from your muscles. 
 
Thin, flexible insole sensors will be inserted into your shoes to measure the pressures on the 
sole of your foot during walking.  
 
We will ask you to wear a light-weight head-band containing a small camera for a short 
period to measure where you look as you walk.  
 
On a few occasions we will also ask you to step over a small obstacle on the ground 
(approximately 10cm high). We will tell you exactly when we place this small obstacle in 
your path so that you are fully aware that it is there. Two members of the research team will 
be in close attendance to ensure your safety.  
 
We will also ask you to walk along at your own speed, stepping onto specific irregularly 
positioned targets for each step. 
 
During this test visit we will also ask you to complete two questionnaires: one about your 
knees and another about your hips. These questionnaires will ask how you feel about your 
knees and hips: whether you experience any symptoms such as pain and how they feel 
when performing certain activities. 
 
Gait laboratory visit 2: [This visit will last approximately 2
1
/2 hours]  
We will again provide you with non-restrictive, but relatively tight-fitting clothing and 
velcro-strap sandals for this test and simply observe and measure as you walk naturally up 
and down a small staircase in our testing area. Handrails will be present to use on the stairs 
if needed and we will secure you in a harness for your safety.  
 
We will place small reflective markers onto different parts of your upper and lower body. 
The movement of these markers will be measured by a number of cameras and will allow us 
to assess the ŵoǀeŵeŶt of your ďody as you ǁalk. These Đaŵeras ǁill oŶly ͚see͛ the 
reflective markers. In a few cases, we may also use a video camera to record how you walk 
and help us further understand the data – if we do so, you will be notified of this and we will 
ask for your consent. 
 
Small sensors will be placed onto the surface of your skin over the muscles on your legs to 
measure the activity from your muscles. 
 
Thin, flexible insole sensors will be inserted into your shoes to measure the pressures on the 
sole of your foot during walking.  
 
  
202 
 
We will ask you to wear a light-weight head-band containing a small camera for a short 
period to measure where you look as you walk.  
 
Muscle Strength Laboratory Visit: [This visit will last approximately 1
1
/2 hours]  
We will assess the strength in your legs using a specific machine. We will test each of your 
legs separately and assess the strength of the muscles on the front of your thigh and those 
on the back of your calf.  
 
You will be seated on the chair of the testing machine and asked to exert force by extending 
your leg at the knee (using the front thigh muscles) and also by extending your foot (using 
the calf muscles).  
 
You will be asked to exert force only for very short periods of time and will be given plenty 
of rest in between efforts.  
 
This experience will be similar to a short gym session for your leg muscles and you may 
experience some muscle stiffness/soreness one or two days afterwards, but this is 
completely normal and will disappear after 3 days.  
 
The Intervention Programme (Participants with diabetes only)  
[One visit per week, for 4-6 months. Each visit will last less than 1 hour] 
As mentioned above, there is a chance that you may not actually receive the intervention 
and will instead go into a comparison group who do not receive any intervention. We will 
randomly allocate people to one of these two groups by giving everyone a number; putting 
these numbers into a computer and using a computer programme to randomly pick out the 
number of people we need in the intervention group. Before and after the intervention 
period, you will also be asked to complete a questionnaire about any difficulties you may 
experience with gait tasks.   
For those people who undertake the intervention programme it will mainly involve exercise 
for your leg muscles. The exercise will be carried out using resistance exercise machines and 
will be individually tailored to your capabilities. You will always be supervised closely during 
the exercise. As part of the intervention for some people, we may also include a walking 
task where we ask you to step onto specific targets that are irregularly spaced along a 
walkway. This intervention programme is designed to increase the strength and speed of 
your leg muscles and to reduce unsteadiness during walking. At the start of the intervention, 
you will be given a leaflet containing more detailed information about the intervention.  
 
What are the potential risks or discomfort? 
The assessment of your leg strength will involve a high level of effort but just in short bursts 
and we will give you plenty of rest between efforts. This experience will be similar to a short 
gym session for your leg muscles and you may experience some muscle stiffness/soreness 
one or two days afterwards, but this is completely normal (it is a sign of your muscles 
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adapting) and will disappear after 3 days. You may experience the same sensation in your 
muscles (stiffness/soreness) for up 3 days after the exercise sessions. This is the sign of your 
muscles adapting and getting stronger and each exercise session you complete will help to 
reduce this sensation. During assessment of your normal walking pattern, just as in 
everyday life, there is a risk of falling. However, this risk is much lower than in normal daily 
life because research staff will monitor you very closely and you will also be secured in a 
harness when walking up and down stairs.  
 
 
 
 
Are there any possible benefits?  
You will receive feedback on how you walk and your level of leg muscle strength. We expect 
that your leg muscles will become stronger as a result of the intervention programme and 
that unsteadiness during walking will be reduced. Ultimately, we expect that the 
intervention programme will make walking and other everyday tasks safer for you. 
 
Do I have to take part? 
No, taking part is entirely voluntary. If you would prefer not to take part you do not have to 
give a reason. If you do take part but later change your mind you can withdraw from the 
study at any time.     
 
GP Letter. 
If you are a person with diabetes and decide to take part, a letter will be sent with your 
consent to your GP to inform him/her of your participation in the study. If you part of the 
control group and we identify that you may have peripheral neuropathy or a particularly 
high level of blood glucose, with your consent we will notify your GP, who may then suggest 
following an appropriate course of action with you.  
 
What if I have any Concerns? 
If you have a concern about any aspect of this study you should ask to speak to the 
researchers who will do their best to answer your questions (Neil Reeves: 0161 2475429, or 
Joe Handsaker: 07779913791). If you remain unhappy and wish to complain formally, you 
can do this by contacting the Director of Research at the Manchester Metropolitan 
University, Prof. Valerie Edwards-Jones by calling 0161 2471025. 
 
In the event that something does go wrong and you are harmed during the research and this 
is due to soŵeoŶe͛s ŶegligeŶĐe theŶ you ŵay haǀe grouŶds for a legal aĐtioŶ for 
compensation against the Manchester Metropolitan University, but you may have to pay 
your legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
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Medical Records. 
If you are a person with diabetes, existing members of the clinical care team at the Central 
Manchester NHS Hospitals Foundation Trust may look at relevant sections of your medical 
notes and data. All information will be kept confidential. Study data that is exported to the 
Manchester Metropolitan University will only be identified by the unique participant code 
and not by name.   
 
Storage and Disposal of Study Data 
All research data will be held in secure storage at the Manchester Metropolitan University. 
The research data may also include video recordings that will be viewed by the research 
team. Any video recordings will be securely stored in a digital format, on password-
protected computers, within a locked office/laboratory. Disposal of this data will be done by 
securely deleting the files. All participant data will be anonymous and only identified by a 
unique number. 
What do I do now? 
Thank you very much for considering taking part in our research. Please discuss this 
information with your family, friends or GP if you wish. 
 
If you would like to obtain any further information about this research project please 
contact a member of the research team or the research nurse by e-mail or telephone. 
 
They will then answer any questions you might have and if you are interested will arrange a 
convenient appointment for you to attend for your initial visit. 
 
 
 
<Researcher’s Name, at the Manchester Metropolitan University> 
<Researcher’s email address> 
<Researcher’s telephone number> 
 
 
<Researcher Nurse’s Name, at the Manchester Diabetes Centre> 
< Researcher Nurse’s email address> 
< Researcher Nurse’s telephone number> 
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FACULTY OF SCIENCE AND ENGINEERING 
 
M E M O R A N D U M 
 
TO Neil Reeves & Frank Bowling 
 
FROM Will Smith 
 
DATE 25 July 2015 
 
SUBJECT Faculty Ethics Committee Application – SE111201 
____________________________________________________________________ 
 
Your recent application to the Ethics Committee (SE111201) entitled ““Factors 
compromising the safety of gait in people with diabetic peripheral neuropathy and the 
influence of intervention” has been considered. 
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The application received a favourable opinion from the committee and was 
approved by Chairs Action. 
 
The application was also held as an excellent example of a detailed Ethics 
Application. 
 
The Committee requires that you report any Adverse Event during this study 
immediately to the Chair and Committee Secretary. Adverse Events are adverse 
reactions to any modality, drug or dietary supplement administered to subjects or 
any trauma resulting from procedures in the protocol of a study. 
 
An Adverse Event may also be accidental loss of data or loss of sample, particularly 
human tissue. Loss of human tissue or cells must also be reported to the designated 
individual for the Human Tissue Authority licence (currently Prof Bill Gilmore). 
 
Regards 
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Will Smith 
Student Information Point 
All Saints North (John Dalton Building) 
http://www.mmu.ac.uk/sas 
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Central Manchester University Hospitals  
NHS Foundation Trust  
Research & Development  
1st Floor Post Graduate Centre  
Manchester Royal Infirmary  
Oxford Road  
Manchester Ml3 9WL  
Tel: 0161-276-3340  
Fax: 0161-276-5766  
Lorraine.BrpadfootjgJcrnft.njis.uk  
 
Professor Andrew Boulton, Dr Frank Bowling  
Professor of Medicine / Consultant Physician  
Central Manchester University Hospitals NHS Foundation Trust  
Department of Medicine  
Manchester Royal Infirmary  
Oxford Road  
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Manchester  
Ml 3 9WL  
 
Ref: R01772-Ltr2-Boulton  
Dear Professor Boulton, Dr Frank Bowling  
PIN: R01772 (Please quote this number in all future correspondence)  
CSP Reference: 85837/GM  
Research Study: Factors compromising the safety of gait in people with diabetic 
peripheral neuropathy and the influence of intervention.  
Thank you for submitting the above study for approval.  
We acknowledge that the Manchester Metropolitan University has accepted the role 
of Research Governance Sponsor for this study.  
We understand that this study has been adopted by the NIHR Portfolio.  
I am pleased to confirm that the Research Office has now received all necessary 
documentation, and the Trust Director of Research &. Innovation has given approval 
for the project to be undertaken.  
This approval is in relation to the documentation supplied to us below.  
  
210 
 
Approval is given subject to the attached conditions - please ensure you and all 
members of the research team are familiar with these before commencing your 
research.  
Please note: You must tell your Divisional Research Manager - Manju Luckson  
• the date that you intend to start recruiting to this study AND  
• the date on which the first participant is recruited/consented  
The Trust aims for its research projects to recruit their first participant within 30 days 
of the recruitment start date. If you do not tell us your actual recruitment start date, 
we will use this approval date. This information is important for monitoring Trust 
recruitment performance for internal and external assessment.  
I would like to take this opportunity to wish you well with your research.  
R01772-Ltr2-Boulton  
Yours sincerely  
Lorraine Broadfoot  
Research Operations Manager  
Encs SSI Form - Fully Signed  
Manju Luckson, Divisional Research Manager for Medicine and Community Services 
Division and Specialist Medical Services Division - CMFT  
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Appendix  
Literature Search Results 
Search History 
 
1. EMBASE; "diabetes mellitus".ti,ab; 175106 results. 
2. EMBASE; "diabetes type 1".ti,ab; 923 results. 
3. EMBASE; "diabetes type 2".ti,ab; 1427 results. 
4. EMBASE; exp DIABETIC NEUROPATHY/; 18269 results. 
5. EMBASE; exp DIABETES MELLITUS/; 631693 results. 
6. EMBASE; neuropathy.ti,ab; 67907 results. 
7. EMBASE; gait.ti,ab; 39761 results. 
8. EMBASE; "gait disorder*".ti,ab; 1426 results. 
9. EMBASE; walk*.ti,ab; 96000 results. 
10. EMBASE; locomotion*.ti,ab; 21917 results. 
11. EMBASE; "gait analysis".ti,ab; 4792 results. 
12. EMBASE; step*.ti,ab; 544766 results. 
13. EMBASE; stair*.ti,ab; 7922 results. 
14. EMBASE; (stair* AND ascen*).ti,ab; 744 results. 
15. EMBASE; (stair* AND descen*).ti,ab; 824 results. 
16. EMBASE; "gait variab*".ti,ab; 788 results. 
17. EMBASE; fall*.ti,ab; 182577 results. 
18. EMBASE; fall*.ti,ab; 182577 results. 
19. EMBASE; exp GAIT DISORDER/; 15152 results. 
20. EMBASE; exp WALKING/; 68096 results. 
21. EMBASE; WALKING AID/; 3799 results. 
22. EMBASE; WALKING HARNESS/; 19 results. 
23. EMBASE; exp WALKING PATTERN/; 30750 results. 
24. EMBASE; WALKING SPEED/; 6648 results. 
25. EMBASE; exp GAIT ANALYSIS/; 30750 results. 
26. EMBASE; exp GAIT/; 30750 results. 
27. EMBASE; exp GAIT DEVIATIONS/ OR exp GAIT/; 44369 results. 
28. EMBASE; exp FALLING/; 26835 results. 
29. EMBASE; FALL RISK/ OR exp FALLING/; 28155 results. 
30. EMBASE; BIOMECHANICS/; 79265 results. 
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31. EMBASE; 1 OR 2 OR 3 OR 5; 652934 results. 
32. EMBASE; 4 OR 6; 76259 results. 
33. EMBASE; 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 
23 OR 
24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 40 OR 41; 943464 results. 
34. EMBASE; 31 AND 32 AND 33; 1650 results. 
35. EMBASE; 34 [Limit to: English Language and (Records From Embase) and (Human Age Groups Adult 18 
to 64 
years or Aged 65+ years)]; 669 results. 
36. EMBASE; 4 AND 31 AND 33; 990 results. 
37. EMBASE; 36 [Limit to: English Language and (Records From Embase) and (Human Age Groups Adult 18 
to 64 
years or Aged 65+ years)]; 394 results. 
38. Medline; "diabetes mellitus".ti,ab; 129937 results. 
39. Medline; "diabetes type 1".ti,ab; 548 results. 
40. Medline; "diabetes type 2".ti,ab; 776 results. 
41. Medline; exp DIABETES COMPLICATIONS/; 105126 results. 
42. Medline; DIABETES MELLITUS, TYPE 1/; 61718 results. 
43. Medline; DIABETES MELLITUS, TYPE 2/; 88217 results. 
44. Medline; "diabetic neuropathy".ti,ab; 5010 results. 
45. Medline; "diabetic neuropathy".ti; 2346 results. 
46. Medline; DIABETIC NEUROPATHIES/; 12181 results. 
47. Medline; gait.ti,ab; 29264 results. 
48. Medline; "gait disorder*".ti,ab; 921 results. 
49. Medline; walk*.ti,ab; 75232 results. 
50. Medline; locomotion*.ti,ab; 19785 results. 
51. Medline; "gait analysis".ti,ab; 3450 results. 
52. Medline; step*.ti,ab; 456175 results. 
53. Medline; stair*.ti,ab; 6469 results. 
54. Medline; (stair* AND ascen*).ti,ab; 636 results. 
55. Medline; (stair* AND descen*).ti,ab; 682 results. 
56. Medline; "gait variab*".ti,ab; 571 results.Evidence Services | library.nhs.u 
57. Medline; fall*.ti,ab; 166327 results. 
58. Medline; fall*.ti,ab; 166327 results. 
59. Medline; GAIT DISORDERS, NEUROLOGIC/; 4183 results. 
60. Medline; WALKING/; 20669 results. 
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61. Medline; LOCOMOTION/; 19240 results. 
62. Medline; exp GAIT/; 18597 results. 
63. Medline; exp ACCIDENTAL FALLS/; 16058 results. 
64. Medline; biomechanics.ti,ab; 10698 results. 
65. Medline; 38 OR 39 OR 40 OR 41 OR 42 OR 43; 284340 results. 
66. Medline; 44 OR 46; 13861 results. 
67. Medline; 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 59 OR 60 OR 61 
OR 62 
OR 63 OR 64; 750338 results. 
68. Medline; 65 AND 66 AND 67; 648 results. 
69. CINAHL; "diabetes mellitus".ti,ab; 14515 results. 
70. CINAHL; "diabetes type 1".ti,ab; 82 results. 
71. CINAHL; "diabetes type 2".ti,ab; 100 results. 
72. CINAHL; exp DIABETES MELLITUS,TYPE 2/ OR exp DIABETES MELLITUS,TYPE 1/ OR exp 
DIABETES 
MELLITUS/; 71694 results. 
73. CINAHL; "diabetic neuropathy".ti,ab; 762 results. 
74. CINAHL; DIABETIC NEUROPATHIES/ OR DIABETIC FOOT/; 6888 results. 
75. CINAHL; gait.ti,ab; 7331 results. 
76. CINAHL; "gait disorder*".ti,ab; 146 results. 
77. CINAHL; walk*.ti,ab; 18661 results. 
78. CINAHL; locomotion*.ti,ab; 835 results. 
79. CINAHL; "gait analysis".ti,ab; 840 results. 
80. CINAHL; step*.ti,ab; 37390 results. 
81. CINAHL; stair*.ti,ab; 1606 results. 
82. CINAHL; (stair* AND ascen*).ti,ab; 213 results. 
83. CINAHL; (stair* AND descen*).ti,ab; 255 results. 
84. CINAHL; "gait variab*".ti,ab; 167 results. 
85. CINAHL; fall*.ti,ab; 22006 results. 
86. CINAHL; exp WALKING/; 13838 results. 
87. CINAHL; exp GAIT ANALYSIS/; 4037 results. 
88. CINAHL; exp GAIT/; 4034 results. 
89. CINAHL; BIOMECHANICS/; 11238 results. 
90. CINAHL; GAIT DISORDERS, NEUROLOGIC/; 430 results. 
91. CINAHL; LOCOMOTION/; 625 results. 
92. CINAHL; exp ACCIDENTAL FALLS/; 11184 results. 
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93. CINAHL; 69 OR 70 OR 71 OR 72; 75475 results. 
94. CINAHL; 73 OR 74; 7047 results. 
95. CINAHL; 75 OR 76 OR 77 OR 78 OR 79 OR 80 OR 81 OR 82 OR 83 OR 84 OR 85 OR 86 OR 87 OR 88 
OR 89 
OR 90 OR 91 OR 92; 97268 results. 
96. CINAHL; 93 AND 94 AND 95; 481 results. 
97. CINAHL; 96 [Limit to: (Language English) and (Age Groups All Adult)]; 239 results. 
98. Medline; adult*.ti,ab; 842952 results. 
99. Medline; aged.ti,ab; 378224 results. 
100. Medline; elder*.ti,ab; 186971 results. 
101. Medline; ageing.ti,ab; 26060 results. 
102. Medline; geriatric.ti,ab; 28925 results. 
103. Medline; old.ti,ab; 755301 results. 
104. Medline; ADULT/; 4002371 results. 
105. Medline; GERIATRICS/; 26880 results. 
106. Medline; 98 OR 99 OR 100 OR 101 OR 102 OR 103 OR 104 OR 105; 5359325 results. 
107. Medline; 68 AND 106; 316 results. 
110. Medline; 107 [Limit to: Publication Year 2005-2015]; 127 results. 
111. CINAHL; 97 [Limit to: Publication Year 2005-2015 and (Language English) and (Age Groups All Adult)]; 
148 
  
RESULTSEvidence Se 
1. EMBASE; "diabetes mellitus".ti,ab; 175106 results. 
2. EMBASE; "diabetes type 1".ti,ab; 923 results. 
3. EMBASE; "diabetes type 2".ti,ab; 1427 results. 
4. EMBASE; exp DIABETIC NEUROPATHY/; 18269 results. 
5. EMBASE; exp DIABETES MELLITUS/; 631693 results. 
6. EMBASE; neuropathy.ti,ab; 67907 results. 
7. EMBASE; gait.ti,ab; 39761 results. 
8. EMBASE; "gait disorder*".ti,ab; 1426 results. 
9. EMBASE; walk*.ti,ab; 96000 results. 
10. EMBASE; locomotion*.ti,ab; 21917 results. 
11. EMBASE; "gait analysis".ti,ab; 4792 results. 
12. EMBASE; step*.ti,ab; 544766 results. 
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13. EMBASE; stair*.ti,ab; 7922 results. 
14. EMBASE; (stair* AND ascen*).ti,ab; 744 results. 
15. EMBASE; (stair* AND descen*).ti,ab; 824 results. 
16. EMBASE; "gait variab*".ti,ab; 788 results. 
17. EMBASE; fall*.ti,ab; 182577 results. 
18. EMBASE; fall*.ti,ab; 182577 results. 
19. EMBASE; exp GAIT DISORDER/; 15152 results. 
20. EMBASE; exp WALKING/; 68096 results. 
21. EMBASE; WALKING AID/; 3799 results. 
22. EMBASE; WALKING HARNESS/; 19 results. 
23. EMBASE; exp WALKING PATTERN/; 30750 results. 
24. EMBASE; WALKING SPEED/; 6648 results. 
25. EMBASE; exp GAIT ANALYSIS/; 30750 results. 
26. EMBASE; exp GAIT/; 30750 results. 
27. EMBASE; exp GAIT DEVIATIONS/ OR exp GAIT/; 44369 results. 
28. EMBASE; exp FALLING/; 26835 results. 
29. EMBASE; FALL RISK/ OR exp FALLING/; 28155 results. 
30. EMBASE; BIOMECHANICS/; 79265 results. 
31. EMBASE; 1 OR 2 OR 3 OR 5; 652934 results. 
32. EMBASE; 4 OR 6; 76259 results. 
33. EMBASE; 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 
23 OR 
24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 40 OR 41; 943464 results. 
34. EMBASE; 31 AND 32 AND 33; 1650 results. 
35. EMBASE; 34 [Limit to: English Language and (Records From Embase) and (Human Age Groups Adult 18 
to 64 
years or Aged 65+ years)]; 669 results. 
36. EMBASE; 4 AND 31 AND 33; 990 results. 
37. EMBASE; 36 [Limit to: English Language and (Records From Embase) and (Human Age Groups Adult 18 
to 64  years or Aged 65+ years)]; 394 results. 
 
38. Medline; "diabetes mellitus".ti,ab; 129937 results. 
39. Medline; "diabetes type 1".ti,ab; 548 results. 
40. Medline; "diabetes type 2".ti,ab; 776 results. 
41. Medline; exp DIABETES COMPLICATIONS/; 105126 results. 
42. Medline; DIABETES MELLITUS, TYPE 1/; 61718 results. 
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43. Medline; DIABETES MELLITUS, TYPE 2/; 88217 results. 
44. Medline; "diabetic neuropathy".ti,ab; 5010 results. 
45. Medline; "diabetic neuropathy".ti; 2346 results. 
46. Medline; DIABETIC NEUROPATHIES/; 12181 results. 
47. Medline; gait.ti,ab; 29264 results. 
48. Medline; "gait disorder*".ti,ab; 921 results. 
49. Medline; walk*.ti,ab; 75232 results. 
50. Medline; locomotion*.ti,ab; 19785 results. 
51. Medline; "gait analysis".ti,ab; 3450 results. 
52. Medline; step*.ti,ab; 456175 results. 
53. Medline; stair*.ti,ab; 6469 results. 
54. Medline; (stair* AND ascen*).ti,ab; 636 results. 
55. Medline; (stair* AND descen*).ti,ab; 682 results. 
56. Medline; "gait variab*".ti,ab; 571 results. 
57. Medline; fall*.ti,ab; 166327 results. 
58. Medline; fall*.ti,ab; 166327 results. 
59. Medline; GAIT DISORDERS, NEUROLOGIC/; 4183 results. 
60. Medline; WALKING/; 20669 results. 
61. Medline; LOCOMOTION/; 19240 results. 
62. Medline; exp GAIT/; 18597 results. 
63. Medline; exp ACCIDENTAL FALLS/; 16058 results. 
64. Medline; biomechanics.ti,ab; 10698 results. 
65. Medline; 38 OR 39 OR 40 OR 41 OR 42 OR 43; 284340 results. 
66. Medline; 44 OR 46; 13861 results. 
67. Medline; 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 59 OR 60 OR 61 
OR 62 
OR 63 OR 64; 750338 results. 
68. Medline; 65 AND 66 AND 67; 648 results. 
69. CINAHL; "diabetes mellitus".ti,ab; 14515 results. 
70. CINAHL; "diabetes type 1".ti,ab; 82 results. 
71. CINAHL; "diabetes type 2".ti,ab; 100 results. 
72. CINAHL; exp DIABETES MELLITUS,TYPE 2/ OR exp DIABETES MELLITUS,TYPE 1/ OR exp 
DIABETES 
MELLITUS/; 71694 results. 
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Appendix ROM and Variability 
Stair Ascent  
 
Parameter     
"Table Analyzed" "Ankle frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0830    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.572    
"  R square" 0.06261    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.675    
"  P value" 0.2625    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 17.18 2 8.589  
"  Residual (within columns)" 257.2 77 3.340  
"  Total" 274.4 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -1.160 3.110 No ns 
"  Ctrl vs DM" -0.2654 --- No ns 
"  DM vs DPN" -0.8949 --- No ns 
 
Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0060    
"  P value summary" **    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 5.472    
"  R square" 0.1244    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.233    
"  P value" 0.3274    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 318.8 2 159.4  
"  Residual (within columns)" 2243 77 29.13  
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"  Total" 2562 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DPN vs DM" -4.574 4.241 Yes * 
"  DPN vs Ctrl" -4.495 4.080 Yes ** 
"  Ctrl vs DM" -0.07960 0.07999 No ns 
 
Parameter     
"Table Analyzed" "Ankle trans"    
     
"One-way analysis of variance"     
"  P value" 0.7374    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.3058    
"  R square" 0.007880    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.378    
"  P value" 0.5022    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 2.551 2 1.276  
"  Residual (within columns)" 321.2 77 4.171  
"  Total" 323.7 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs Ctrl" -0.4101 1.089 No ns 
"  DM vs DPN" -0.1242 --- No ns 
"  DPN vs Ctrl" -0.2859 --- No ns 
 
Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0001    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 10.39    
"  R square" 0.2216    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.7815    
"  P value" 0.6765    
"  P value summary" ns    
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"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 767.9 2 384.0  
"  Residual (within columns)" 2698 73 36.96  
"  Total" 3466 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DPN vs Ctrl" -7.921 6.099 Yes *** 
"  DPN vs DM" -6.927 5.405 Yes *** 
"  DM vs Ctrl" -0.9934 0.8794 No ns 
 
Parameter     
"Table Analyzed" "Ankle transverse"    
     
"One-way analysis of variance"     
"  P value" 0.4950    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.7100    
"  R square" 0.01908    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.2477    
"  P value" 0.8835    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 6.755 2 3.377  
"  Residual (within columns)" 347.2 73 4.757  
"  Total" 354.0 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -0.7841 1.683 No ns 
"  Ctrl vs DM" -0.3389 --- No ns 
"  DM vs DPN" -0.4452 --- No ns 
ROM ANKLE STAIR ASCENT  
 
Parameter     
"Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0060    
"  P value summary" **    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
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"  F" 5.472    
"  R square" 0.1244    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.233    
"  P value" 0.3274    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 318.8 2 159.4  
"  Residual (within columns)" 2243 77 29.13  
"  Total" 2562 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DPN vs DM" -4.574 4.241 Yes * 
"  DPN vs Ctrl" -4.495 4.080 Yes ** 
"  Ctrl vs DM" -0.07960 0.07999 No ns 
 
Parameter     
"Table Analyzed" "Ankle trans"    
     
"One-way analysis of variance"     
"  P value" 0.7374    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.3058    
"  R square" 0.007880    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.378    
"  P value" 0.5022    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 2.551 2 1.276  
"  Residual (within columns)" 321.2 77 4.171  
"  Total" 323.7 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs Ctrl" -0.4101 1.089 No ns 
"  DM vs DPN" -0.1242 --- No ns 
"  DPN vs Ctrl" -0.2859 --- No ns 
 
Parameter     
"Table Analyzed" "Hip frontal"    
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"One-way analysis of variance"     
"  P value" 0.4311    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.8508    
"  R square" 0.02162    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 3.075    
"  P value" 0.2149    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 15.43 2 7.713  
"  Residual (within columns)" 698.0 77 9.065  
"  Total" 713.5 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -1.131 1.841 No ns 
"  Ctrl vs DM" -0.4266 --- No ns 
"  DM vs DPN" -0.7048 --- No ns 
 
 
Parameter     
"Table Analyzed" "Hip Sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0054    
"  P value summary" **    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 5.593    
"  R square" 0.1268    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.146    
"  P value" 0.5637    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 228.9 2 114.5  
"  Residual (within columns)" 1576 77 20.46  
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"  Total" 1805 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DM" -3.821 4.582 Yes ** 
"  Ctrl vs DPN" -2.962 3.208 Yes * 
"  DPN vs DM" -0.8586 0.9497 No ns 
 
Parameter     
"Table Analyzed" "Hip trans"    
     
"One-way analysis of variance"     
"  P value" 0.0520    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 3.073    
"  R square" 0.07391    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.941    
"  P value" 0.3790    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 88.43 2 44.22  
"  Residual (within columns)" 1108 77 14.39  
"  Total" 1197 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -2.712 3.503 Yes * 
"  Ctrl vs DM" -1.072 1.532 No ns 
"  DM vs DPN" -1.641 2.164 No ns 
 
 
Parameter     
"Table Analyzed" "Knee frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0005    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 8.482    
"  R square" 0.1805    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.424    
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"  P value" 0.4906    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 357.0 2 178.5  
"  Residual (within columns)" 1621 77 21.05  
"  Total" 1978 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -5.354 5.717 Yes *** 
"  Ctrl vs DM" -3.123 3.693 Yes * 
"  DM vs DPN" -2.231 2.433 No ns 
 
Parameter     
"Table Analyzed" "Knee sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0241    
"  P value summary" *    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 3.912    
"  R square" 0.09223    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 3.195    
"  P value" 0.2024    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 400.2 2 200.1  
"  Residual (within columns)" 3939 77 51.15  
"  Total" 4339 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DM" -5.212 3.953 Yes * 
"  Ctrl vs DPN" -2.546 1.744 No ns 
"  DPN vs DM" -2.666 1.865 No ns 
 
 
Parameter     
"Table Analyzed" "Knee trans"    
     
"One-way analysis of variance"     
"  P value" 0.4929    
"  P value summary" ns    
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"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.7141    
"  R square" 0.01821    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.192    
"  P value" 0.5510    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 11.78 2 5.889  
"  Residual (within columns)" 635.0 77 8.247  
"  Total" 646.8 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.9146 1.594 No ns 
"  DM vs Ctrl" -0.6372 --- No ns 
"  Ctrl vs DPN" -0.2774 --- No ns 
 
Stair Descent 
Parameter     
"Table Analyzed" "Ankle frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0067    
"  P value summary" **    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 5.363    
"  R square" 0.1281    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.6495    
"  P value" 0.7227    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 42.35 2 21.18  
"  Residual (within columns)" 288.3 73 3.949  
"  Total" 330.6 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
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"  Ctrl vs DPN" -1.676 3.949 Yes * 
"  Ctrl vs DM" -1.454 3.938 Yes ** 
"  DM vs DPN" -0.2222 0.5304 No ns 
Parameter     
"Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0001    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 10.39    
"  R square" 0.2216    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.7815    
"  P value" 0.6765    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 767.9 2 384.0  
"  Residual (within columns)" 2698 73 36.96  
"  Total" 3466 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DPN vs Ctrl" -7.921 6.099 Yes *** 
"  DPN vs DM" -6.927 5.405 Yes *** 
"  DM vs Ctrl" -0.9934 0.8794 No ns 
 
Parameter     
"Table Analyzed" "Ankle transverse"    
     
"One-way analysis of variance"     
"  P value" 0.4950    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.7100    
"  R square" 0.01908    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.2477    
"  P value" 0.8835    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 6.755 2 3.377  
"  Residual (within columns)" 347.2 73 4.757  
"  Total" 354.0 75   
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"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -0.7841 1.683 No ns 
"  Ctrl vs DM" -0.3389 --- No ns 
"  DM vs DPN" -0.4452 --- No ns 
Parameter     
"Table Analyzed" "Hip frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0003    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 9.215    
"  R square" 0.2016    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.579    
"  P value" 0.2755    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 183.7 2 91.83  
"  Residual (within columns)" 727.4 73 9.965  
"  Total" 911.1 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -4.032 5.979 Yes *** 
"  Ctrl vs DM" -2.131 3.633 Yes * 
"  DM vs DPN" -1.901 2.857 Yes * 
 
Parameter     
"Table Analyzed" "Hip frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0003    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 9.215    
"  R square" 0.2016    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.579    
"  P value" 0.2755    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
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"  Treatment (between columns)" 183.7 2 91.83  
"  Residual (within columns)" 727.4 73 9.965  
"  Total" 911.1 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -4.032 5.979 Yes *** 
"  Ctrl vs DM" -2.131 3.633 Yes * 
"  DM vs DPN" -1.901 2.857 Yes * 
Parameter     
"Table Analyzed" "Hip Sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0873    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.522    
"  R square" 0.06463    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 3.957    
"  P value" 0.1383    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 58.14 2 29.07  
"  Residual (within columns)" 841.3 73 11.53  
"  Total" 899.5 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DM" -1.973 3.128 No ns 
"  Ctrl vs DPN" -1.378 --- No ns 
"  DPN vs DM" -0.5949 --- No ns 
 
Parameter      
"Table Analyzed" "Hip transverse"     
      
"One-way analysis of variance"      
"  P value" "< 0.0001"     
"  P value summary" ****     
"  Are means signif. different? (P < 0.05)" Yes     
"  Number of groups" 3     
"  F" 11.57     
"  R square" 0.2406     
      
"Bartlett's test for equal variances"      
"  Bartlett's statistic (corrected)" 1.936     
"  P value" 0.3798     
"  P value summary" ns     
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"  Do the variances differ signif. (P < 0.05)" No   
  
      
"ANOVA Table" SS df MS   
"  Treatment (between columns)" 378.2 2 189.1   
"  Residual (within columns)" 1193 73 16.35   
"  Total" 1572 75    
      
"Bonferroni's Multiple Comparison Test" "Mean Diff." t
 "Significant? P < 0.05?" Summary "95% CI of diff" 
"  Ctrl vs DM" -1.668 1.570 No ns "-4.271 to 0.9356" 
"  Ctrl vs DPN" -5.822 4.767 Yes **** "-8.815 to -2.829" 
"  DM vs DPN" -4.154 3.446 Yes ** "-7.108 to -1.201" 
 
Parameter     
"Table Analyzed" "Knee frontal"    
     
"One-way analysis of variance"     
"  P value" 0.0007    
"  P value summary" ***    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 8.119    
"  R square" 0.1820    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.09664    
"  P value" 0.9528    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 184.6 2 92.29  
"  Residual (within columns)" 829.8 73 11.37  
"  Total" 1014 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -3.435 4.769 Yes ** 
"  Ctrl vs DM" -3.089 4.932 Yes *** 
"  DM vs DPN" -0.3454 0.4860 No ns 
 
Parameter     
"Table Analyzed" "Knee sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0539    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 3.041    
"  R square" 0.07691    
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"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.5000    
"  P value" 0.7788    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 164.8 2 82.41  
"  Residual (within columns)" 1978 73 27.10  
"  Total" 2143 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DM" -3.308 3.420 Yes * 
"  Ctrl vs DPN" -1.034 0.9296 No ns 
"  DPN vs DM" -2.275 2.073 No ns 
 
Parameter     
"Table Analyzed" "Knee transverse"   
     
"One-way analysis of variance"     
"  P value" 0.0546    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 3.026    
"  R square" 0.07656    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.949    
"  P value" 0.2289    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 45.22 2 22.61  
"  Residual (within columns)" 545.4 73 7.471  
"  Total" 590.6 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -2.031 3.478 Yes * 
"  Ctrl vs DM" -0.7471 1.471 No ns 
"  DM vs DPN" -1.283 2.227 No ns 
 
Ascent Variability  
 
Parameter     
"Table Analyzed" "Ankle frontal"    
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"One-way analysis of variance"     
"  P value" 0.0965    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.411    
"  R square" 0.05893    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 17.39    
"  P value" 0.0002    
"  P value summary" ***    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 6.693 2 3.346  
"  Residual (within columns)" 106.9 77 1.388  
"  Total" 113.6 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.6971 2.961 No ns 
"  DM vs Ctrl" -0.09858 --- No ns 
"  Ctrl vs DPN" -0.5985 --- No ns 
 
Parameter     
"Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0764    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.659    
"  R square" 0.06461    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 46.88    
"  P value" "< 0.0001"    
"  P value summary" ****    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 26.18 2 13.09  
"  Residual (within columns)" 379.0 77 4.922  
"  Total" 405.2 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
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"  Ctrl vs DPN" -1.421 3.138 No ns 
"  Ctrl vs DM" -0.2893 --- No ns 
"  DM vs DPN" -1.132 --- No ns 
 
Parameter     
"Table Analyzed" "Ankle trans"    
     
"One-way analysis of variance"     
"  P value" 0.5680    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.5699    
"  R square" 0.01459    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 10.90    
"  P value" 0.0043    
"  P value summary" **    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 1.718 2 0.8591  
"  Residual (within columns)" 116.1 77 1.508  
"  Total" 117.8 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs Ctrl" -0.3301 1.458 No ns 
"  DM vs DPN" -0.2429 --- No ns 
"  DPN vs Ctrl" -0.08725 --- No ns 
 
Parameter     
"Table Analyzed" "Hip frontal"    
     
"One-way analysis of variance"     
"  P value" 0.1768    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 1.772    
"  R square" 0.04400    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.1973    
"  P value" 0.9061    
"  P value summary" ns    
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"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 3.011 2 1.506  
"  Residual (within columns)" 65.42 77 0.8496  
"  Total" 68.43 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -0.4997 2.656 No ns 
"  Ctrl vs DM" -0.1859 --- No ns 
"  DM vs DPN" -0.3138 --- No ns 
 
Parameter     
"Table Analyzed" "Hip Sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.2775    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 1.303    
"  R square" 0.03275    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 15.25    
"  P value" 0.0005    
"  P value summary" ***    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 23.81 2 11.90  
"  Residual (within columns)" 703.2 77 9.132  
"  Total" 727.0 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -1.350 2.189 No ns 
"  Ctrl vs DM" -0.2604 --- No ns 
"  DM vs DPN" -1.090 --- No ns 
 
Parameter     
"Table Analyzed" "Hip trans"    
     
"One-way analysis of variance"     
"  P value" 0.7841    
"  P value summary" ns    
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"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.2439    
"  R square" 0.006296    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 9.464    
"  P value" 0.0088    
"  P value summary" **    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 4.968 2 2.484  
"  Residual (within columns)" 784.1 77 10.18  
"  Total" 789.1 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.6008 0.9420 No ns 
"  DM vs Ctrl" -0.3998 --- No ns 
"  Ctrl vs DPN" -0.2010 --- No ns 
Parameter     
"Table Analyzed" "Knee frontal"    
     
"One-way analysis of variance"     
"  P value" 0.9414    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.06039    
"  R square" 0.001566    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 3.923    
"  P value" 0.1407    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 1.265 2 0.6324  
"  Residual (within columns)" 806.4 77 10.47  
"  Total" 807.7 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.3152 0.4874 No ns 
"  DM vs Ctrl" -0.1613 --- No ns 
"  Ctrl vs DPN" -0.1540 --- No ns 
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Parameter     
"Table Analyzed" "Knee sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.0732    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.706    
"  R square" 0.06566    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 41.57    
"  P value" "< 0.0001"    
"  P value summary" ****    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 41.50 2 20.75  
"  Residual (within columns)" 590.5 77 7.669  
"  Total" 632.0 79   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -1.753 3.168 No ns 
"  DM vs Ctrl" -0.3010 --- No ns 
"  Ctrl vs DPN" -1.452 --- No ns 
 
Parameter     
"Table Analyzed" "Knee trans"    
     
"One-way analysis of variance"     
"  P value" 0.6992    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.3595    
"  R square" 0.009251    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 0.1150    
"  P value" 0.9441    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 4.257 2 2.129  
"  Residual (within columns)" 455.9 77 5.921  
"  Total" 460.2 79   
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"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs Ctrl" -0.5194 1.158 No ns 
"  DM vs DPN" -0.1102 --- No ns 
"  DPN vs Ctrl" -0.4093 --- No ns 
 
Descent Variability  
 
Parameter     
"Table Analyzed" "Ankle frontal"    
     
"One-way analysis of variance"     
"  P value" 0.1429    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 1.998    
"  R square" 0.05191    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 8.330    
"  P value" 0.0155    
"  P value summary" *    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 2.477 2 1.238  
"  Residual (within columns)" 45.24 73 0.6198  
"  Total" 47.72 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -0.4610 2.741 No ns 
"  Ctrl vs DM" -0.08984 --- No ns 
"  DM vs DPN" -0.3711 --- No ns 
 
Parameter     
"Table Analyzed" "Ankle sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.1233    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 2.154    
"  R square" 0.05573    
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"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 5.482    
"  P value" 0.0645    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 15.93 2 7.965  
"  Residual (within columns)" 269.9 73 3.698  
"  Total" 285.9 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -1.142 2.816 No ns 
"  DM vs Ctrl" -0.1604 --- No ns 
"  Ctrl vs DPN" -0.9812 --- No ns 
 
Parameter     
"Table Analyzed" "Ankle transverse"    
     
"One-way analysis of variance"     
"  P value" 0.4655    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.7728    
"  R square" 0.02073    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 9.245    
"  P value" 0.0098    
"  P value summary" **    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 1.497 2 0.7484  
"  Residual (within columns)" 70.70 73 0.9685  
"  Total" 72.20 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.3439 1.657 No ns 
"  DM vs Ctrl" -0.03191 --- No ns 
"  Ctrl vs DPN" -0.3120 --- No ns 
 
Parameter     
"Table Analyzed" "Hip frontal"    
     
"One-way analysis of variance"     
"  P value" 0.4178    
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"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.8832    
"  R square" 0.02363    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.737    
"  P value" 0.4196    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 1.229 2 0.6145  
"  Residual (within columns)" 50.79 73 0.6958  
"  Total" 52.02 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.3019 1.717 No ns 
"  DM vs Ctrl" -0.005913 --- No ns 
"  Ctrl vs DPN" -0.2960 --- No ns 
 
Parameter     
"Table Analyzed" "Hip sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.2908    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 1.256    
"  R square" 0.03327    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 2.159    
"  P value" 0.3398    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 3.795 2 1.898  
"  Residual (within columns)" 110.3 73 1.511  
"  Total" 114.1 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -0.5267 2.033 No ns 
"  DM vs Ctrl" -0.002136 --- No ns 
"  Ctrl vs DPN" -0.5245 --- No ns 
 
Parameter     
  
279 
 
"Table Analyzed" "Hip transverse"    
     
"One-way analysis of variance"     
"  P value" 0.0257    
"  P value summary" *    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 3.851    
"  R square" 0.09544    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 3.803    
"  P value" 0.1493    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 19.05 2 9.523  
"  Residual (within columns)" 180.5 73 2.473  
"  Total" 199.6 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -1.268 3.775 Yes * 
"  Ctrl vs DM" -0.2155 0.7376 No ns 
"  DM vs DPN" -1.052 3.175 Yes * 
 
Parameter     
"Table Analyzed" "Knee frontal"    
     
"One-way analysis of variance"     
"  P value" 0.2404    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 1.454    
"  R square" 0.03830    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 16.22    
"  P value" 0.0003    
"  P value summary" ***    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 12.20 2 6.100  
"  Residual (within columns)" 306.4 73 4.197  
"  Total" 318.6 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs DPN" -1.024 2.372 No ns 
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"  DM vs Ctrl" -0.2342 --- No ns 
"  Ctrl vs DPN" -0.7901 --- No ns 
 
Parameter     
"Table Analyzed" "Knee sagittal"    
     
"One-way analysis of variance"     
"  P value" 0.4987    
"  P value summary" ns    
"  Are means signif. different? (P < 0.05)" No    
"  Number of groups" 3    
"  F" 0.7024    
"  R square" 0.01888    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 1.737    
"  P value" 0.4196    
"  P value summary" ns    
"  Do the variances differ signif. (P < 0.05)" No    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 2.392 2 1.196  
"  Residual (within columns)" 124.3 73 1.703  
"  Total" 126.7 75   
     
"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  DM vs Ctrl" -0.3649 1.505 No ns 
"  DM vs DPN" -0.3599 --- No ns 
"  DPN vs Ctrl" -0.004936 --- No ns 
 
Parameter     
"Table Analyzed" "Knee transverse"   
     
"One-way analysis of variance"     
"  P value" 0.0446    
"  P value summary" *    
"  Are means signif. different? (P < 0.05)" Yes    
"  Number of groups" 3    
"  F" 3.247    
"  R square" 0.08170    
     
"Bartlett's test for equal variances"     
"  Bartlett's statistic (corrected)" 7.551    
"  P value" 0.0229    
"  P value summary" *    
"  Do the variances differ signif. (P < 0.05)" Yes    
     
"ANOVA Table" SS df MS  
"  Treatment (between columns)" 12.62 2 6.308  
"  Residual (within columns)" 141.8 73 1.943  
"  Total" 154.4 75   
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"Newman-Keuls Multiple Comparison Test" "Mean Diff." q
 "Significant? P < 0.05?" Summary 
"  Ctrl vs DPN" -1.071 3.598 Yes * 
"  Ctrl vs DM" -0.4667 1.802 No ns 
"  DM vs DPN" -0.6047 2.058 No ns 
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Stair ascent 
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Stair descent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
284 
 
Level walking 
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